Robotic-assisted surgery compared with laparoscopic resection surgery for rectal cancer: the ROLARR RCT by Jayne, D et al.
Journals Library
DOI 10.3310/eme06100
Robotic-assisted surgery compared  
with laparoscopic resection surgery  
for rectal cancer: the ROLARR RCT 
David Jayne, Alessio Pigazzi, Helen Marshall, Julie Croft, Neil Corrigan,  
Joanne Copeland, Philip Quirke, Nicholas West, Richard Edlin,  
Claire Hulme and Julia Brown
Efficacy and Mechanism Evaluation
Volume 6 • Issue 10 • September 2019
ISSN 2050-4365

Robotic-assisted surgery compared with
laparoscopic resection surgery for rectal
cancer: the ROLARR RCT
David Jayne,1* Alessio Pigazzi,2 Helen Marshall,3
Julie Croft,3 Neil Corrigan,3 Joanne Copeland,3
Philip Quirke,4 Nicholas West,4 Richard Edlin,5
Claire Hulme6 and Julia Brown3
1Academic Surgery, Leeds Institute of Biological and Clinical Sciences,
University of Leeds, Leeds, UK
2Department of Surgery, University of California, Irvine, CA, USA
3Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research,
University of Leeds, Leeds, UK
4Pathology and Tumour Biology, Leeds Institute of Cancer and Pathology,
University of Leeds, Leeds, UK
5Faculty of Medical and Health Sciences, University of Auckland, Auckland,
New Zealand
6Academic Unit of Health Economics, University of Leeds, Leeds, UK
*Corresponding author
Declared competing interests of authors: Alessio Pigazzi is a consultant and proctor for Intuitive
Surgical Inc. (Sunnyvale, CA, USA) and receives personal fees from Covidien plc (Medtronic plc; Dublin,
Ireland) and Ethicon, Inc. (Somerville, NJ, USA) outside the submitted work. David Jayne is a proctor for
Intuitive Surgical Inc. and was formerly a member of the Efficacy and Mechanism Evaluation (EME) Strategy
Group and the EME Prioritisation Group, and was previously involved in an EME Intraoperative Imaging
Review. Claire Hulme was formerly a member of the National Institute for Health Research (NIHR) Health
Technology Assessment (HTA) Commissioning Board. Julia Brown is a member of the HTA Clinical Evaluation
and Trials Board, HTA Funding Board Policy Group, HTA Mental, Psychological and Occupational Health
Methods Group, HTA Post-Board Funding Teleconference Group and NIHR Standing Advisory Committee.
Published September 2019
DOI: 10.3310/eme06100
This report should be referenced as follows:
Jayne D, Pigazzi A, Marshall H, Croft J, Corrigan N, Copeland J, et al. Robotic-assisted surgery
compared with laparoscopic resection surgery for rectal cancer: the ROLARR RCT. Efficacy Mech
Eval 2019;6(10).

Efficacy and Mechanism Evaluation
ISSN 2050-4365 (Print)
ISSN 2050-4373 (Online)
This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/).
Editorial contact: journals.library@nihr.ac.uk
The full EME archive is freely available to view online at www.journalslibrary.nihr.ac.uk/eme. Print-on-demand copies can be purchased from
the report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk
Criteria for inclusion in the Efficacy and Mechanism Evaluation journal
Reports are published in Efficacy and Mechanism Evaluation (EME) if (1) they have resulted from work for the EME programme, and
(2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.
EME programme
The Efficacy and Mechanism Evaluation (EME) programme funds ambitious studies evaluating interventions that have the potential to make
a step-change in the promotion of health, treatment of disease and improvement of rehabilitation or long-term care. Within these studies,
EME supports research to improve the understanding of the mechanisms of both diseases and treatments.
The programme support translational research into a wide range of new or repurposed interventions. These may include diagnostic or prognostic
tests and decision-making tools, therapeutics or psychological treatments, medical devices, and public health initiatives delivered in the NHS.
The EME programme supports clinical trials and studies with other robust designs, which test the efficacy of interventions, and which may use
clinical or well-validated surrogate outcomes. It only supports studies in man and where there is adequate proof of concept. The programme
encourages hypothesis-driven mechanistic studies, integrated within the efficacy study, that explore the mechanisms of action of the intervention
or the disease, the cause of differing responses, or improve the understanding of adverse effects. It funds similar mechanistic studies linked to
studies funded by any NIHR programme.
The EME programme is funded by the Medical Research Council (MRC) and the National Institute for Health Research (NIHR), with contributions
from the Chief Scientist Office (CSO) in Scotland and National Institute for Social Care and Health Research (NISCHR) in Wales and the Health
and Social Care Research and Development (HSC R&D), Public Health Agency in Northern Ireland.
This report
The research reported in this issue of the journal was funded by the EME programme as project number 08/52/01. The contractual start date
was in March 2010. The final report began editorial review in March 2018 and was accepted for publication in March 2019. The authors have
been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The EME editors and production
house have tried to ensure the accuracy of the authors’ report and would like to thank the reviewers for their constructive comments on the
final report document. However, they do not accept liability for damages or losses arising from material published in this report.
This report presents independent research. The views and opinions expressed by authors in this publication are those of the authors and do
not necessarily reflect those of the NHS, the NIHR, the MRC, NETSCC, the EME programme or the Department of Health and Social Care. If
there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees
and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the EME programme or the Department of Health
and Social Care.
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Jayne et al. under the terms of a commissioning
contract issued by the Secretary of State for Health and Social Care. This issue may be freely reproduced for the purposes of
private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for
commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation,
Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.
Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland
(www.prepress-projects.co.uk).
NIHR Journals Library Editor-in-Chief
Professor Ken Stein  Professor of Public Health, University of Exeter Medical School, UK
NIHR Journals Library Editors
Professor John Powell  Chair of HTA and EME Editorial Board and Editor-in-Chief of HTA and EME journals. 
Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK, and Honorary Professor, 
University of Manchester, and Senior Clinical Researcher and Associate Professor, Nuffield Department of 
Primary Care Health Sciences, University of Oxford, UK
Professor Andrée Le May  Chair of NIHR Journals Library Editorial Group (HS&DR, PGfAR, PHR journals) and 
Editor-in-Chief of HS&DR, PGfAR, PHR journals
Professor Matthias Beck  Professor of Management, Cork University Business School, Department of Management 
and Marketing, University College Cork, Ireland
Dr Tessa Crilly  Director, Crystal Blue Consulting Ltd, UK
Dr Eugenia Cronin  Senior Scientific Advisor, Wessex Institute, UK
Dr Peter Davidson  Consultant Advisor, Wessex Institute, University of Southampton, UK
Ms Tara Lamont  Director, NIHR Dissemination Centre, UK
Dr Catriona McDaid  Senior Research Fellow, York Trials Unit, Department of Health Sciences, 
University of York, UK 
Professor William McGuire  Professor of Child Health, Hull York Medical School, University of York, UK
Professor Geoffrey Meads  Professor of Wellbeing Research, University of Winchester, UK
Professor John Norrie  Chair in Medical Statistics, University of Edinburgh, UK
Professor James Raftery  Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, 
University of Southampton, UK
Dr Rob Riemsma  Reviews Manager, Kleijnen Systematic Reviews Ltd, UK
Professor Helen Roberts  Professor of Child Health Research, UCL Great Ormond Street Institute of Child Health, UK
Professor Jonathan Ross  Professor of Sexual Health and HIV, University Hospital Birmingham, UK
Professor Helen Snooks  Professor of Health Services Research, Institute of Life Science, College of Medicine, 
Swansea University, UK
Professor Ken Stein  Professor of Public Health, University of Exeter Medical School, UK
Professor Jim Thornton  Professor of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences,  
University of Nottingham, UK
Professor Martin Underwood  Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, UK
Please visit the website for a list of editors: www.journalslibrary.nihr.ac.uk/about/editors
Editorial contact: journals.library@nihr.ac.uk
NIHR Journals Library www.journalslibrary.nihr.ac.uk
Abstract
Robotic-assisted surgery compared with laparoscopic
resection surgery for rectal cancer: the ROLARR RCT
David Jayne,1* Alessio Pigazzi,2 Helen Marshall,3 Julie Croft,3
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Richard Edlin,5 Claire Hulme6 and Julia Brown3
1Academic Surgery, Leeds Institute of Biological and Clinical Sciences, University of Leeds, Leeds, UK
2Department of Surgery, University of California, Irvine, CA, USA
3Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK
4Pathology and Tumour Biology, Leeds Institute of Cancer and Pathology, University of Leeds,
Leeds, UK
5Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand
6Academic Unit of Health Economics, University of Leeds, Leeds, UK
*Corresponding author d.g.jayne@leeds.ac.uk
Background: Robotic rectal cancer surgery is gaining popularity, but there are limited data about its safety
and efficacy.
Objective: To undertake an evaluation of robotic compared with laparoscopic rectal cancer surgery to
determine its safety, efficacy and cost-effectiveness.
Design: This was a multicentre, randomised trial comparing robotic with laparoscopic rectal resection in
patients with rectal adenocarcinoma.
Setting: The study was conducted at 26 sites across 10 countries and involved 40 surgeons.
Participants: The study involved 471 patients with rectal adenocarcinoma. Recruitment took place from
7 January 2011 to 30 September 2014 with final follow-up on 16 June 2015.
Interventions: Robotic and laparoscopic rectal cancer resections were performed by high anterior
resection, low anterior resection or abdominoperineal resection. There were 237 patients randomised to
robotic and 234 to laparoscopic surgery. Follow-up was at 30 days, at 6 months and annually until 3 years
after surgery.
Main outcome measures: The primary outcome was conversion to laparotomy. Secondary end points
included intra- and postoperative complications, pathological outcomes, quality of life (QoL) [measured using
the Short Form questionnaire-36 items version 2 (SF-36v2) and the Multidimensional Fatigue Inventory-20
(MFI-20)], bladder and sexual dysfunction [measured using the International Prostatic Symptom Score (I-PSS),
the International Index of Erectile Function (IIEF) and the Female Sexual Function Index (FSFI)], and oncological
outcomes. An economic evaluation considered the costs of robotic and laparoscopic surgery, including
primary and secondary care costs up to 6 months post operation.
Results: Among 471 randomised patients [mean age 64.9 years, standard deviation (SD) 11.0 years;
320 (67.9%) men], 466 (98.9%) patients completed the study. Data were analysed on an intention-to-treat
basis. The overall rate of conversion to laparotomy was 10.1% and occurred in 19 (8.1%) patients in the
robotic-assisted group and in 28 (12.2%) patients in the conventional laparoscopic group {unadjusted risk
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difference 4.12% [95% confidence interval (CI) –1.35% to 9.59%], adjusted odds ratio 0.61 [95% CI 0.31
to –1.21]; p = 0.16}. Of the nine prespecified secondary end points, including circumferential resection
margin positivity, intraoperative complications, postoperative complications, plane of surgery, 30-day
mortality and bladder and sexual dysfunction, none showed a statistically significant difference between the
groups. No difference between the treatment groups was observed for longer-term outcomes, disease-free
and overall survival (OS). Males were at a greater risk of local recurrence than females and had worse OS
rates. The costs of robotic and laparoscopic surgery, excluding capital costs, were £11,853 (SD £2940) and
£10,874 (SD £2676) respectively.
Conclusions: There is insufficient evidence to conclude that robotic rectal surgery compared with
laparoscopic rectal surgery reduces the risk of conversion to laparotomy. There were no statistically
significant differences in resection margin positivity, complication rates or QoL at 6 months between the
treatment groups. Robotic rectal cancer surgery was on average £980 more expensive than laparoscopic
surgery, even when the acquisition and maintenance costs for the robot were excluded.
Future work: The lower rate of conversion to laparotomy in males undergoing robotic rectal cancer surgery
deserves further investigation. The introduction of new robotic systems into the market may alter the
cost-effectiveness of robotic rectal cancer surgery.
Trial registration: Current Controlled Trials ISRCTN80500123.
Funding: This project was funded by the Efficacy and Mechanism Evaluation (EME) programme, a Medical
Research Council and National Institute for Health Research (NIHR) partnership, with contributions from
the Chief Scientist Office, Scottish Government Health and Social Care Directorate, the Health and Care
Research Wales and the Health and Social Care Research and Development Division, Public Health Agency
in Northern Ireland. The funders of the study had no role in the design and conduct of the study; collection,
management, analysis and interpretation of the data; and preparation, review or approval of the manuscript
or the decision to submit for publication. The project will be published in full in Efficacy and Mechanism
Evaluation; Vol. 6, No. 10. See the NIHR Journals Library website for further project information. Philip Quirke
and Nicholas West were supported by Yorkshire Cancer Research Campaign and the MRC Bioinformatics
initiative. David Jayne was supported by a NIHR Research Professorship.
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Robotic systems are being used to remove cancers of the rectum (back passage), but there is littleevidence that they produce better results than standard laparoscopic (keyhole) surgery. The aim of the
ROLARR study was to perform a thorough investigation of the benefits of robotic rectal cancer surgery,
comparing it with laparoscopic rectal cancer surgery.
A total of 471 patients with rectal cancer, from 26 hospitals in 10 countries, were allocated at random to
undergo either robotic or laparoscopic surgery. Data were collected at 30 days, at 6 months and annually
until 3 years following surgery.
There was no significant difference in the numbers of patients who required conversion to an open
operation, involving a large cut on the abdomen, to complete their surgery between the robotic (8.1%)
and laparoscopic (12.2%) treatments. Male patients undergoing robotic surgery were less likely to need an
open operation. Similarly, there were no differences in surgical complications, bladder and sexual function,
and quality of life between the robotic and laparoscopic surgery. Robotic surgery produced similar results
to laparoscopic surgery in treating rectal cancer. Overall, males were more at risk of the cancer coming
back. Robotic operations were £980 more expensive than laparoscopic operations because the surgery
took longer and the robotic instruments were more expensive.
We conclude that robotic surgery does not reduce the need to perform open surgery in a small number of
patients with rectal cancer. Robotic surgery is more expensive than laparoscopic surgery, with no obvious
benefits for patients in the short or long term.
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Total mesorectal excision is the standard of care in rectal cancer surgery, involving complete removal of the
tumour along with the draining lymphatics within an intact mesorectal envelope. The feasibility and safety
of laparoscopic surgery have been established for colon cancer, but the case for rectal cancer is less clear.
At the time of the study’s design in 2010, the MRC CLASICC trial [Guillou PJ, Quirke P, Thorpe H, Walker J,
Jayne DG, Smith AM, et al. Short-term endpoints of conventional versus laparoscopic-assisted surgery in
patients with colorectal cancer (MRC CLASICC trial): multicentre, randomised controlled trial. Lancet
2005;365:1718–26] was the only randomised study, to our knowledge, to include an evaluation of
laparoscopic compared with open rectal cancer surgery. Concern was expressed about the higher rate of
circumferential resection margin (CRM) involvement in the laparoscopic group (12.4%) than in the open
group (6.3%) for patients undergoing anterior resection. This, however, did not translate into a difference
in local recurrence at either 3-year follow-up or 5-year follow-up. The difference in CRM involvement was
felt to reflect the increased technical difficulties associated with the laparoscopic technique in the rectal
cancer group.
Since completion of the CLASICC trial, the COLOR II [van der Pas MH, Haglind E, Cuesta MA, Fürst A,
Lacy AM, Hop WC, Bonjer HJ, COlorectal cancer Laparoscopic or Open Resection II (COLOR II) Study Group.
Laparoscopic versus open surgery for rectal cancer (COLOR II): short-term outcomes of a randomised,
phase 3 trial. Lancet Oncol 2013;14:210–18] and COREAN studies [Kang SB, Park JW, Jeong SY, Nam BH,
Choi HS, Kim DW, et al. Open versus laparoscopic surgery for mid or low rectal cancer after neoadjuvant
chemoradiotherapy (COREAN trial): short-term outcomes of an open-label randomised controlled trial.
Lancet Oncol 2010;11:637–45] compared laparoscopic with open surgery for rectal cancer. Both studies
reported better short-term outcomes following laparoscopic rectal cancer resection than open surgery,
and similar pathological outcomes compared with open surgery. In contrast, there have been two large
randomised trials, AlaCarte (Stevenson AR, Solomon MJ, Lumley JW, Hewett P, Clouston AD, Gebski VJ,
et al. Effect of laparoscopic-assisted resection vs open resection on pathological outcomes in rectal cancer:
the ALaCaRT randomized clinical trial. JAMA 2015;314:1356–63) and ACOSOG (Fleshman J, Branda M,
Sargent DJ, Boller AM, George V, Abbas M, et al. Effect of laparoscopic-assisted resection vs open resection
of stage II or III Rectal Cancer on Pathologic Outcomes: the ACOSOG Z6051 randomized clinical trial.
JAMA 2015;314:1346–55), that have cast doubt on the benefits of laparoscopic compared with open rectal
cancer surgery.
Robotic-assisted laparoscopic surgery was introduced with the promise to eliminate many of the technical
difficulties inherent in laparoscopic surgery, providing intuitive manipulation of the laparoscopic instruments
with 7 degrees of freedom of movement, a three-dimensional field of view, a stable camera platform with
zoom magnification, dexterity enhancement and an ergonomic operating environment.
There have been numerous reports from single centres, analyses of national databases and several
systematic reviews and meta-analyses, but no large randomised comparison with laparoscopic or open
rectal cancer surgery. Results from the meta-analyses tell a broadly similar story, with no clear advantage
of robotic over laparoscopic surgery in terms of short-term outcomes, with the exception of lower
conversion rates and a suggestion of improved postoperative bladder and sexual function. The main
disadvantage of robotic, compared with laparoscopic, surgery is the increased hospital costs.
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Objectives
The purpose of the trial was to perform a rigorous evaluation of robotic-assisted rectal cancer surgery
compared with laparoscopic rectal cancer surgery by means of a randomised controlled trial. The key
short-term outcomes included assessment of technical ease of the operation, as determined by the
clinical indicator of low conversion rate to open operation, and clear pathological resection margins
as an indicator of surgical accuracy and improved oncological outcome. In addition, quality-of-life (QoL)
assessment and analysis of cost-effectiveness were performed. Longer-term outcomes concentrated
on oncological aspects of the surgery with analysis of disease-free survival (DFS) and overall survival (OS)
and local recurrence rates at the 3-year follow-up.
Methods
The ROLARR trial was an international, multicentre, prospective, randomised, controlled, unblinded,
parallel-group trial comparing robotic-assisted versus laparoscopic surgery for the curative treatment of
rectal cancer. Participating surgeons had to have previously performed a minimum of 30 minimally invasive
(laparoscopic or robotic) rectal cancer resections (at least 10 laparoscopic and at least 10 robotic). The trial
received national ethics approval in the UK and either ethics committee approval or institutional review
board (IRB) approval as required at the location of each of the international centres; all participants gave
written informed consent.
Patients were eligible if they were aged ≥ 18 years with a diagnosis of rectal adenocarcinoma amenable to
curative surgery by low anterior resection, high anterior resection (HAR) or abdominoperineal resection
(APR). Patients had to be suitable and fit for robotic-assisted or standard laparoscopic rectal resection.
Exclusion criteria included locally advanced cancers not amenable to curative surgery or requiring en bloc
multivisceral resection, synchronous colorectal tumours, coexistent inflammatory bowel disease, malignancy
within the past 5 years, or pregnancy.
Preoperative investigation and preparation was as per institutional protocol. Laparoscopic mesorectal
resection was performed in accordance with each surgeon’s usual practice. Robotic surgery involved either
a totally robotic approach or a hybrid approach; the only absolute requirement was that the robot had to
be used for mesorectal resection. The specifics of each operation were at the discretion of the operating
surgeon, as was the decision to convert to an open operation. Detailed guidance was provided to ensure
consistent histopathological analysis and reporting of the rectal dissection specimens according to
internationally agreed criteria. Digital photographs of the specimen and sequential cross-sectional views
were collected to allow blinded assessment of the quality of the plane of surgery. To enable a central
pathology review, the tissue slides (or high-quality digital slide images) were submitted.
Postoperative care was as per institutional protocol; however, the protocol required that patients underwent
a clinical assessment at 30 days and at 6 months post operation. Follow-up data were collected on an
annual basis until the last participant reached 3 years post randomisation.
Participants completed questionnaires prior to randomisation (baseline) and at 30 days and at 6 months
postoperatively. General QoL [Short Form questionnaire-36 items version 2 (SF-36v2)] and fatigue
[Multidimensional Fatigue Inventory-20 (MFI-20)] data were collected at baseline and at 30 days and
at 6 months postoperatively. In addition, patient-reported bladder and sexual function questionnaires
[International Prostatic Symptom Score (I-PSS) and International Index of Erectile Function/ Female Sexual
Function Index (IIEF/FSFI)] were completed at baseline and at 6 months post operation. Participants in the
UK and USA also completed the EuroQol-5 Dimensions (EQ-5D) at baseline, at 30 days and at 6 months
post operation, and a resource utilisation questionnaire at 30 days and at 6 months post operation for the
health economic component of the trial.
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Results
Between 7 January 2011 and 30 September 2014, 1276 patients were assessed for eligibility by 40 surgeons
from 26 sites across 10 countries (i.e. UK, Italy, Denmark, USA, Finland, South Korea, Germany, France,
Australia and Singapore). The numbers of patients recruited in each country (together with the number of
sites in the country) were as follows: UK, n = 131 (6); Italy, n = 105 (5); Denmark, n = 92 (3); USA, n = 59 (9);
Finland, n = 35 (1); South Korea, n = 18 (1); Germany, n = 16 (1); France, n = 11 (1); Australia, n = 2 (1);
and Singapore, n = 2 (1). Four hundred and seventy-one (36.9%) of these patients were randomised:
234 to laparoscopic and 237 to robotic surgery. From this group, 466 patients underwent an operation,
with 456 (97.9%) undergoing the allocated treatment. The final follow-up date was 16 June 2015.
The two treatment groups were well balanced with respect to baseline characteristics and operative
procedures. On average, patients received an operation performed by a surgeon with experience of around
a median of 91 [interquartile range (IQR) 45–180] previous laparoscopic and a median of 50 (IQR 30–101)
previous robotic operations.
The rate of conversion to open surgery was 47 out of 466 (10.1%) patients overall, 28 out of 230 (12.2%)
in the laparoscopic group and 19 out of 236 (8.1%) in the robotic group (unadjusted difference in
proportions 4.12%, 95% CI –1.35% to 9.59%). There was no statistically significant difference between
robotic surgery and conventional laparoscopic surgery with respect to odds of conversion [adjusted odds
ratio (OR) 0.614, 95% CI 0.311 to 1.211; p = 0.16].
Of the 466 patients who had an operation, 459 (98.5%) had complete pathology data available. Furthermore,
26 out of 459 (5.7%) patients had a positive CRM: 14 out of 224 (6.25%) in the laparoscopic group and
12 out of 235 (5.11%) in the robotic group (unadjusted difference in proportions 1.14%, 95% CI –3.10%
to 5.38%). There was no statistically significant difference in the odds of CRM positivity between the groups
(adjusted OR 0.785, 95% CI 0.350 to 1.762; p = 0.56).
There were 70 out of 466 (15.0%) patients who had an intraoperative complication, 34 out of 230 (14.8%)
in the laparoscopic group and 36 out of 236 (15.3%) in the robotic group (unadjusted risk difference –0.5%,
95% CI –6.0% to 7.0%). There was no significant difference between the groups (adjusted OR 1.020,
95% CI 0.599 to 1.736; p = 0.94). There was a significant difference in the odds of having an intraoperative
complication between males and females (adjusted OR 3.083, 95% CI 1.543 to 6.158; p = 0.0015).
There were 151 out of 466 (32.4%) patients who had a postoperative complication within 30 days of their
operation, 73 out of 230 (31.7%) in the laparoscopic group and 78 out of 236 (33.1%) in the robotic
group (unadjusted risk difference –1.3%, 95% CI –9.8% to 7.2%). There was no significant difference
between the treatment groups (adjusted OR 1.043, 95% CI 0.689 to 1.581; p = 0.84). There was a
significant difference in the odds of having a postoperative complication within 30 days of operation
between males and females (adjusted OR 3.083, 95% CI 1.573 to 4.183; p = 0.0002).
There were 72 out of 466 (15.5%) patients who had a postoperative complication after 30 days and within
6 months of their operation, 38 out of 230 (16.5%) in the laparoscopic group and 34 out of 236 (14.4%)
in the robotic group (unadjusted risk difference 2.1%, 95% CI –4.5% to 8.7%). There was no significant
difference between the groups (adjusted OR 0.719, 95% CI 0.411 to 1.258; p = 0.25).
Bladder function scores, as measured by the I-PSS, were similar between the groups at baseline and at
6 months. The adjusted estimated difference in mean I-PSS (robotic minus standard) was –0.7426 (95% CI
–2.0722 to 0.5870; p = 0.2726). The estimated difference in mean I-PSS between patients with a difference
in baseline score of 10 points, all else being equal, was 4.20 (95% CI 3.23 to 5.17; p < 0.0001).
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The distribution of sexual function scores, as measured by the IIEF, was very similar between the treatment
groups at baseline and at 6 months. Median IIEF scores at 6 months were notably lower than at baseline in
both groups; the estimated difference in mean IIEF (robotic minus standard) was –0.8020 (95% CI –5.7039
to 4.1000; p = 0.7468).
The female sexual function score, as measured by the FSFI, at baseline was marginally lower in the robotic
group. The distribution of scores was very similar between the treatment groups at 6 months; the estimated
difference in mean FSFI (robotic minus standard) was –1.2309 (95% CI –6.0030 to 3.5413; p = 0.6010).
Patient-reported generic health was measured using the SF-36v2, providing a physical component score
(PCS) and a mental component score (MCS). The baseline PCS and MCS were similar in the two treatment
groups at all time points. At the 6-month follow-up, the adjusted estimated difference in mean PCS between
the groups (robotic vs. laparoscopic) was –0.1220 (95% CI –1.6281 to 1.3840; p = 0.8737). The adjusted
estimated difference in MCS between the groups (robotic vs. laparoscopic) was –0.4875 (95% CI –2.6008 to
1.6258; p = 0.6508).
The Multidimensional Fatigue Inventory is a self-report instrument consisting of five scales of fatigue:
general fatigue, physical fatigue, reduced activity, reduced motivation and mental fatigue. The distribution
of scores was similar between the two treatment groups at all time points for all five scales. At the
6-month follow-up, the estimated adjusted difference in mean general fatigue between the groups
(robotic vs. laparoscopic) was –0.2517 (95% CI –0.5965 to 1.0999; p = 0.5603), the difference in physical
fatigue was 0.3964 (95% CI –0.4404 to 1.2332; p = 0.3527), the difference in reduced activity was
–0.1634 (95% CI –0.9777 to 0.6510; p = 0.6938), the difference in reduced motivation was –0.03917
(95% CI –0.7324 to 0.6540; p = 0.9117) and the difference in mental fatigue was 0.1374 (95% CI
–0.6626 to 0.9374; p = 0.7360).
A total of 351 out of 456 (77.0%) patients’ specimens were graded by pathological assessment of the plane
of surgery. There were 178 out of 233 (76.4%) in the laparoscopic group and 173 out of 223 (77.6%) in
the robotic group who had best-quality surgery (mesorectal plane) (unadjusted risk difference 1.2%, 95% CI
–6.5% to 8.9%). There was no significant difference of the odds of a mesorectal plane surgery between the
groups (adjusted OR 0.943, 95% CI 0.565 to 1.572; p = 0.821).
Local recurrence was observed in 30 out of 471 (6.4%) patients, 14 out of 234 (6.0%) in the laparoscopic
group and 16 out of 237 (6.8%) in the robotic group. There was no difference between the treatment
groups in local recurrence rates at the 3-year follow-up; the estimated difference in cumulative incidence
of local recurrence was 0.002 (95% CI –0.041 to 0.046). There was a difference in the probability of local
recurrence between males and females, with males being more likely to experience local recurrence
[adjusted hazard ratio (HR) 3.184, 95% CI 1.109 to 9.174; p = 0.031].
No difference was observed between the treatment groups in DFS at the 3-year follow-up, estimated
adjusted HR (robotic vs. laparoscopic) of 1.030 (95% CI 0.713 to 1.489; p = 0.874). Disease recurrence
was more common following APR and least common following HAR.
Death was observed for 46 out of 471 (9.8%) patients, 23 out of 234 (9.8%) in the laparoscopic group
and 23 out of 237 (9.7%) in the robotic group, estimated HR (robotic vs. laparoscopic) 0.945 (95% CI
0.530 to 1.686; p = 0.848). Males were 2.187 (95% CI 1.017 to 4.700; p = 0.045) times more likely to die
than females at 3 years’ follow-up.
Quality-of-life scores were very similar between the treatment groups, with a difference in favour of
robotic surgery of 0.013 quality-adjusted life-years (QALYs) at 6 months’ follow-up. The overall cost
difference was £980, with higher costs associated with robotic surgery, driven by longer operating times
and higher instrument costs. The estimated incremental cost-effectiveness ratio (ICER) for robotic surgery
was £69,837 per QALY, which is well in excess of the standard threshold of £20,000–30,000 per QALY.
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Conclusions
Robotic rectal cancer surgery results in comparable outcomes to laparoscopic surgery. There is no statistical
benefit in terms of conversion to open surgery, bladder or sexual function, pathological outcomes, or DFS and
OS. The observed trend to reduced conversion in male patients requires further confirmation. Robotic rectal
cancer surgery is not cost-effective compared with laparoscopic rectal cancer surgery because the increased
costs far outweigh any marginal benefit in QoL.
Trial registration
This trial is registered as ISRCTN80500123.
Funding
This project was funded by the Efficacy and Mechanism Evaluation (EME) programme, a Medical Research
Council and National Institute for Health Research (NIHR) partnership, with contributions from the Chief
Scientist Office, Scottish Government Health and Social Care Directorate, the Health and Care Research Wales
and the Health and Social Care Research and Development Division, Public Health Agency in Northern Ireland.
The funders of the study had no role in the design and conduct of the study; collection, management, analysis
and interpretation of the data; and preparation, review or approval of the manuscript or the decision to submit
for publication. Philip Quirke and Nicholas West were supported by Yorkshire Cancer Research Campaign
and the MRC Bioinformatics initiative. David Jayne was supported by a NIHR Research Professorship.
DOI: 10.3310/eme06100 EFFICACY AND MECHANISM EVALUATION 2019 VOL. 6 NO. 10
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Jayne et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science




Total mesorectal excision (TME) is the standard of care in rectal cancer surgery, involving completeremoval of the tumour along with the draining lymphatics within an intact mesorectal envelope.1
The feasibility and safety of laparoscopic surgery has been established for colon cancer.2–4 The case for
rectal cancer is less clear, and, of the reported multicentre trials at the time of study design in 2010, only
the MRC CLASICC trial included an evaluation of laparoscopic rectal cancer surgery compared with open
rectal cancer surgery.5 Although both laparoscopic and open rectal cancer resection were associated
with similar lymph node yields, concern was expressed at the higher rate of circumferential resection
margin (CRM) involvement in the laparoscopic group (12.4%) than in the open group (6.3%) for patients
undergoing anterior resection (AR). This, however, did not translate into a difference in local recurrence
at either 3-year2 or 5-year follow-up.6 The difference in CRM involvement was felt to reflect the increased
technical difficulties associated with the laparoscopic technique in the rectal cancer subgroup. This was
supported by the higher conversion rate in the laparoscopic rectal subgroup (34%) than the laparoscopic
colon subgroup (25%).5 Analysis of CLASICC data revealed higher morbidity and mortality rates associated
with laparoscopic cases converted to open operation. Some of this increased morbidity may be related to
more advanced cancers requiring conversion, but a proportion of it will inevitably have resulted from the
increased operative time, increased technical difficulty and the need for a laparotomy wound in converted cases.
Since completion of the CLASICC trial, there have been several other large studies comparing laparoscopic
with open surgery for rectal cancer. A large European randomised controlled trial, COLOR II, recruited
1103 participants to a non-inferiority study involving 30 centres in eight countries.7 Laparoscopic surgery
was reported to be advantageous in terms of short-term outcomes (quicker return of bowel function,
reduced hospital stay), with similar morbidity and pathological outcomes to open surgery. The 3-year
results from the same study were reported in 2015 and showed similar rates of locoregional recurrence
and disease-free survival (DFS) and overall survival (OS) in both the laparoscopic and the open groups.8
These findings were echoed by the results of the COREAN trial, which again reported better short-term
outcomes following laparoscopic rectal cancer resection and similar pathological outcomes compared with
open surgery.9
In contrast, there have been two large randomised trials, ALaCaRT10 and ACOSOG,11 that have cast doubt
on the benefits of laparoscopic rectal cancer surgery compared with open rectal cancer surgery. Both were
non-inferiority studies and both used a novel composite primary outcome combining rates of negative
circumferential and distal cancer margins with completeness of mesorectal excision as a measure of
oncological clearance. Both studies failed to demonstrate the non-inferiority of the laparoscopic compared
with the open surgery approach, concluding that the evidence was not sufficient to support the routine
use of the laparoscopic technique.
Robotic-assisted laparoscopic surgery was introduced into clinical practice in the early 1990s with the
promise to eliminate many of the technical difficulties inherent in laparoscopic surgery. The technical
advantages associated with robotic-assisted surgery include intuitive manipulation of the laparoscopic
instruments with 7 degrees of freedom of movement, a three-dimensional field of view, a stable camera
platform with zoom magnification, dexterity enhancement and an ergonomic operating environment.
The feasibility of robotics for TME rectal cancer resection was established by Pigazzi et al. in a series of six low
rectal cancers.12 A subsequent follow-up study of 39 rectal cancers treated prospectively by robotic-assisted
resection reported a zero rate of conversion with a mortality of 0% and morbidity of 12.8%.13 The only
randomised trial at the time of design of the ROLARR study compared 18 patients assigned to robotic-assisted
resection with 18 patients assigned to standard laparoscopic resection.14 No difference was observed in the
operative times, the conversion rates (two laparoscopic, zero robotic), or the quality of mesorectal resection.
The only difference was the length of hospital stay, which was significantly shorter following robotic-assisted
laparoscopic surgery (robotic assisted: 6.9 ± 1.3 days; standard laparoscopic: 8.7 ± 1.3 days; p < 0.001) and
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attributed by the authors to a reduction in surgical trauma. Since the commencement of the ROLARR trial,
there have been numerous reports from single centres, analyses of national databases,15 and several
systematic reviews and meta-analyses,16–18 but no large randomised comparison with laparoscopic or open
rectal cancer surgery. Results from the meta-analyses tell a broadly similar story, with no clear advantage for
robotic over laparoscopic surgery in terms of short-term outcomes, with the exception of lower conversion
rates and a suggestion of improved postoperative bladder and sexual function.19 The disadvantage of
robotic surgery, compared with laparoscopic surgery, appears to be the longer operating times and perhaps
an increase in operative blood loss. Importantly, the hospital costs associated with the use of the robot are
higher, which has fuelled the ongoing debate about whether or not robotic-assisted rectal cancer surgery
can be justified in the absence of clear patient benefits and considering its higher hospital costs.15,20,21
The ROLARR trial was designed with the above concerns in mind and with the primary objective to evaluate
the short-term safety and efficacy of robotic-assisted surgery compared with laparoscopic surgery for rectal
cancer resection. The primary end point chosen was conversion to open surgery, on the basis that if the
robot offered a technical advantage over laparoscopic surgery it should be reflected in a reduced conversion
rate. Secondary end points were chosen to reflect the oncological nature of the investigation and the
compelling need for rigorous patient-reported outcomes and cost-effectiveness evaluation.
INTRODUCTION




The purpose of the trial was to perform a rigorous evaluation of robotic-assisted rectal cancer surgery by
means of a randomised controlled trial. The chosen comparator was standard laparoscopic rectal cancer
resection, which is essentially the same procedure but without the use of the robotic device. The two
operative interventions were evaluated for short- and longer-term outcomes. The key short-term outcomes
included assessment of technical ease of the operation, as determined by the clinical indicator of low
conversion rate to open operation, and clear pathological resection margins as an indicator of surgical
accuracy and improved oncological outcome. In addition, quality-of-life (QoL) assessment and analysis of
cost-effectiveness were performed to aid evidence-based knowledge to inform the NHS and other service
providers and decision-makers. The short-term outcomes were analysed after the last randomised patient
had had 6 months of follow-up, to provide a timely assessment of the new technology, and were made
available to the public, clinicians and health-care providers to inform health-care decision-making. Longer-
term outcomes concentrated on oncological aspects of the disease and its surgical treatment with analysis
of DFS, OS and local recurrence rates at 3 years’ follow-up.
Trial design
The ROLARR trial was an international, multicentre, prospective, unblinded, parallel-group randomised
controlled trial22 comparing robotic-assisted with laparoscopic surgery for the curative treatment of rectal
cancer (defined as an adenocarcinoma whose distal extent was situated at or within 15 cm of the anal
margin) by low anterior resection (LAR), high anterior resection (HAR) or abdominoperineal resection (APR).
The trial design required that each participating surgeon had performed a minimum of 30 minimally invasive
(laparoscopic or robotic) rectal cancer resections (at least 10 laparoscopic and at least 10 robotic). The trial
received national ethics approval in the UK and either ethics committee or institutional review board (IRB)
approval as was required at the location of each of the international centres; all participants gave written
informed consent. The trial conduct was overseen by an independent Trial Steering Committee (TSC) and
Data Monitoring and Ethics Committee (DMEC). The trial was registered on the International Standard
Randomised Controlled Trial Number (ISRCTN) register (ISRCTN80500123).
Participants
The inclusion criteria were:
1. Aged ≥ 18 years.
2. Able to provide written informed consent.
3. Diagnosis of rectal cancer (defined as an adenocarcinoma for which distal extent is situated at or within
15 cm of the anal margin, as assessed by endoscopic examination or radiological contrast study) amenable
to curative surgery by LAR, HAR or APR, for example, staged T1–3, N0–2, M0 by imaging as per local
practice. Although not mandated, computed tomography (CT) imaging with either additional magnetic
resonance imaging (MRI) or transrectal ultrasound is recommended to assess distant and local disease.
4. Rectal cancer suitable for resection by either standard laparoscopic procedure or robotic-assisted
laparoscopic procedure.
5. Fit for robotic-assisted or standard laparoscopic rectal resection.
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6. An American Society of Anesthesiologists (ASA) physical status of ≤ 3.
7. Capable of completing required questionnaires at time of consent (provided questionnaires were
available in a language spoken fluently by the participant).
The exclusion criteria were:
1. benign lesions of the rectum
2. benign or malignant diseases of the anal canal
3. locally advanced cancers not amenable to curative surgery
4. locally advanced cancers requiring en bloc multivisceral resection
5. synchronous colorectal tumours requiring multisegment surgical resection (a benign lesion within the
resection field in addition to the main cancer would not exclude a patient)
6. coexistent inflammatory bowel disease
7. clinical or radiological evidence of metastatic spread
8. concurrent or previous diagnosis of invasive cancer within 5 years that could confuse diagnosis
(non-melanomatous skin cancer or superficial bladder cancer treated with curative intent were
acceptable; other cases were individually discussed with the chief investigator)
9. history of psychiatric or addictive disorder or other medical condition that in the opinion of the
investigator would preclude the patient from meeting the trial requirements
10. pregnancy
11. participation in another rectal cancer clinical trial relating to surgical technique.
Preoperative investigation and preparation was as per institutional protocol. Laparoscopic mesorectal
resection was performed in accordance with each surgeon’s usual practice. Robotic surgery involved either
a totally robotic approach or a hybrid approach; the only absolute requirement was that the robot had
to be used for mesorectal resection. For the purposes of the trial, a totally robotic operation was defined
as a resection of the entire surgical specimen with the use of robotic assistance. A hybrid operation was
defined as use of laparoscopic techniques to mobilise the proximal colon, with robotic assistance employed
to perform the rectal mesorectal dissection. It was permissible to perform a partial mesorectal excision with
a suitable distal margin, rather than a TME.
The specifics of each operation were at the discretion of the operating surgeon (e.g. port-site placement,
mobilisation of the splenic flexure, inferior mesenteric artery/vein division, high vs. low vascular division,
etc.), as was the decision to convert to an open operation. Detailed guidance was provided to ensure
consistent histopathological analysis and reporting of the rectal dissection specimens in accordance with
internationally agreed criteria.23 Digital photographs of the anterior and posterior of the specimen and
sequential cross-sectional views of the surgical specimen, as well as close-ups of the front and back of the
levator/anal sphincter (if appropriate), were collected (prior to dissection) to allow blinded assessment of
the quality of the plane of surgery. To enable a central pathology review, the tissue slides (or high-quality
digital slide images) were submitted.
Postoperative care was as per institutional protocol; however, the protocol required that patients underwent
a clinical assessment at 30 days and at 6 months post operation. Any further visits were in accordance with
local standard clinical practice. Follow-up data were collected on an annual basis until the last participant
reached 3 years post randomisation.
Participants completed questionnaires prior to randomisation (baseline), and at 30 days and 6 months
postoperatively. General QoL [Short Form questionnaire-36 items version 2 (SF-36v2)] and fatigue
[Multidimensional Fatigue Inventory-20 (MFI-20)] data were collected at baseline and at the 30-day and
6-month postoperative visits. In addition, bladder and sexual function questionnaires [International
Prostatic Symptom Score (I-PSS) and International Index of Erectile Function/Female Sexual Function Index
(IIEF/FSFI)] were completed by patients at baseline and at 6 months post operation. Participants in the UK
and USA also completed the EuroQol-5 Dimensions (EQ-5D) at baseline and at 30 days and at 6 months
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post operation, and a resource utilisation questionnaire at 30 days and at 6 months post operation for the
health economic component of the trial.
The SF-36v2,24 a well-validated, multipurpose standard health-related QoL evaluation questionnaire, was
used to assess generic QoL. It generates an eight-scale profile of functional health and well-being scores,
as well as summary measures of physical and mental health. This information related to the previous
4-week time period.
The MFI-20 was used to assess fatigue;25 it is a 20-item self-report validated instrument designed to
measure current fatigue. It creates a global score as well as individual scale scores that cover the following
dimensions: general fatigue, physical fatigue, reduced activity, reduced motivation and mental fatigue.
The I-PSS26 was used to assess bladder function. This questionnaire includes seven questions relating to
lower urinary tract function, which form an overall symptom score that can be used to classify bladder
dysfunction as mild, moderate or severe. To assess sexual function, the IIEF27 and FSFI28 were used. Both
are brief male-/female-specific questionnaires developed to assess various domains of sexual function.
The IIEF, FSFI and I-PSS questionnaires obtained information relating to the patient’s functioning over the
previous 4 weeks.
For the health economic analysis, the EQ-5D questionnaire was used to assess self-reported utility. This is a
standardised non-disease-specific instrument that describes and values health-related QoL and provides a
single index value for a number of different health states. In addition, the resource utilisation questionnaire
collected information on community-based medical resource usage [e.g. general practitioners (GPs), nurses,
physiotherapists/occupational therapists, outpatients and medications]. Please refer to Appendix 12 for a
summary of protocol changes.
End points
Primary end point
Rate of intraoperative conversion to open surgery
Conversion to open surgery was defined as the use of a laparotomy wound for any part of the mesorectal
dissection. The use of a small abdominal wound to facilitate a low, stapled anastomosis and/or specimen
extraction was permissible and not considered as a conversion to open surgery. The decision to convert to
an open operation was at the discretion of the operating surgeon. Details relating to the planned and
actual operation were collected on the baseline and operative case report forms (CRFs).
Key secondary end points
Pathological circumferential resection margin positivity
Pathological circumferential resection margin positivity (CRM+) was defined as a distance of ≤ 1 mm of the
cancer from the CRM as recorded on the local histopathology review.
Three-year local recurrence
Local recurrence was defined as evidence of locoregional disease within the surgical field. Time to local
recurrence was calculated from the date of randomisation to the date of local recurrence, defined as the
date of the relevant assessment (i.e. clinical, radiological and pathological) that first detected the local
recurrence.
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Further secondary end points
Intraoperative complications
Defined as adverse events occurring during surgery related to the surgical or related procedures
(e.g. anaesthetic).
Thirty-day postoperative complications
Defined as an adverse event occurring during the first 30 days postoperatively and related to surgery or
related procedures (e.g. anaesthetic).
Six-month postoperative complications (after 30 days)
Defined as an adverse event occurring during the first 6 months (after 30 days) postoperatively and related
to surgery or related procedures (e.g. anaesthetic).
Thirty-day postoperative mortality
Defined as death from any cause within 30 days postoperatively.
Patient self-reported bladder function
Assessed by the patient self-reported I-PSS.
Patient self-reported sexual function
Assessed in males by the patient self-reported IIEF questionnaire and in females by the patient self-reported
FSFI questionnaire.
Patient self-reported generic health
Assessed by the patient self-reported SF-36v2 questionnaire.
Patient self-reported fatigue
Assessed by the patient self-reported MFI-20 questionnaire.
Quality of the plane of surgery
Defined by the grading criteria using the local histological review. For an AR there was only one criterion:
the quality of the mesorectum. For APR, the quality of the plane of surgery was assessed by the grade for
the mesorectum and a second grade for the anorectal dissection below the levators. The quality of resection
of the mesorectum was assessed as muscularis propria plane (worst), intramesorectal plane (intermediate)
and mesorectal plane (best). The quality of surgery of the anorectum below the levators was assessed as
intrasphincteric/submucosal plane (worst), sphincteric plane (intermediate) and levator plane (best).
Three-year disease-free survival
Disease-free survival time was defined as the time from date of randomisation to date of death from any
cause, recurrent disease (locoregional or distant recurrence) or occurrence of a second primary cancer.
Three-year overall survival
Overall survival time was calculated from the date of randomisation to the date of death from any cause.
l Health economics evaluation (see Health economic evaluation).
Pathology central review
Local pathology data were used to carry out the analyses. A central blinded review of the local pathology
data for all assessable patients was carried out. The agreement of local pathology and central pathology
with respect to factors feeding into the analyses (e.g. T-staging) was assessed via summaries.
METHODS
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Sample size
Original sample size calculation and justification
The sample size calculation was based on ensuring that sufficient numbers of patients were recruited to
address the primary end point of conversion to open rectal resection. A relative reduction of at least 50%
(in absolute terms, 25% to 12.5% in the robotic-assisted laparoscopic group) was strongly believed to be
achievable and also represented an extremely clinically important difference, not only in terms of outcomes
for health-care providers but also in terms of patient-related outcomes, as it had been shown that patients
who convert during surgery have worse outcomes. Therefore, using a conversion rate of 25% for standard
laparoscopic surgery and a 50% relative reduction to be clinically relevant, with 80% power and a 5%
(two-sided) significance level, 336 patients were required using a two-group continuity corrected chi-squared
test of equal proportions (nQuery Advisor 6.01, Statistical Solutions, Saugus, MA, USA). Therefore, it was
planned to recruit 400 patients (200 per group) to allow for early withdrawals, cross-over, protocol violations
(e.g. benign tumours) and missing follow-up data.
Updated sample size
Recruitment to the original target sample size of 400 patients was completed 5 months earlier than
planned and was under budget. Note that the original sample size of 400 patients aimed to achieve
80% power. Although this is conventionally considered to be sufficient, it is also commonly argued that
90% power is preferable. Given this, coupled with the fact that there was the opportunity to continue
recruitment as a result of reaching the target of 400 patients early and under budget, we proposed to
continue to recruit to the ROLARR trial until the date that was originally set to end recruitment. The aim
of recruitment during this period was to recruit as many additional patients as possible to maximise power,
up to a maximum of 520 patients (which, under the original sample size assumptions, would provide 90%
power to detect a difference of at least 12.5% in conversion rates between the groups). This plan was
endorsed by the EME programme, the DMEC and the TSC. This decision to continue recruitment was made
before seeing any data or interim analyses. Consequently, a total of 471 patients had been randomised by
the time the trial closed to recruitment. Under the original sample size assumptions, this provides around
86% power to detect a difference of at least 12.5% in conversion rates between the groups.
Randomisation
Randomisation took place as soon as possible after consent was obtained and after patients had completed
their baseline patient-reported questionnaires (I-PSS, IIEF/FSFI, SF-36v2, MFI-20, EQ-5D). Randomisation
took place as close to the date of surgery as possible. Surgeons were strongly encouraged to consent and
randomise patients within 14 days of the planned surgery date whenever possible.
Following confirmation of written informed consent and eligibility, patients were randomised into the trial
by authorised members of staff at the trial sites. Randomisation was performed centrally using the Clinical
Trials Research Unit (CTRU) automated 24-hour telephone randomisation system. Authorisation codes and
personal identification numbers (PINs), provided by the CTRU, were required to access the randomisation
system.
Patients were randomised on a 1 : 1 basis to receive either robotic-assisted or standard laparoscopic rectal
cancer surgery and were allocated a unique trial number. A computer-generated minimisation programme
that incorporated a random element was used, with the following minimisation factors:
l treating surgeon
l patient sex (male or female)
l neo-adjuvant therapy (yes or no)
l nature of intended procedure (HAR, LAR or APR)
DOI: 10.3310/eme06100 EFFICACY AND MECHANISM EVALUATION 2019 VOL. 6 NO. 10
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Jayne et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
7
l body mass index (BMI) [calculated automatically from height (cm) and weight (kg) provided at
randomisation and classified according to World Health Organization (WHO) criteria29]:
¢ underweight/normal
¢ overweight
¢ obese class I
¢ obese class II
¢ obese class III.
Participating research sites were required to complete a log of all patients screened for eligibility who were
not randomised either because they were ineligible or because they declined participation. Anonymised




l reason not eligible for trial participation
l eligible but declined and reason for this
l other reason for non-randomisation.
Blinding
As the two surgical procedures create incisions that can allow the patient to be blinded to the operative
procedure performed, it arguably would have been scientifically preferable to blind patients to their
surgical procedure, particularly in respect of patient-reported outcomes. However, it was anticipated that in
practice maintaining the blind would have been extremely problematic (e.g. in countries such as the USA
where private health-care insurance companies require disclosure of surgery details). Furthermore, it was
anticipated that patients would also be seen by many health-care professionals throughout their time in
the trial, increasing the risk that the blind may be broken. As a consequence, the trial design did not
involve blinding patients to the operative procedure.
It should be noted that the trial end points are mainly objective measures and a central blinded assessment
of these measures was included when possible (e.g. blinded central assessment of the quality of the plane
of surgery).
Statistical methods
Unless otherwise stated, all analyses were prespecified and conducted on the intention-to-treat population
(i.e. all randomised patients were categorised into treatment groups based on their randomisation, regardless
of what treatment they subsequently received). All hypothesis tests were two-sided and conducted at the
5% level of significance. Estimates and their corresponding 95% confidence intervals (CIs) and p-values are
presented for fixed effects. For the (random) surgeon effect, the intracluster correlation coefficient (ICC),
estimated via the analysis-of-variance method, and bias-corrected bootstrapped 95% CIs are reported.
For most end points there was only a small number of missing data, such that a complete-case analysis
was appropriate. For end points with non-negligible numbers of missing data, exploratory analyses were
performed to consider the potential impact of the missing data. All models were fitted using SAS® version 9.4
(SAS Institute Inc., Cary, NC, USA).
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All analyses, unless otherwise stated, adjusted for the minimisation factors only (see Randomisation). For
each end point, sensitivity analyses to include adjustment for treating centre and country were considered;
Subgroup analyses gives further details of this.
Primary end point: conversion to open surgery
The primary analysis was a complete-case analysis. Multilevel logistic regression was used to estimate the
odds ratios (ORs) between treatment groups for conversion to open surgery, adjusting for all minimisation
factors. All minimisation factors were included as fixed effects except intended operating surgeon, which
was included as a random effect. A random intercept model was fitted first, then a model with both a
random intercept and a random slope (i.e. random treatment effect) was fitted (hereafter referred to as
the ‘random slope’ model). The need for the random slope term was assessed via consideration of a
likelihood ratio test and the Akaike information criterion (AIC). The models were fitted using SAS version
9.4 glimmix procedure.
A number of prespecified sensitivity analyses were also performed.
Additional covariates
Fixity of tumour, whether or not the tumour was an obstructing tumour, T-stage or N-stage, whether or
not the patient had abdominal surgery prior to their ROLARR operation and the level of scarring, whether
or not adhesions were identified and whether or not there was a tumour perforation (non-iatrogenic) or
abscess were all considered for inclusion in the model via examination of their effect on the model fit.
Actual operating surgeon
The primary analysis adjusted for the minimisation factors (i.e. the values of those factors that were used
in the minimisation, regardless of whether or not those values were correct). In some cases, patients may
have been allocated treatment under incorrect minimisation factors. In particular, their intended operating
surgeon (used for minimisation) may not have been their actual operating surgeon. A sensitivity analysis
was performed that incorporated actual operating surgeon rather than intended operating surgeon as a
random effect in the model.
Learning effects
For each surgeon, the number of robotic-assisted and laparoscopic rectal operations relevant to the ROLARR
trial performed by that surgeon was collected at regular intervals throughout the trial. From this, the number
of ROLARR-relevant robotic-assisted and laparoscopic operations previously performed by the operating
surgeon before each patient’s operation was derived, assuming that the timings of all counted previous
operations were uniformly distributed across the interval in which they occurred. These patient-level
covariates (‘number of previous robotic operations’ and ‘number of previous laparoscopic operations’)
were included in the multilevel model used in the primary analysis to explore potential associations between
increased numbers of operations and patient outcomes. Interactions between the numbers of operations
performed and the treatment effect were also considered.
Actual operation (post hoc)
The primary analysis adjusted for the minimisation factors (i.e. the values of those factors that were used
in the minimisation, regardless of whether or not those values were correct). In some cases, patients may
have been allocated treatment under incorrect minimisation factors. In particular, their intended procedure
(used for minimisation) may not have been the actual procedure that they received. A sensitivity analysis
was performed that incorporated actual procedure rather than intended procedure as a fixed effect in
the model.
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Key secondary end points
Circumferential resection margin positivity
The analysis of CRM+ was a complete-case analysis. Multilevel logistic regression was used to estimate the
ORs between treatment groups for CRM+, adjusting for all minimisation factors. All minimisation factors
were included as fixed effects except intended operating surgeon, which was included as a random effect.
A random intercept model was fitted first, then a random slope model was fitted and the need for the
random slope term was assessed via consideration of a likelihood ratio test and the AIC. The models were
fitted using SAS version 9.4 glimmix procedure.
A number of prespecified sensitivity analyses were also performed.
Additional covariates
Fixity of tumour, T-stage and N-stage (post neo-adjuvant therapy) and whether or not there was a tumour
perforation (non-iatrogenic)/abscess were all considered for inclusion in the model via examination of their
effect on the model fit.
Three-year local recurrence
All patient follow-up, including follow-up beyond 3 years post randomisation, was incorporated into the
analysis of local recurrence. Time to local recurrence was defined as the time from randomisation to the
date of the relevant assessment (i.e. clinical, radiological and pathological) that first detected the local
recurrence.
Differences in time to local recurrence between the treatment groups were estimated using a shared frailty
model (Cox proportional hazards regression with mixed effects), including intended operating surgeon as a
random effect. The models were fitted using SAS version 9.4 phreg procedure. The 3-year local recurrence
rate was estimated using cumulative incidence functions for time to local recurrence, treating death as a
competing risk.
Patients who were alive and without any local recurrence at the time of analysis were censored at the time
they were last known to be alive and local recurrence free. If patients were lost to follow-up, they were
also censored at the time they were last known to be alive and local recurrence free. Patients who died
without any local recurrence were censored at date of death in analyses estimating treatment effects,
but were classed as having a competing risk event in the analysis estimating incidence of local recurrence
(as calculated using cumulative incidence functions) to avoid overestimation of cumulative incidence.30
In certain non-standard circumstances (prespecified in the statistical analysis plan), patients were censored
at time 0. Patients with non-standard circumstances who were censored at time 0 are summarised, and
reasons are given in the results (see Chapter 3, Disease-free survival).
Further secondary end points
The analyses of further binary secondary end points – intraoperative complications, postoperative complications
within 30 days, after 30 days and within 6 months, and quality of the plane of surgery (i.e. mesorectal plane
Yes/No) – were complete-case analyses. Multilevel logistic regression was used to estimate the ORs between
treatment groups for each end point, adjusting for all minimisation factors. All minimisation factors were
included as fixed effects except intended operating surgeon, which was included as a random effect via a
random intercept term. The models were fitted using SAS version 9.4 glimmix procedure.
For further continuous secondary end points [bladder function (I-PSS), sexual function in males (IIEF) and
in females (FSFI), generic health-related QoL (SF-36v2) and fatigue (MFI-20)], multilevel generalised linear
models were used to estimate the mean difference between treatment groups, adjusting for all minimisation
factors and the baseline score. All minimisation factors were included as fixed effects except intended
operating surgeon, which was included as a random effect via a random intercept term. The I-PSS, IIEF and
FSFI were modelled using a two-level model: patients nested within surgeon. The SF-36v2 questionnaire and
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MFI-20 were modelled using a three-level model: repeated assessments within patient within surgeon.
The models were fitted using the SAS version 9.4 glimmix procedure.
All patient follow-up, including follow-up beyond 3 years post randomisation, was incorporated into the
analysis of DFS and OS. For DFS and OS, shared frailty models were used to estimate the hazard ratios
(HRs) between treatment groups, adjusting for all minimisation factors. All minimisation factors were
included as fixed effects except intended operating surgeon, which was included as a random effect via a
random intercept term. In certain non-standard circumstances (prespecified in the statistical analysis plan),
patients were censored at time 0. Patients with non-standard circumstances who were censored at time 0
are summarised and reasons are given in the results (see Chapter 3, Disease-free survival). The models
were fitted using SAS version 9.4 phreg procedure.
Subgroup analyses
Subgroup analyses relating to the primary end point across sex, BMI class and procedure received, as well
as relating to CRM+ across sex, BMI class and T-stage, were performed. Subgroup analyses relating to
each of local recurrence, DFS and OS across type of operation, T-stage and neo-adjuvant therapy were also
performed. All subgroup analyses tested heterogeneity of the treatment effect across the subgroups and
also estimated the treatment effect within each subgroup, via the addition of an appropriate interaction
term to the primary analysis model.
Model diagnostics
Multilevel logistic regression models
Model fit was assessed by examining the raw residuals on the probability scale outputted from SAS version 9.4
glimmix procedure, for example the residual for patient i:
ri = Yi − p^i, (1)
in which:
Yi = f1, Patient had the event (e:g: was converted to open surgery)0, Otherwise , (2)
and p^i is the predicted probability of the event (e.g. conversion to open surgery) for patient i [including
empirical Bayes’ estimate (EBE) of the random effect]. Index plots (plots of the raw residuals vs. patient
identification) were used to identify potential outliers. Empirical probability plots were also used to assess
model fit and identify potential outliers. These plots plotted the observed, ordered Pearson residuals
(outputted from SAS version 9.4 glimmix procedure) against expected, ordered Pearson residuals under
the model assumptions – analogous to a normal Q–Q plot for normal-errors regression. The expected
sampling distributions of Pearson residuals were determined empirically via simulations. Specifically, for
each simulation each patient’s outcome was randomly drawn from a Bernoulli (p) distribution with:
p = p^i, (3)
for patient i.
The model was refitted to this simulated data set and the Pearson residuals recorded.
This was repeated 100 times to yield an empirical sampling distribution of Pearson residuals for each
patient. In the empirical probability plot, the actual observed Pearson residuals for each patient were
plotted against the median, 2.5th percentile and 97.5th percentile of the empirical sampling distribution.
Observations were considered to be potential outliers if they lay outside the 2.5th percentile to 97.5th
percentile range [analogous to considering Pearson residuals lying outside the interval (–2,2) to be
potential outliers in a normal-errors regression].
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Overly influential observations on the treatment effect regression coefficient were identified via the
calculation of exponentiated delta-betas. The exponentiated delta-beta was calculated for each patient;
for example, for patient i, the exponentiated delta-beta for the treatment effect regression coefficient was:




in which β1 is the regression coefficient for the treatment effect in the full model and β1(i) is the treatment
effect regression coefficient in the model where patient i has been omitted. Note that this is the ratio of
the estimated ORs from the two models; for example, an exponentiated delta-beta for the treatment effect
for patient i of 1.05 would imply that the inclusion of patient i increases the treatment effect OR estimate
by 5% compared with the omission of patient i. The exponentiated delta-betas were plotted against
patient identifier (ID) in order to visually identify highly influential observations.
Shared frailty models
Models were refitted as Cox proportional hazards models with robust standard errors, without the random
effect for operating surgeon. This gave the same point estimates as the shared frailty model, and broadly
similar standard errors. Deviance residuals were used to identify any potential outliers. The proportional
hazards (PH) assumption for the treatment effect was assessed via a plot of the standardised Schoenfeld
residuals over time, as well as a plot of the observed standardised score process versus simulated
standardised score processes under PH. The PH assumption was also tested via the Supremum test.
Exponentiated delta-betas (as described in Multilevel logistic regression models) were used to identify
overly influential observations.
Health economic evaluation
An economic evaluation was performed using a UK NHS perspective to aid the development of an
evidence base to support NHS service providers and budget holders in their decision-making processes.
Costs associated with robotic surgery excluded acquisition and maintenance costs. The evaluation estimated
the expected incremental cost-effectiveness of robotic resection compared with laparoscopic resection at
6 months. It was planned that this would be extrapolated using a decision-analytic model to estimate
lifetime cost-effectiveness.
The ROLARR trial collected information on the nature of all initial resection operations using trial CRFs.
This included information on the type of operation and resources used within this operation, including
instrumentation and times for operation theatres and staff. CRF data also captured information on
postoperative and distal complications on all trial patients.
However, many types of resource utilisation were not collected for all patients in the ROLARR trial. In
particular, given the challenges of conducting research within global trials, data on resource utilisation
after the initial operation were collected only on patients from the UK and the USA. As the adjuvant
chemotherapy is likely to both vary widely and be expensive, there is a danger that any small differences
at this stage will be both unrelated to the surgery received and, given the cost of chemotherapy, outweigh
any cost differences that are related to the intended type of surgery. For this reason, the cost data do not
attempt to consider the chemotherapies received or antinausea drugs attached to these chemotherapies.
For patients in the UK and USA, information was collected alongside the trial-related questionnaires at
approximately 30 days and at 6 months. It was expected that data collection might be poor and as a result
it would be necessary to impute data for a substantial number of these patients.
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Data were collected on both primary care and secondary care, including contact with GPs and primary care
physicians (including the location of any contacts), nurse contacts (including at primary care, district/at
home nursing, and stoma nursing) and outpatient visits.
The analysis considered costs in GBP with 2015 as the base year, from an NHS-payer perspective. Given
the focus of this perspective, when clinical practice appeared to differ in the USA, particularly around pain
medication, the approach taken was the one that appeared to apply in the UK. This perspective also
means that unit costs are those costs that apply within the NHS.
Costing individual resource utilisation
Surgery
Surgical costs were computed by first identifying an overall global average for resection surgeries, for which
a weighted sum of non-elective complex large intestine operative costs was used. Individualised surgical
costs allowed for both excess bed-days (at £326.11 per day) and differences in the time and staffing within
the theatre. For the laparoscopic group, costs were calculated based on data provided on the operative team
and time, and it was assumed that on average this group would cost the same as the baseline surgical cost.
Therefore, those patients receiving a laparoscopic operation might have had a cheaper or more extensive
operation than ‘average’ but would be similar overall. Given that robotic surgeries were expected to require
longer use of the operating theatre (e.g. including greater setup time), incorporating staffing/time costs
modifies the resection surgery costs to reflect this. The instrumentation costs were included separately for
those items that, in the opinion of the chief investigator, would not necessarily be considered an automatic
inclusion within the operating theatre. (So, for instance, although data were collected on suction, this is not
costed.)
As staff costs appear below (Table 1), and instrument costs are assessed, it is not appropriate to include
these. Excluding these costs, the use of theatres costs £339 per hour.
TABLE 1 Surgical unit costs
Surgical costs Unit Cost (£) Source
Baseline resection surgery: operative cost Per operation 8307.78 aNHS Reference Costs 2014 to 201531




326.11 aNHS Reference Costs 2014 to 201531
Other surgeries for complications Per operation 8307.78 cNHS Reference Costs 2014 to 201531
Surgeon Per hour 138.00 Personal Social Services Research Unit32
Anaesthetist Per hour 60.74 Personal Social Services Research Unit32
First surgical assistant (band 7) Per hour 60.00 Personal Social Services Research Unit32
(including qualifications)
Subsequent surgical assistants (band 5) Per hour 43.00 Personal Social Services Research Unit32
(including qualifications)
Operating theatre (no staff or specialist
instruments)
Per hour 339.00 dDerived from Information Services
Division, NHS National Services Scotland33
a Assumed to reflect weighted average of NHS Reference Costs 2014 to 2015,31 as a weighted sum by subcategories of
FZ74 complex large intestines. Non-elective only.
b Applies per diem to stays > 44 days (as weighted boundary).
c Assumed to reflect weighted average of NHS Reference Costs 2014 to 2015,31 as a weighted sum by subcategories of
FZ74 complex large intestines. Includes both elective and non-elective.
d All costs (medical, nursing, other staff, drugs, central sterile services department, other supplies) come out at £1172 per
theatre hour.
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Instrumentation costs were identified in discussion with the chief investigator who provided data on which
of the instruments to specifically include (and which were more or less trivial given operating theatre costs)
and unit costs for each instrument (Table 2).
An overall in-theatre cost was calculated for each surgery (where data were complete on the fields above)
and calculated, including the theatre, staff and instrumental costs. The mean of these costs among the
group who received laparoscopic surgery (as opposed to allocated) was identified, and this was subtracted
from all individual cost figures to indicate how costs would be likely to differ from a typical operation. As
such, the average laparoscopic difference is zero, although the robotic difference could be positive (if more
expensive) or negative (if less expensive). The difference in the cost figure was then added back onto the
reference cost to give an estimated cost for each individual surgery.
It should be noted that the analysis presented here does not include the cost of the surgical robot (when
applicable), in order to provide an optimistic case figure for the cost-effectiveness of robotic surgery.
Other inpatient visits
The main inpatient costs assessed after the initial surgery were for stoma reversal operations and for other
related colorectal surgeries identified from the CRFs. When other major related surgery was indicated, this
was coded as an average of complex large intestine surgeries at £7621.24.31
Following approaches used elsewhere, stoma reversals are coded as elective intermediate procedures
(FZ50Z, intermediate large intestine procedures, aged ≥ 19 years) at £1691.06 per case.31
The unit costs of all other inpatient visits are taken from NHS Reference Costs 2014 to 201531 and are
shown in Table 3.
TABLE 2 Instrument unit costs
Robotic Unit Cost (£)
Aspirator Each 150
Bipolar forceps Each 150





Needle driver Each 150
Scissors Each 150
Stapler Per firing 150
Laparoscopic and open
Disposable Babcock Each 150
Graspers Each 100
Stapler (including open staplers) Initial 300
Per reload 80
Scissors Each 100
Vascular clips Each 80
Wound protector Each 50
Wound retractor Each 50
Vessel sealers (e.g. Ligasure) Each 500
METHODS
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Primary care
When possible, unit costs for GPs were taken from the Personal Social Services Research Unit (PSSRU) 201532
using qualification costs and direct care staff costs, with similar figures (without direct care staff costs) used
for nurse-based visits. For primary care, GP costs assumed a mean duration of surgery visits of 11.7 minutes
(£44) and of 11.4 minutes for home visits (plus 10 minutes of travel) (£81), and a cost of £27 for telephone
consultations. Nurse costs were assessed based on location, assuming 15.5 minutes of contact for each visit,
with an additional 10 minutes of travel for visits away from surgeries (surgery £14.47, other £21.25).
Outpatient and other health professional visits
Outpatient visits costed using unit costs (consultant-led outpatient attendances) from NHS Reference Costs
2014 to 15,31 after grouping most visits into colorectal surgery, gastroenterology, medical oncology, medical
ophthalmology, trauma and orthopaedics, nephrology, urology and others. Accident and emergency visits
were costed using the overall average of all emergency medical attendances with the NHS Reference Costs
2014 to 2015.31
Contacts for many of the remaining health professionals were taken from the PSSRU costs, including
occupational therapy (PSSRU 201532) and counselling (PSSRU 201434), and chiropody/podiatry (PSSRU
201035), with costs inflated to 2015 figures using either the HCHS (Health and Community Health Service)
price index for health or mid-point changes in Agenda for Change pay bands.36
TABLE 3 Other inpatient procedure unit costs
Procedure Code Unit costsa (£)
Non-reversal stoma
operations
FZ50Z. Elective inpatient 1691.06
Transient ischaemic
attack
AA29F. Transient ischaemic attack with a CC score of 0–4 (Non-elective) 1252.81
Deep-vein thrombosis YQ51E. Deep-vein thrombosis with a CC score of 0–2 1361.97
Pulmonary embolism DZ09 K. Pulmonary embolus with interventions, with a CC score of 0–8 3509.12
Renal failure Acute kidney injury without interventions, with a CC score of 0–3 1785.63
LA07 K. Acute kidney injury with interventions, with a CC score of 0–5 3784.72
Abdominal infections,
anastomotic leak





LA04S. Kidney or urinary tract infections, without interventions, with a CC
score of 0–1
1502.55
Haemorrhage FZ38P. Gastrointestinal bleed without interventions, with a CC score of 0–4 1370.09
Cardiac events EB12C. Unspecified chest pain with a CC score of 0–4 1088.68
Protracted ileus FZ13C. Minor therapeutic or diagnostic, general abdominal procedures,
≥ 19 years. Non-elective
3471.40
Urinary retention LA09Q. General renal disorders without interventions, with a CC score of 0–2 1399.13
Gastrointestinal
obstruction
FZ27G. Intermediate therapeutic general abdominal procedures,
≥ 19 years and over, with a CC score of 0
3335.27
High stoma output (not
coded as serious though)
FZ50Z Intermediate large intestine procedures, ≥ 19 years 1836.19
Respiratory inpatient
(non-infection)
DZ19 N. Other respiratory disorders without interventions, with a CC
score of 0–4
1163.67
Not specified Average of all elective inpatients, all sources 3573.02
CC, complication and comorbidity.
a All taken from NHS Reference Costs 2014 to 2015.31
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Stoma costs
The costs of ongoing stoma were calculated from Jones,37 who reported on figures from the Cwm Taf
Health Board (NHS Wales) (Table 4). This assumes a monthly cost of £84 per 30 colostomy bags and £94
per 30 ileostomy bags. These 2011/12 figures were inflated to 2014/15 figures using the HCHS price
index.32 It should be noted that this is likely to underestimate the true costs of stoma, as this does not
include items such as wipes, although there do not appear to be clear, published figures available that
include such items.
Medication costs
Medication costs were found by coding responses from UK/US patients on a line-by-line basis initially and
then across all responses for specified pharmaceuticals (Table 5). When possible, individual statements
about frequency and duration of treatment were used to inform assumptions about utilisation. In cases
where no statements were made to identify utilisation, the British National Formulary38 was used to
identify an indicative strength/dosage. Unit costs are taken from eMIT (the drugs and pharmaceutical
electronic market information tool),39 when possible, or the NHS Indicative Drug Tariff40 figures, when not.
Medications for unrelated events (e.g. shingles, thyroid conditions, chronic obstructive pulmonary disease,
glaucoma) were ignored. Information on dietary supplementation (e.g. vitamins) was provided infrequently
but was not included.
For some pain medications, differences in clinical practice mean that medications have been recoded.
For example, although hydrocodone is widely used in the USA, it does not appear within the (UK) British
National Formulary;38 codeine phosphate is used in preference to hydrocodone. Codeine phosphate is also
used when several other medications (i.e. Norco®, codeine sulphate) are indicated.
Given the cost of chemotherapies and the relatively sparse information collected on these (and the danger
that the costs involved mask all useful information), these have been ignored in the range of medications
being considered. Furthermore, most of the stoma-related costs are removed, as the stoma unit costs
specified in Table 4 include a range of costs that may overlap. Chemotherapies as adjunct therapies and
anti-emetic/anti-nausea drugs (including anti-psychotics) are also ignored, since the cost of these drugs
risks swamping any useful information provided.
TABLE 4 Stoma unit costs
Stoma costs Unit Unit cost Source
Colostomy costs @ two bags per day (2011/12) Per 30 days £84.00 Cwm Taf Health Board (Jones, 201537)
Ileostomy costs @ one bag per day (2011/12) Per 30 days £94.00 Cwm Taf Health Board (Jones, 201537)
Inflation between 2011/12 and 2014/15 using
HCHS (293.1 vs. 282.5)
3.75%
Stoma reversals Per operation £1691.06 aNHS Reference Costs 2014 to 201531
Colostomy costs @ two bags per day (2011/12) Per 30 days £84.00 Cwm Taf Health Board (Jones, 201537)
Ileostomy costs @ one bag per day (2011/12) Per 30 days £94.00 Cwm Taf Health Board (Jones, 201537)
Inflation between 2011/12 and 2014/15 using
HCHS (293.1 vs. 282.5)
3.75%
Stoma reversals Per operation £1691.06 aNHS Reference Costs 2014 to 201531
a Stoma reversals (intermediate procedures). FZ50Z Intermediate Large Intestine Procedures, 19 years and over.
Elective inpatient.
METHODS
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TABLE 5 Medication unit costs
Symptom Drug Unit Cost (£)
Cardiac/statins Simvastatin Per 28 units 0.16
Cardiac/statins Atorvastatin Per 28 units 0.49
Cardiac/statins Rosuvastatin Per 28 units 18.03
Cardiac/statins Doxazosin Per 28 units 0.19
Cardiac/statins Candesartan Per 28 units 0.55
Cardiac/statins Losartan Per 28 units 0.30
Cardiac/statins Olmesartan (Benicar®) Per 28 units 10.95
Cardiac/statins Lisinopril Per 28 units 0.29
Cardiac/statins Perindopril Per 30 units 0.61
Cardiac/statins Ramipril Per 28 units 0.27
Cardiac/statins Bisprolol Per 28 units 0.25
Cardiac/statins Metaprolol (plus unspecified beta blocker) Per 28 units 0.55
Cardiac/statins Carvedilol Per 28 units 0.59
Cardiac/statins Propranolol Per 56 units 1.67
Cardiac/statins Atenolol Per 28 units 0.18
Cardiac/statins Amlodipine Per 28 units 0.16
Cardiac/statins Feoldipine Per 28 units 0.55
Cardiac/statins Lercanidipine Per 28 units 1.42
Cardiac/statins Nifedipine Per 56 units 21.00
Cardiac/statins Cartia Per 56 units 41.87
Cardiac/statins Furosemide Per 28 units 0.13
Cardiac/statins Indapamide Per 28 units 1.02
Cardiac/statins Esomeprazole Daily 2.22
Cardiac/statins Lansoprazole Per 28 units 0.98
Cardiac/statins Glytrin Daily 1.13
Cardiac/statins Amiodarone Once 13.17
Pain Tramadola Per 14 units 1.67
Pain Paracetamolb Per 16 units 0.13
Pain Ibuprofen Per 16 units 0.17
Pain Codeine phosphatec Per 28 units 0.37
Pain Gabapentin Per 100 units 1.30
Pain Cocodamol Per 30 units 0.65
Pain Codrydramol Per 30 units 0.47
Pain Oramorph Single use 1.89
Pain Oxycodone Per 56 units 6.06
Pain Indomethacin Single pack 0.55
Pain Meloxicam Single pack 0.43
continued
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TABLE 5 Medication unit costs (continued )
Symptom Drug Unit Cost (£)
Pain Solaraze Single pack 0.67
Pain Naproxen Per 28 units 0.70
Anticoagulants Aspirin Per 28 units 0.14
Anticoagulants Clopidogrel Per 30 units 4.58
Anticoagulants Heparin Per 10 units 16.62
Anticoagulants Delteparin Per 10 units 51.22
Anticoagulants Warfarin Per 28 units 0.25
Anticoagulants Tinzaparin Per 10 vials 105.66
Anticoagulants Enoxaparin Per 10 units 20.86
Anticoagulants Rivaroxaban Per 28 units 50.40
Antibiotics and immunological Amoxicillin (plus unspecified antibiotics) Per 21 units 0.45
Antibiotics and immunological Trimethoprim Per 14 units 0.89
Antibiotics and immunological Nitrofurantoin Per 28 units 3.57
Antibiotics and immunological Cephalexin Per 28 tablets 0.73
Antibiotics and immunological Lexofloxacin Per 5 tablets 0.92
Antibiotics and immunological Bactrim Per 28 units 3.03
Antibiotics and immunological Oxytetracycline Per 28 units 0.43
Antibiotics and immunological Vancomycin Per 28 units 32.90
Antibiotics and immunological Ciprofloxacin Per 20 units 0.42
Antibiotics and immunological Metronidazole Per 21 tablets 0.39
Antibiotics and immunological Fluconazole Per unit 0.22
Stool thickeners Loperamide Per 30 units 1.61
Stool thickeners Atropine diphenoxylate Per 100 units 10.74
Stool softeners/laxatives Domperidone Per 100 units 0.91
Stool softeners/laxatives Lactulose (laxative if not clearly stated) Per bottle 1.21
Stool softeners/laxatives Docusate Per 30 units 2.09
Stool softeners/laxatives Metamucil Per 10 units 4.22
Stool softeners/laxatives Movicol/Laxido Per 30 units 2.99
Stool softeners/laxatives Clorphenamine Per 28 units 0.84
Stool softeners/laxatives Fluticasone Per bottle 4.17
Other stomach/digestive Mebeverine Per unit 4.68
Other stomach/digestive Ranitidine Per 12 units 0.30
Other stomach/digestive Omeprazole Per 28 units 0.44
Urinary Bendoflumethiazide Per 28 units 0.11
Urinary Tamsulosin Per 30 units 0.73
Urinary Solifenacin succinate Per 30 units 27.62
Antidepressants/anti-anxiety Alprazolam Per 60 units 3.18
Antidepressants/anti-anxiety Citalopram Per 28 units 0.18
METHODS
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Quality of life
The outcome measure for the economic evaluation was the quality-adjusted life-year (QALY). Health-related
quality of life (HRQoL) was measured using the EQ-5D and valued using the standard UK tariff.41 The EQ-5D
data were obtained using English-language version questionnaires completed by patients recruited from UK
and North American trial sites. The data were collected alongside resource data at baseline and at 30 days
and at 6 months postoperatively. Multiple imputation methods were used to estimate HRQoL for those
patients not completing this questionnaire. In this way, the analysis includes HRQoL for all patients in the
trial, regardless of language.
Quality-of-life estimates were constructed using the EuroQol-5 Dimensions, three-level version (EQ-5D-3L),
responses, valued using the standard UK tariff. Responses were in most cases valued as an area under
the curve. The exception to this was when the data indicated that a stoma reversal operation occurred
between 30 days and 6 months postoperatively; in this case, the 30-day figure was assumed to apply
between 30 days and the reversal operation, and the 6-month figure was assumed to apply from the
reversal date through to the end of follow-up.
As a sensitivity analysis (which has been run but is additional to those analyses displayed here), values
were also inferred from the SF-36v2 data obtained from all patients in the ROLARR trial. Health-related
quality-of-life figures were obtained as Short Form questionnaire-6 Dimensions (SF-6D) utilities by applying
the algorithm developed by Brazier et al.42
Imputing costs and quality of life
Given that not all UK and US patients answered the medical resource utilisation questionnaire, imputation
was necessary within the trial. Values were multiply imputed by category of variable and timing, using 100
imputations for each incomplete observation. By using a large number of multiple imputations, we aimed
to more accurately reflect uncertainty.
The first set of variables imputed as chained equations related to the original inpatient admission, being
the duration of surgery, the number of assistants and length of stay. These figures were imputed based
on the procedure reviewed, whether or not this was a low anterior operation, whether or not there was
evidence of locoregional spread, whether or not there had been any CT staging and using age/sex as
TABLE 5 Medication unit costs (continued )
Symptom Drug Unit Cost (£)
Antidepressants/anti-anxiety Diazepam Per 28 units 0.23
Antidepressants/anti-anxiety Lorazepam Per 28 units 1.19
Antidepressants/anti-anxiety Sertraline Per 28 units 0.48
Antidepressants/anti-anxiety Duloxetine Per 28 units 22.40
Antidepressants/anti-anxiety Amitripyline Per 28 units 0.14
Sexual dysfunction Tadalafil Per 28 units 54.99
Sexual dysfunction Sildenafil Per 28 units 0.92
Sleeping pills Zopiclone Per 28 units 0.41
a Tramadol use varied substantially. Use costed as provided but when detail was lacking a ‘default’ case of 4 weeks/28 tablets
was used.
b Short courses assumed to be six tablets per day. Other non-specified courses take an average length of 72 days.
c Where codeine sulphate, Norco and hydrocodone are indicated (USA), these replace codeine phosphate (as per UK).
Codeine sulphate sees an average course of 101 pills taken in the subgroup when exact numbers are not specified,
and 30 when stated as ‘Norco’ but not specified (as this reflects the utilisation in this subgroup).
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demographics. Once these figures for the incomplete variables were imputed (and so non-missing), then
they were used to inform subsequent variables. These figures also allowed the calculation of a (complete)
series of figures for operative costs.
Figures were then imputed to find both the number of other surgeries required and the number of days a
stoma would be in place and the type of stoma.
Quality-of-life observations were imputed next, with the EQ-5D-3L and SF-6D data as chained equations
using age/sex and information about baseline health conditions. For time periods after baseline, the
previous observation for both the EQ-5D and the SF-6D were also used as predictors. With data now
complete on these observations, and for the number of stoma days, QALYs could then be calculated.
Other costs were imputed based on the EQ-5D-3L utilities and observed complications, as represented by
dummy variables representing common (n > 10) complications graded on the Clavien–Dindo classification to
≥ 3. As these equations were lengthy, each equation was examined and terms removed where p > 0.200.
For all health professional and outpatient visits, the equations estimated the number of events. In order to
turn these into costs, these utilisation figures were multiplied by the average cost of events observed within
the data. There were no clear significant predictors of medication costs within the data. Medication costs
were imputed by predicting first whether or not any medication costs existed for that patient, within the
relevant period (i.e. post discharge within the first 30 days, between 30 days and 6 months), and then as
random variables reflecting those patients with data in that period.
Analysis
Data for all cost items were combined together to form an estimate of total costs, alongside the estimated
total number of QALYs within the first 6 months. Because this covers only a 6-month time period, the
maximum number of QALYs that could be observed is 0.500 QALYs (or, more properly, 0.499, given that
182 days are used).
With these figures, total costs and costs within different cost categories are presented in terms of both
tables and probabilistic sensitivity analyses. As missing data are multiply imputed, it is efficient to conduct
the probabilistic sensitivity analysis by bootstrapping (sampling with replacement) among the relevant data
set, selecting from the imputed data set until the number of patients in the initial sample has been reached.
For example, if a laparoscopic group had 75 patients within a particular scenario, the multiply-imputed
data set would have 75 × 100 = 7500 observations, and the procedure would choose one of these 7500
observations, 75 times, in order to obtain a resampled estimate. The results in terms of total costs and
total QALYs for each group are then compared and assessed to identify the most cost-effective option.
Repeating this resampling procedure 10,000 times provides an estimate of the distribution of incremental
costs and incremental benefits between the two options under consideration. This also allows the calculation
of cost-effectiveness acceptability curves, which display the probability of each of the options under
consideration being cost-effective at different values of the cost-effectiveness threshold. By convention,
the values of £20,000 and £30,000 per QALY are focused on,43 although the evidence is that the true
cost-effectiveness threshold may be lower than these figures.44
The primary analysis used imputed data for UK and US patients (n = 190). Secondary analyses were
undertaken using the following:
l complete data for all patients (n = 97)
l imputed data for UK and US patients intended to receive low anterior surgery (n = 135)
l imputed data for all observations (n = 471).
METHODS




Between 7 January 2011 and 30 September 2014, 1276 patients were assessed for eligibility by 40 surgeons
from 26 sites across 10 countries (i.e. UK, Italy, Denmark, USA, Finland, South Korea, Germany, France,
Australia and Singapore). In total, 471 (36.9%) of these patients were randomised: 234 to laparoscopic and
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• Not meeting inclusion criteria, n = 570
• Eligible but did not consent, n = 225
• Eligible and consented but not
   randomised, n = 8
• Missing data, n = 2
• Withdrew from trial, no reason given,
   n = 2
• Withdrew from trial due to strong
   preference for robotic-assisted surgery,
   n = 1
• Patient’s insurance policy required them
   to undergo their surgery at another
   hospital that was not involved in the
   study, n = 1
• Received robotic-assisted surgery because
   patient/surgeon refused randomisation
   result, n = 7
• Complete response to pre-operative
   therapy – did not receive surgery, n = 1
• Received standard laparoscopic surgery
   because robot not available/logistics,
   n = 3

















































FIGURE 1 The CONSORT flow diagram. ITT, intention to treat.
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one patient did not undergo surgery because of a complete clinical response to neo-adjuvant therapy. The
remaining 466 patients underwent an operation, with 456 (97.9%) undergoing the allocated treatment.
Baseline data
All minimisation factors except treating surgeon are summarised by treatment group across all randomised
patients in Table 6. The minimisation factor intended operating surgeon is summarised by treatment group
for all randomised patients in Table 7. Summaries of selected additional baseline fields are given in Table 8.
Operative and pathology summaries
Crude summaries of operative and local pathology data fields are given in Table 9. The primary end point,
conversion to open surgery, is summarised here but is considered in more detail in Primary end point:
conversion to open surgery. The key secondary end point, CRM+, is also summarised here but is considered
in more detail in Key secondary end point: circumferential resection margin positivity (CRM+).
Table 10 presents the different pathways of intraoperative conversions between robotic, laparoscopic and
open surgery. For example, the pathway ‘Laparoscopic→ Robotic’ indicates that the patient’s operation
began as a standard laparoscopic operation, but was converted to a robotic operation intraoperatively.
A pathway with only one type of operation indicates no conversions, for example ‘Laparoscopic’ indicates
that the patient’s operation began as a standard laparoscopic operation and was completed without
conversion to robotic or open surgery.
TABLE 6 Minimisation factors by treatment group
Minimisation factor
Treatment group, n (%)






Male 159 (67.9) 161 (67.9) 320 (67.9)
Female 75 (32.1) 76 (32.1) 151 (32.1)
BMI classification
Underweight/normal 87 (37.2) 93 (39.2) 180 (38.2)
Overweight 92 (39.3) 90 (38.0) 182 (38.6)
Obese class I 38 (16.2) 41 (17.3) 79 (16.8)
Obese class II 10 (4.3) 9 (3.8) 19 (4.0)
Obese class III 7 (3.0) 4 (1.7) 11 (2.3)
Neo-adjuvant therapy
Yes 103 (44.0) 109 (46.0) 212 (45.0)
No 131 (56.0) 128 (54.0) 259 (55.0)
Intended procedure
HAR 34 (14.5) 35 (14.8) 69 (14.6)
LAR 158 (67.5) 159 (67.1) 317 (67.3)
APR 42 (17.9) 43 (18.1) 85 (18.0)
RESULTS
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TABLE 7 Recruitment by surgeon
Surgeon ID
Treatment group, n (%)





1 20 (47.6) 22 (52.4) 42 (8.9)
2 20 (57.1) 15 (42.9) 35 (7.4)
3 17 (51.5) 16 (48.5) 33 (7.0)
4 17 (51.5) 16 (48.5) 33 (7.0)
5 11 (40.7) 16 (59.3) 27 (5.7)
6 12 (46.2) 14 (53.8) 26 (5.5)
7 13 (52.0) 12 (48.0) 25 (5.3)
8 11 (52.4) 10 (47.6) 21 (4.5)
9 9 (50.0) 9 (50.0) 18 (3.8)
10 10 (55.6) 8 (44.4) 18 (3.8)
11 9 (50.0) 9 (50.0) 18 (3.8)
12 9 (50.0) 9 (50.0) 18 (3.8)
13 7 (43.8) 9 (56.3) 16 (3.4)
14 6 (46.2) 7 (53.8) 13 (2.8)
15 6 (46.2) 7 (53.8) 13 (2.8)
16 5 (45.5) 6 (54.5) 11 (2.3)
17 3 (30.0) 7 (70.0) 10 (2.1)
18 5 (50.0) 5 (50.0) 10 (2.1)
19 3 (33.3) 6 (66.7) 9 (1.9)
20 4 (44.4) 5 (55.6) 9 (1.9)
21 3 (42.9) 4 (57.1) 7 (1.5)
22 5 (83.3) 1 (16.7) 6 (1.3)
23 1 (20.0) 4 (80.0) 5 (1.1)
24 2 (40.0) 3 (60.0) 5 (1.1)
25 3 (60.0) 2 (40.0) 5 (1.1)
26 3 (75.0) 1 (25.0) 4 (0.8)
27 3 (75.0) 1 (25.0) 4 (0.8)
28 0 (0.0) 3 (100.0) 3 (0.6)
29 2 (66.7) 1 (33.3) 3 (0.6)
30 2 (66.7) 1 (33.3) 3 (0.6)
31 1 (33.3) 2 (66.7) 3 (0.6)
32 3 (100.0) 0 (0.0) 3 (0.6)
33 1 (33.3) 2 (66.7) 3 (0.6)
34 1 (50.0) 1 (50.0) 2 (0.4)
35 1 (50.0) 1 (50.0) 2 (0.4)
36 2 (100) 0 (0.0) 2 (0.4)
37 2 (100) 0 (0.0) 2 (0.4)
38 1 (50.0) 1 (50.0) 2 (0.4)
39 0 (0.0) 1 (100.0) 1 (0.2)
40 1 (100) 0 (0.0) 1 (0.2)
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TABLE 8 Baseline demographics
Treatment group, n (%)





Age (years), mean (SD) 65.5 (11.93) 64.4 (10.98) 64.9 (11.01)
ASA classification
I: A normal healthy patient 52 (22.2) 39 (16.5) 91 (19.3)
II: A patient with mild systemic disease 124 (53.0) 150 (63.3) 274 (58.2)
III: A patient with severe systemic disease 52 (22.2) 46 (19.4) 98 (20.8)
IV: A patient with severe systemic disease
that is a constant threat to life
1 (0.4) 0 (0.0) 1 (0.2)
Missing 5 (2.1) 2 (0.8) 7 (1.5)
Prior abdominal surgery
Yes 67 (28.6) 62 (26.2) 129 (27.4)
No 162 (69.2) 174 (73.4) 336 (71.3)
Missing 5 (2.2) 1 (0.4) 6 (1.3)
TABLE 9 Summaries of operative and pathological variables
Operative
Treatment group, n (%)






HAR 19 (8.3) 28 (11.9) 47 (10.1)
LAR 165 (71.7) 152 (64.4) 317 (68.0)
APR 45 (19.6) 52 (22.0) 97 (20.8)
Othera 1 (0.4) 4 (1.7) 5 (1.1)
Operative time (minutes)
Mean (SD) 261 (83.24) 298.5 (88.71) 280.0 (87.98)
Missing 4 1 5
Stoma formation
Temporary 157 (68.3) 142 (60.2) 299 (64.2)
Permanent 49 (21.3) 53 (22.5) 102 (21.9)
No 24 (10.4) 41 (17.4) 65 (13.9)
Length of stay (days)
Mean (SD) 8.2 (6.03) 8.0 (5.85) 8.1 (5.94)
Missing 13 14 27
Intraoperative conversion to open surgery
Yes 28 (12.2) 19 (8.1) 47 (10.1)
No 202 (87.8) 217 (91.9) 419 (89.9)
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TABLE 9 Summaries of operative and pathological variables (continued )
Operative
Treatment group, n (%)







0 24 (10.4) 22 (9.3) 46 (9.9)
1 20 (8.7) 24 (10.2) 44 (9.4)
2 61 (26.5) 64 (27.1) 125 (26.8)
3 114 (49.6) 117 (49.6) 231 (49.6)
4 8 (3.5) 5 (2.1) 13 (2.8)
Tx or missing 3 (1.3) 4 (1.7) 7 (1.5)
N-stage
0 150 (65.2) 146 (61.9) 296 (63.5)
1 58 (25.2) 63 (26.7) 121 (26.0)
2 21 (9.1) 25 (10.6) 46 (9.9)
Missing 1 (0.4) 2 (0.8) 3 (0.6)
Lymph node yield
Mean (SD) 24.1 (12.91) 23.2 (11.97) 23.6 (12.43)
Missing 9 1 10
Plane of surgery
Mesorectal area (all specimens)
Mesorectal plane 173 (75.2) 178 (75.4) 351 (75.3)
Intramesorectal plane 38 (16.5) 33 (14.0) 71 (15.2)
Muscularis propria plane 12 (5.2) 22 (9.3) 34 (7.3)
Missing 7 (3.1) 3 (1.3) 10 (2.1)
Sphincter area (APRs only) (n = 45) (n = 52) (n = 97)
Levator plane 18 (40.0) 18 (34.6) 36 (37.1)
Sphincteric plane 19 (42.2) 22 (42.3) 41 (42.3)
Intrasphincteric/submucosal plane 5 (11.0) 9 (17.3) 14 (14.4)
Missing 3 (6.7) 3 (5.8) 6 (6.2)
CRM involvement (n = 224) (n = 235) (n = 459)
Yes 14 (6.3) 12 (5.1) 26 (5.7)
No 210 (93.7) 223 (94.9) 433 (94.3)
a ’Other’ operations: Laparoscopic group – ‘Laparoscopic biopsy of peritoneum’. Robotic group – ‘Dorsal pelvic exenteration,
ureter resection distally right sided’, ‘Hartmann’s procedure’ (× 2), ‘High anterior resection+ subtotal colectomy’.
b Pathology data summarised here over the 466 patients who had an operation. CRM involvement summarised only over
the 459 patients who had a pathology report available (i.e. the analysis population for that end point).
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Primary end point: conversion to open surgery
The rate of conversion to open surgery was 47 out of 466 (10.1%) patients overall: 28 out of 230 (12.2%)
in the laparoscopic group and 19 out of 236 (8.1%) in the robotic group (unadjusted difference in
proportions 4.12%, 95% CI –1.35% to 9.59%). There was no statistically significant difference between
robotic surgery and conventional laparoscopic surgery with respect to odds of conversion (adjusted OR
0.614, 95% CI 0.311 to 1.211; p = 0.16).
The random intercept model was preferred to the random slope model, because the random slope model
did not offer sufficient improvement in model fit, which is clear from both the non-significant likelihood
ratio test result and the increase in AIC (see Appendix 1, Table 51).
Table 11 presents adjusted estimates of ORs and 95% CIs from the random intercept model, as well as
crude summaries and unadjusted risk difference estimates and 95% CIs for conversion to open surgery by
treatment group and also by each of the minimisation factors. The model shows significantly increased
odds of conversion in obese patients versus underweight/normal patients (adjusted OR 4.691, 95% CI
2.080 to 10.581; p < 0.01) and in males versus females (adjusted OR 2.444, 95% CI 1.047 to 5.708;
p = 0.04). Patients whose intended procedure was a LAR had a significantly higher rate of conversion than
patients whose intended procedure was APR (adjusted OR 5.435, 95% CI 1.595 to 18.519; p = 0.007).
Operating surgeon had a mild to moderate effect on odds of conversion, as reflected by the ICC estimate
of 0.056 (95% CI 0.007 to 0.056).
Subgroup analyses
Odds ratios presented in Tables 13–15 are derived from the linear combination of the estimated treatment
(main effect) and treatment-by-subgroup interaction terms on the logit scale. The p-values are presented
for the test of the treatment effect within each subgroup – this is the first column of p-values [e.g. in
Table 13 the test that the treatment effect is null (OR = 1) within the male subgroup is 0.0429]. The
p-values are also presented for the test of heterogeneity of treatment effect across subgroups, the details
of which are given in the footnotes of the tables (Table 12).
In the sex subgroup analysis, 39 out of 317 (12.3%) male patients underwent conversion to laparotomy:
25 out of 156 (16.0%) in the laparoscopic group and 14 out of 161 (8.7%) in the robotic group (unadjusted
difference in proportions 7.3%, 95% CI 0.1% to 14.6%). There were 8 out of 149 (5.4%) female patients
who underwent conversion to laparotomy: 3 out of 74 (4.1%) in the laparoscopic group and 5 out of
75 (6.7%) in the robotic group (unadjusted difference in proportions –2.6%, 95% CI –9.8% to 4.6%).
TABLE 10 Robotic and laparoscopic conversions
Intraoperative conversion pathway







Laparoscopic 194 (82.9) 3 (1.3) 197 (41.8)
Laparoscopic → Open 28 (12.0) 0 (0.0) 28 (5.9)
Laparoscopic → Robotic 1 (0.4) 0 (0.0) 1 (0.2)
Robotic 7 (3.0) 209 (88.2) 216 (45.9)
Robotic → Open 0 (0.0) 14 (5.9) 14 (3.0)
Robotic → Laparoscopic 0 (0.0) 5 (2.1) 5 (1.1)
Robotic → Laparoscopic→ Open 0 (0.0) 5 (2.1) 5 (1.1)
Did not receive surgery 1 (0.4) 0 (0.0) 1 (0.2)
Missing 3 (1.3) 1 (0.4) 4 (0.8)
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28/230 (12.2) 19/236 (8.1) 4.1 (–1.4 to 9.6) 0.614 0.311 to 1.211 0.16
Sex: male (vs. female) 8/149 (5.4) 39/317 (12.3) –6.9 (–12.1 to –1.8) 2.444 1.047 to 5.708 0.04
BMI class: overweight
(vs. underweight/normal)
13/179 (7.3) 9/180 (5.0) 2.3 (–2.7 to 7.2) 0.538 0.210 to 1.374 0.19
BMI class: obese
(vs. underweight/normal)




27/262 (10.3) 20/204 (9.8) 0.5 (–5.0 to 6.0) 1.069 0.504 to 2.265 0.86
Intended procedure:
HAR (vs. LAR)
37/312 (11.9) 6/68 (8.8) 3.0 (–4.6 to 10.7) 0.551 0.194 to 1.563 0.26
Intended procedure:
APR (vs. LAR)
37/312 (11.9) 4/86 (4.7) 7.2 (1.5 to 12.9) 0.184 0.054 to 0.627 0.007





95% CI for ICC
Estimate Standard error Lower limit Upper limit
Operating surgeon (random effect) 0.626 0.431 0.050 0.007 0.056








95% CI)a p-valueLaparoscopic Robotic
Treatment in males: robotic
surgery (vs. laparoscopic)






3/74 (4.1) 5/75 (6.7) –2.6 (–9.8 to 4.6) 2.022
(0.425 to 9.621)
0.3757
a Adjusted for BMI class, preoperative radiotherapy, intended procedure and operating surgeon.
b The p-value for the treatment effect is referring to a test of heterogeneity of treatment effect between the subgroups.
ORs derived from the treatment term and treatment-by-sex interaction term.
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A Wald test of interaction between treatment effect and sex in the adjusted model yielded p = 0.094. This
acts as moderate evidence that the difference between treatment groups is different for males and females.
Furthermore, the estimated adjusted OR for conversion to laparotomy (robotic vs. conventional laparoscopic)
in males is 0.455 (95% CI 0.209 to 0.987; p = 0.043), suggesting that there may in fact be a significant
benefit of robotic surgery compared with laparoscopic surgery in terms of odds of conversion in male patients.
No substantial interactions between treatment effect and BMI or type of operation were found. The treatment
effect OR in patients who underwent LAR was 0.486 (95% CI 0.210 to 1.123; p = 0.091), which may warrant
further investigation into a potential benefit of robotic surgery in this group of patients.

























7/86 (8.1) 6/93 (6.5) 1.7 (–6.0 to 9.3) 0.751
(0.227 to 2.492)
0.6396
a Adjusted for sex, preoperative radiotherapy, intended procedure and operating surgeon.
b The p-value for the treatment effect is referring to a (pairwise) test of heterogeneity of treatment effect between the
subgroups. For example, the second p-value in the ‘Treatment in obese patients’ row refers to a test of heterogeneity of
treatment effect between obese patients and underweight/normal patients.
























22/165 (13.3) 11/152 (7.2) 6.1 (–0.5 to 12.7) 0.486
(0.210 to 1.123)
0.0909
a Adjusted for sex, BMI class, preoperative radiotherapy and operating surgeon.
b The p-value for the treatment effect is referring to a (pairwise) test of heterogeneity of treatment effect between the
subgroups. For example, the second p-value in the ‘Treatment (HAR)’ row refers to a test of heterogeneity of treatment
effect between patients who underwent HAR and patients who underwent LAR.
Five patients underwent a procedure other than HAR, APR or LAR, 1 in the laparoscopic treatment group (no conversion to
open surgery) and four in the robotic treatment group (two conversions). These patients were excluded from this model.
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Sensitivity analysis: learning effects
For 464 out of 471 (98.5%) patients we had sufficient data to derive the level of experience of the
operating surgeon, expressed in terms of ‘number of previous laparoscopic operations performed’ and
‘number of previous robotic operations performed’ by the operating surgeon, at the time of the patient’s
operation. Table 16 presents the distribution across patients of the previous experience of the operating
surgeon who performed their operation. The amount of previous laparoscopic and robotic experience
varied widely between participating surgeons, and there was a clear disparity between laparoscopic and
robotic experience.
The patient-level variables ‘number of previous laparoscopic operations performed by the operating surgeon,
at the time of the patient’s operation’ and ‘number of previous robotic operations performed by the operating
surgeon, at the time of the patient’s operation’ were added to the primary analysis model as centred, linear
fixed effects terms. Interactions between each of these variables and the treatment allocation were also
included. The resulting estimated treatment effect ORs at various levels of operating surgeon laparoscopic and
robotic experience are presented in Table 17. The model suggests that increasing operating surgeon robotic
experience notably affects the treatment effect OR in favour of robotic surgery, regardless of the level of
laparoscopic experience. The full fitted model is given in Tables 18 and 19, with untransformed estimates
(i.e. on the log-odds scale).
TABLE 16 Previous experience of operating surgeons
Statistic
Previous experience (number of patients)
Laparoscopic (n= 464) Robotic (n= 464)
Mean (SD) 152.5 (178.38) 67.9 (48.75)
Median (range) 91.4 (10.0–853.0) 49.5 (10.3–183.0)
(Q1, Q3) (44.9, 180.1) (30.4, 101.3)
Q1, first interquartile; Q3, third interquartile.
TABLE 17 Estimated treatment effect OR by surgeon experience
Effect
Surgeon’s experience level
(number of previous operations)
OR (robotic vs.








45 30 0.961 0.336 to 2.747
50 0.691 0.277 to 1.721
100 0.303 0.090 to 1.018
91 30 0.963 0.383 to 2.424
50 0.692 0.317 to 1.513
100 0.303 0.096 to 0.959
180 30 0.966 0.416 to 2.245
50 0.694 0.336 to 1.437
100 0.304 0.094 to 0.989
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Sensitivity analysis: actual operating surgeon
The overall proportion of patients who were operated on by a surgeon other than their intended operating
surgeon was low [42/466 (9.0%)] and occurred mainly at high recruiting sites, so the discrepancies were
not influential on the results.
Adjusting for actual operating surgeon instead of intended operating surgeon made little difference to the
model estimates. In particular, the treatment effect estimate (OR) adjusting for actual operating surgeon
was 0.612 (95% CI 0.310 to 1.207), a negligible change from the primary analysis model.
Further details are given in Appendix 1, Sensitivity analysis: actual operating surgeon – further details.
Sensitivity analysis: actual procedure
The numbers of patients whose actual procedure was different from their intended procedure (the
stratification factor) are summarised in Table 20. There were 65 out of 466 patients (13.9%) who had a
procedure other than their ‘intended procedure’. The most common discrepancy was for patients whose
intended procedure was a HAR to actually undergo a LAR.
TABLE 18 Conversion to open surgery (learning effects): adjusted estimates of ORs and 95% CIs from random
intercept model including covariates related to operating surgeon’s experience
Effect Estimate
Standard
error Pr> |t| 95% CI
Intercept –3.0056 0.5794 < 0.0001 –4.1787 to –1.8326
Treatment: robotic surgery (vs. laparoscopic) –0.6618 0.3893 0.0899 –1.4271 to 0.1035
Sex: male (vs. female) 0.8688 0.4355 0.0467 0.01283 to 1.7248
BMI class: overweight (vs. underweight/normal) –0.6763 0.4832 0.1623 –1.6262 to 0.2735
BMI class: obese (vs. underweight/normal) 1.4781 0.4257 0.0006 0.6413 to 2.3149
Previous radiotherapy or chemoradiotherapy:
yes (vs. no)
0.1537 0.3924 0.6956 –0.6177 to 0.9250
Intended procedure: HAR (vs. LAR) –0.5234 0.5342 0.3278 –1.5734 to 0.5267
Intended procedure: APR (vs. LAR) –1.7021 0.6267 0.0069 –2.9340 to –0.4702
Surgeon’s laparoscopic experience level (number of
previous operations)
–0.00038 0.001759 0.8307 –0.00383 to 0.003082
Surgeon’s robotic experience level (number of previous
operations)
–0.00232 0.006330 0.7141 –0.01476 to 0.01012
Interaction term: treatment × surgeon’s laparoscopic
experience level
0.000037 0.002728 0.9891 –0.00533 to 0.005399
Interaction term: treatment × surgeon’s robotic
experience level
–0.01651 0.009887 0.0958 –0.03594 to 0.002929





Operating surgeon (random effect) 0.640 0.429
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Adjusting for actual procedure instead of intended procedure had a minor effect on model estimates.
The treatment effect estimate (OR) adjusting for actual procedure was 0.572 (95% CI 0.289 to 1.132),
which was a minor change from the primary analysis model, although it still points to the same conclusion.
Further details are given in Appendix 2.
Key secondary end point: circumferential resection margin
positivity (CRM+)
A total of 459 (98.5%) patients of the 466 who had an operation had complete pathology data available
(Table 21). In that group, 26 out of 459 (5.7%) patients were CRM+, 14 out of 224 (6.25%) patients in
the laparoscopic group and 12 out of 235 (5.11%) patients in the robotic group (unadjusted difference
in proportions 1.14%, 95% CI –3.10% to 5.38%). There was no statistically significant difference in the
odds of CRM+ between the groups (adjusted OR 0.785, 95% CI 0.350 to 1.762; p = 0.56). It should be
noted that the variance component estimate for operating surgeon is 0, and consequently there is not a
valid standard error estimate for this. This indicates that the variation of odds of CRM+ between surgeons
was negligible (Table 22).
TABLE 20 Actual procedure performed vs. intended procedure
Actual procedure performed
Intended procedure, n (%)
HAR (N= 68) LAR (N= 312) APR (N= 86) Total (N= 466)
HAR 37 (54.4) 10 (3.2) 0 (0.0) 47 (10.1)
LAR 29 (42.6) 283 (90.7) 5 (5.8) 317 (68.0)
APR 1 (1.5) 15 (4.8) 81 (94.2) 97 (20.8)
Other 1 (1.5) 4 (1.3) 0 (0.0) 5 (1.1)
















14/224 (6.3) 12/235 (5.1) 1.1 (–3.1 to 5.4) 0.785 0.350 to 1.762 0.5566
Sex: male (vs. female) 4/148 (2.7) 22/311 (7.1) –4.4 (–8.2 to –0.5) 2.770 0.928 to 8.270 0.0679
BMI class: overweight
(vs. underweight/normal)
12/178 (6.7) 12/176 (6.8) –0.1 (–5.3 to 5.2) 1.099 0.471 to 2.563 0.8272
BMI class: obese
(vs. underweight/normal)




13/258 (5.0) 13/201 (6.5) –1.4 (–5.8 to 2.9) 1.136 0.491 to 2.628 0.7647
Intended procedure: HAR
(vs. LAR)
16/308 (5.2) 2/68 (2.9) 2.3 (–7.0 to 2.5) 0.593 0.129 to 2.736 0.5022
Intended procedure: APR
(vs. LAR)
16/308 (5.2) 8/83 (9.6) –4.4 (–11.3 to 2.4) 2.010 0.799 to 5.056 0.1377
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Subgroup analyses
As a result of the low frequency of CRM+, many subgroups had insufficient numbers to yield meaningful
estimates of the treatment effect.
Further details are given in Appendix 2.
Key secondary end point: 3-year local recurrence
Follow-up times are summarised in Table 23. Median follow-up time from randomisation was 3.1 years.
The seven patients with missing data in Table 23 had non-standard circumstances; three patients had
benign disease (two laparoscopic, one robotic), one patient did not undergo surgery (laparoscopic) and
three patients had palliative surgery only (one laparoscopic, two robotic). These seven patients were
censored at time 0.
A local recurrence was observed in 30 out of 471 (6.4%) patients, 14 out of 234 (6.0%) in the laparoscopic
group and 16 out of 237 (6.8%) in the robotic group. The date of local recurrence was defined as the date
of the relevant assessment (i.e. clinical, radiological and pathological) that first detected the local recurrence.
The estimated cumulative incidence of local recurrence in each treatment group is presented in Figure 2
(note that the y-axis is truncated to 0–0.1). At 3 years, the estimated difference (robotic minus laparoscopic)
in cumulative incidence of local recurrence is 0.002 (95% CI –0.041 to 0.046).
Table 24 presents the estimated adjusted HRs and corresponding 95% CIs and Wald test p-values from
the shared frailty model. There is not a statistically significant difference between the treatment groups.
The estimated adjusted HR suggests that a patient undergoing robotic surgery is 1.137 (95% CI 0.554,
2.335; p = 0.756) times more likely to experience local recurrence than a patient undergoing laparoscopic
surgery, all else being equal.
There appears to be a substantial difference in probability of local recurrence between males and females, with
males much more likely to experience the event (adjusted HR 3.184, 95% CI 1.109 to 9.174; p = 0.031). This
is reflected in the plot of cumulative incidence by sex in Figure 3 (note that the y-axis is truncated to 0–0.1).




Operating surgeon (random effect) 0.000 N/A
N/A, not applicable.
TABLE 23 Length of follow-up from randomisation, by treatment group









Mean (SD) 3.1 (1.07) 3.2 (1.12) 3.2 (1.10)
Median (range) 3.1 (0.0–6.1) 3.1 (0.0–6.0) 3.1 (0.0–6.1)
(Q1, Q3) (3.0, 4.0) (3.0, 3.9) (3.0, 4.0)
Missing 4 3 7
Q1, first interquartile; Q3, third interquartile.
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Subgroup analyses
None of the prespecified subgroup analyses yielded meaningful evidence of an interaction between
treatment effect and subgroup, or evidence of a treatment effect within any individual subgroup. Given
the clear (main) effect of sex on local recurrence, and the clinical plausibility of a potential difference of
treatment effect by sex, an ad-hoc sex subgroup analysis was performed. Similarly, this subgroup analysis

























Time from randomisation (years)



















FIGURE 2 Estimated cumulative incidence of local recurrence, by treatment group.
TABLE 24 Three-year local recurrence: adjusted estimates of HRs and 95% CIs from random shared frailty model
Parameter HR 95% CI p-value
Treatment allocation: robotic (vs. laparoscopic) 1.137 0.554 to 2.335 0.7257
Sex: male (vs. female) 3.184 1.109 to 9.174 0.0314
Neo-adjuvant therapy: yes (vs. no) 1.083 0.510 to 2.299 0.8361
BMI classification obese (vs. underweight/normal) 0.954 0.345 to 2.634 0.927
BMI classification overweight (vs. underweight/normal) 1.366 0.603 to 3.095 0.4545
Intended procedure HAR (vs. LAR) 0.645 0.187 to 2.224 0.4873
Intended procedure APR (vs. LAR) 1.07 0.423 to 2.707 0.886
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Intraoperative complications
A total of 70 out of 466 (15.0%) patients had an intraoperative complication, 34 out of 230 (14.8%) in the
laparoscopic group and 36 out of 236 (15.3%) in the robotic group (unadjusted risk difference 0.5%, 95% CI
–6.0% to 7.0%). Table 25 presents the numbers of patients experiencing different types of intraoperative
complications. The most common intraoperative complications were damage to an organ/structure, significant
haemorrhage and surgical equipment failure. Table 26 presents the multilevel logistic regression model.
There was no significant difference between the groups (adjusted OR 1.020, 95% CI 0.599 to 1.736; p = 0.94).
There is significant evidence of a difference in the odds of having an intraoperative complication between males
and females (adjusted OR 3.083, 95% CI 1.543 to 6.158; p = 0.0015). Note that the variance component
estimate for operating surgeon is 0 and consequently there is not a valid standard error estimate for this.
This indicates that the variation of odds of CRM+ between surgeons was negligible (Table 27).
Thirty-day postoperative complications
A total of 151 out of 466 (32.4%) patients had a postoperative complication within 30 days of their
operation, 73 out of 230 (31.7%) in the laparoscopic group and 78 out of 236 (33.1%) in the robotic
group (unadjusted risk difference –1.3%, 95% CI –9.8% to 7.2%). Table 28 presents the numbers of
patients who experienced different types of postoperative complications within 30 days of their operation.
The most common were gastrointestinal complications (including anastomotic leak), surgical site infections
and urinary complications. Tables 29 and 30 present the multilevel logistic regression model. There was no
significant difference between the groups (adjusted OR 1.043, 95% CI 0.689 to 1.581; p = 0.84). There is
significant evidence of a difference in the odds of having a postoperative complication within 30 days of
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FIGURE 3 Estimated cumulative incidence of local recurrence by sex.
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TABLE 25 Numbers of patients experiencing intraoperative complications
Intraoperative complications
Treatment group, n (%)
Laparoscopic surgery (N= 230) Robotic surgery (N= 236)
Damage to organ/structure 5 (2.2) 11 (4.7)
Significant haemorrhage 11 (4.8) 4 (1.7)
Equipment failure 6 (2.6) 8 (3.4)
Faecal contamination 6 (2.6) 7 (3.0)
Anastomotic complication 6 (2.6) 7 (3.0)
Iatrogenic tumour perforation 3 (1.3) 2 (0.8)
Inadequate tumour localisation/clearance 2 (0.9) 2 (0.8)
Respiratory event 2 (0.9) 1 (0.4)
Cardiac event 1 (0.4) 1 (0.4)
Overall 34 (14.8) 36 (15.3)
Counts are the number of patients who experienced the complication; the categories are not mutually exclusive.















34/230 (14.8) 36/236 (15.3) –0.5 (–6.0 to 7.0) 1.020 0.599 to 1.736 0.9426
Sex: male (vs. female) 11/149 (7.4) 59/317 (18.6) –11.2 (–17.2 to –5.2) 3.083 1.543 to 6.158 0.0015
BMI class: overweight
(vs. underweight/normal)
25/179 (14.0) 30/180 (16.7) –2.7 (–10.2 to 4.7) 1.280 0.699 to 2.344 0.4222
BMI class: obese
(vs. underweight/normal)




24/262 (9.2) 46/204 (22.6) –13.4 (–20.1 to –6.7) 3.480 1.955 to 6.192 < 0.0001
Intended procedure:
HAR (vs. LAR)
53/312 (17.0) 9/68 (13.2) 3.8 (–5.3 to 12.8) 1.143 0.502 to 2.601 0.7504
Intended procedure:
APR (vs. LAR)
53/312 (17.0) 8/86 (9.3) 7.7 (0.3 to 15.1) 0.403 0.179 to 0.908 0.0284




Operating surgeon (random effect) 0.0 N/A
N/A, not applicable.
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TABLE 28 Numbers of patients experiencing postoperative complications within 30 days of their operation
30-day complications
Treatment group, n (%)
Laparoscopic surgery (N= 230) Robotic surgery (N= 236)
Gastrointestinal complication 40 (17.4) 35 (14.8)
Surgical site infection 19 (8.3) 21 (8.9)
Urinary complication 14 (6.1) 17 (7.2)
Respiratory complication 6 (2.6) 4 (1.7)
Cardiac complication 6 (2.6) 3 (1.3)
Other 12 (5.2) 17 (7.2)
Overall 73 (31.7) 78 (33.1)
Counts are the number of patients who experienced the complication; the categories are not mutually exclusive.
















73/230 (31.7) 78/236 (33.1) –1.3 (–9.8 to 7.2) 1.043 0.689 to 1.581 0.8407
Sex: male (vs. female) 30/149 (20.1) 121/317 (38.2) –18.0 (–26.4 to –9.7) 2.565 1.573 to 4.183 0.0002
BMI class: overweight
(vs. underweight/normal)
53/179 (29.6) 52/180 (28.9) 0.1 (–8.7 to 10.1) 0.946 0.578 to 1.548 0.8236
BMI class: obese
(vs. underweight/normal)




75/262 (28.6) 76/204 (37.3) –8.6 (–17.2 to –0.3) 1.432 0.906 to 2.264 0.1241
Intended procedure:
HAR (vs. LAR)
101/312 (32.4) 15/68 (22.1) 10.3 (–21.5 to 0.8) 0.599 0.304 to 1.180 0.1383
Intended procedure:
APR (vs. LAR)
101/312 (32.4) 35/86 (40.7) –8.3 (–19.9 to 3.3) 1.278 0.740 to 2.209 0.3778





Operating surgeon (random effect) 0.286 0.213
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Six-month postoperative complications (after 30 days)
A total of 72 out of 466 (15.5%) patients had a postoperative complication after 30 days and within 6 months
of their operation, 38 out of 230 (16.5%) in the laparoscopic group and 34 out of 236 (14.4%) in the robotic
group (unadjusted risk difference 2.1%, 95% CI –4.5% to 8.7%). Table 31 presents the numbers of patients
to experience different types of postoperative complications after 30 days and within 6 months of their
operation. The most common was gastrointestinal complication (including anastomotic leak). Tables 32 and 33
present the multilevel logistic regression model. There was no significant difference between the groups
(adjusted OR 0.719, 95% CI 0.411 to 1.258; p = 0.25).




Treatment group, n (%)
Laparoscopic surgery (N= 230) Robotic surgery (N= 236)
Gastrointestinal complication 18 (7.8) 20 (8.5)
Urinary complication 6 (2.6) 7 (3.0)
Surgical site infection 8 (3.5) 4 (1.7)
Respiratory complication 3 (1.3) 2 (0.8)
Cardiac complication 1 (0.4) 0 (0.0)
Cerebrovascular complication 1 (0.4) 0 (0.0)
Other 12 (5.2) 7 (3.0)
Overall 38 (16.5) 34 (14.4)
Counts are the number of patients who experienced the complication; the categories are not mutually exclusive.
















38/230 (16.5) 34/236 (14.4) 2.1 (–4.5 to 8.7) 0.719 0.411 to 1.258 0.2468
Sex: male (vs. female) 19/149 (12.8) 53/317 (16.7) –4.0 (–10.7 to 2.8) 1.230 0.654 to 2.313 0.5197
BMI class: overweight
(vs. underweight/normal)
31/179 (17.3) 24/180 (13.3) 4.0 (–3.5 to 11.4) 0.715 0.371 to 1.378 0.3156
BMI class: obese
(vs. underweight/normal)




31/262 (11.8) 41/204 (20.1) –8.3 (–15.0 to –1.5) 1.704 0.906 to 3.206 0.0979
Intended procedure:
HAR (vs. LAR)
50/312 (16.0) 6/68 (8.8) 7.2 (–0.7 to 15.1) 0.620 0.228 to 1.686 0.3479
Intended procedure:
APR (vs. LAR)
50/312 (16.0) 16/86 (18.6) –2.6 (–11.8 to 6.6) 1.166 0.561 to 2.423 0.6794
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Thirty-day operative mortality
Death within 30 days of operation was a rare event, with 2 out of 230 (0.87%) and 2 out of 236 (0.85%)
events in the standard laparoscopic and robotic groups, respectively. All deaths involved a septic complication
and were related to the surgical intervention. Owing to the small number of events, sophisticated statistical
models were not fitted.
Patient self-reported bladder function
Higher I-PSS indicates worse bladder function and is measured on a scale of 0–35.
Baseline characteristics of the population of patients with complete I-PSS data, and a comparison with
those patients with missing I-PSS data, are given in Appendix 4.
Figure 4 visualises the distribution of I-PSS scores at 6 months post operation in the two treatment groups.
The distribution of scores is very similar between the groups.
Tables 34 and 35 present the multilevel generalised linear model. Normal errors were assumed, so the
estimates represent differences in the mean I-PSS. The estimated difference in mean I-PSS (robotic minus
standard) is –0.7426 (95% CI –2.0722 to 0.5870; p = 0.2726). On the 35-point scale, this is a very small
effect size that is also not statistically significant. The baseline score is highly prognostic of the 6-month
score. The estimated difference in mean I-PSS between patients with a difference in baseline score of
10 points, all else being equal, is 4.20 (95% CI 3.23 to 5.17; p < 0.0001).




















FIGURE 4 Box plot of observed I-PSS values at baseline and at 6 months post randomisation, by treatment group.
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Patient self-reported sexual function: males
A higher IIEF score indicates better sexual function; the score is measured on a scale of 5–75.
Baseline characteristics of the population of patients with complete IIEF data, and a comparison with those
patients with missing IIEF data, are given in Appendix 5.
Figure 5 visualises the distribution of IIEF scores at 6 months post operation in the two treatment groups.
The distribution of scores is very similar between the treatment groups. Median IIEF scores at 6 months
were notably lower than at baseline in both groups.
Tables 36 and 37 present the multilevel generalised linear model. Normal errors were assumed, so the
estimates represent differences in the mean IIEF score. The estimated difference in mean IIEF (robotic minus
standard) is –0.8020 (95% CI –5.7039 to 4.1000; p = 0.7468). On the 70-point scale, this is a very small
effect size that is also not statistically significant.
Patient self-reported sexual function: females
A higher FSFI score indicates better sexual function; the score is measured on a scale of 2–36.
Baseline characteristics of the population of patients with complete FSFI data, and a comparison with those
patients with missing FSFI data, are given in Appendix 6.
Figure 6 visualises the distribution of FSFI scores at 6 months post operation in the two treatment groups.
The distribution of scores is very similar between the treatment groups.
TABLE 34 The I-PSS: adjusted estimates of mean effects and 95% CIs from random intercept model
Effect Estimate Standard error p-value 95% CI
Intercept 3.8249 0.9557 0.0003 1.8867 to 5.7631
Treatment: robotic-assisted surgery (vs. standard) –0.7426 0.6757 0.2726 –2.0722 to 0.5870
Sex: male (vs. female) 1.7798 0.7425 0.0171 0.3188 to 3.2407
BMI class: overweight (vs. underweight/normal) 0.3740 0.7741 0.6293 –1.1493 to 1.8973
BMI class: obese (vs. underweight/normal) 0.2473 0.9268 0.7898 –1.5764 to 2.0710
Previous neo-adjuvant therapy: yes (vs. no) –1.1450 0.7345 0.1201 –2.5903 to 0.3003
Intended procedure: HAR (vs. LAR) –1.0208 1.0117 0.3138 –3.0116 to 0.9699
Intended procedure: APR (vs. LAR) 2.7760 0.9326 0.0031 0.9410 to 4.6111
Baseline I-PSS (1-unit increase) 0.4198 0.04933 < 0001 0.3228 to 0.5169
TABLE 35 The I-PSS: estimate of the variance component from random intercept model
Parameter Subject Estimate Standard error
Intercept Surgeon 1.2834 1.4209
Residual 38.9462 3.1275
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Tables 38 and 39 present the multilevel generalised linear model. Normal errors were assumed, so the
estimates represent differences in the mean FSFI score. The estimated difference in the mean FSFI score
(robotic minus standard) is –1.2309 (95% CI –6.0030 to 3.5413; p = 0.6010). On the 34-point scale, this is
a small effect size that is also not statistically significant.
Patient self-reported generic health
The SF-36 is a multipurpose, short-form health survey with 36 questions. It has eight scales of functional
health: physical functioning, social functioning, role limitation physical, role limitation emotional, mental
health, vitality, pain and general health that are scored on a 0–100 scale. It also provides a physical




















FIGURE 5 Box plot of observed IIEF values at baseline and at 6 months post randomisation, by treatment group.
TABLE 36 The IIEF: adjusted estimates of mean effects and 95% CIs from random intercept model
Effect Estimate Standard error Pr> |t| 95% CI
Intercept 9.7690 3.6018 0.0104 2.4493 to 17.0887
Treatment: robotic-assisted surgery (vs. standard) –0.8020 2.4793 0.7468 –5.7039 to 4.1000
BMI class: overweight (vs. underweight/normal) –0.7386 2.9556 0.8030 –6.5823 to 5.1051
BMI class: obese (vs. underweight/normal) 3.0106 3.3590 0.3717 –3.6307 to 9.6519
Previous neo-adjuvant therapy: yes (vs. no) –5.1767 3.0462 0.0915 –11.1996 to 0.8462
Intended procedure: HAR (vs. LAR) 7.2280 3.7064 0.0532 –0.1001 to 14.5562
Intended procedure: APR (vs. LAR) –0.7213 3.6837 0.8450 –8.0046 to 6.5620
Baseline total IIEF score (1-unit increase) 0.5171 0.05045 < 0001 0.4174 to 0.6169
TABLE 37 The IIEF: estimate of the variance component from random intercept model
Parameter Subject Estimate Standard error
Intercept Surgeon 51.9161 29.1957
Residual 250.47 29.2417
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The SF-36 was collected at baseline, and at 30 days and at 6 months post operation.
A higher score indicates a better QoL.
Baseline characteristics of the population of patients with complete generic QoL data, and a comparison
with those patients with missing generic QoL data, are given in Appendix 7.
Tables 40 and 41 show the multilevel linear model for the PCS and MCS, respectively. Figures 7 and 8 illustrate
the model estimates and 95% CIs at baseline and at 1 month and 6 months post randomisation of the





















FIGURE 6 Box plot of observed FSFI values at baseline and at 6 months post randomisation, by treatment group.
TABLE 38 The FSFI: adjusted estimates of mean effects and 95% CIs from random intercept model
Effect Estimate Standard error Pr> |t| 95% CI
Intercept 9.0710 3.2464 0.0116 2.2762 to 15.8657
Treatment: robotic-assisted surgery (vs. standard) –1.2309 2.3258 0.6010 –6.0030 to 3.5413
BMI class: overweight (vs. underweight/normal) 4.1518 2.7584 0.1439 –1.5079 to 9.8116
BMI class: obese (vs. underweight/normal) –0.9541 3.2873 0.7738 –7.6992 to 5.7909
Previous neo-adjuvant therapy: yes (vs. no) –0.8097 2.7129 0.7676 –6.3761 to 4.7567
Intended procedure: HAR (vs. LAR) –0.7669 3.2401 0.8147 –7.4151 to 5.8813
Intended procedure: APR (vs. LAR) –4.9505 3.1579 0.1286 –11.4300 to 1.5289
Baseline FSFI score (1-unit increase) 0.4629 0.1147 0.0004 0.2275 to 0.6982
TABLE 39 The FSFI: estimate of the variance component from random intercept model
Parameter Subject Estimate Standard error
Intercept Surgeon 0.1703 10.2019
Residual 70.5888 16.9383
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the groups at baseline is negligible: –0.1220 (95% CI –1.6281 to 1.3840; p = 0.8737). This is also the case
at 1 month and 6 months post randomisation, as shown by the small magnitude and large p-values for the
estimates of interaction between treatment effect and time (see Table 40). The estimated average difference
in MCS between the groups at baseline is also negligible, –0.4875 (95% CI –2.6008 to 1.6258; p = 0.6508).
Again this does not change notably over time, as seen in Figure 8 and by the small magnitude and large
p-values of the estimates of interaction between time and treatment effect in Table 32.
TABLE 40 The SF-36v2 PCS: adjusted estimates of mean effects and 95% CIs from random intercept model
Effect Estimate Standard error Pr> |t| 95% CI
Intercept 54.5476 1.6592
30 days –7.3421 1.7918 < 0.0001 –10.8595 to –3.8247
6 months –2.1738 1.8099 0.2301 –5.7266 to 1.3791
Treatment: robotic-assisted laparoscopic surgery
(vs. standard)
–0.1220 0.7672 0.8737 –1.6281 to 1.3840
Sex: female (vs. male) –1.4117 0.6549 0.0314 –2.6974 to –0.1260
Neo-adjuvant therapy: no (vs. yes) 3.0683 0.8419 0.0003 1.4156 to 4.7210
Intended procedure: APR (vs. HAR) –2.8637 1.4321 0.0459 –5.6750 to –0.05246
Intended procedure: LAR (vs. HAR) –0.2736 1.1468 0.8115 –2.5249 to 1.9776
BMI class: obese (vs. underweight/normal) –0.2153 1.0415 0.8363 –2.2597 to 1.8292
BMI class: overweight (vs. underweight/normal) 0.9225 0.8818 0.2958 –0.8085 to 2.6535
ASA grade: (II vs. I) –3.8012 1.0400 0.0003 –5.8427 to –1.7597
ASA grade: (III vs. I) –6.6250 1.2870 < 0001 –9.1513 to –4.0986
Robotic-assisted laparoscopic surgery and 30-day
interaction
0.4651 0.8664 0.5916 –1.2357 to 2.1659
Robotic-assisted laparoscopic surgery and
6-month interaction
0.6086 0.8777 0.4882 –1.1143 to 2.3315
ASA grade II and 30-day interaction 2.4549 1.1467 0.0326 0.2039 to 4.7058
ASA grade III and 30-day interaction 3.4690 1.3853 0.0125 0.7495 to 6.1884
ASA grade II and 6-month interaction 0.5546 1.1382 0.6262 –1.6797 to 2.7889
ASA grade III and 6-month interaction 2.7739 1.3844 0.0455 0.05625 to 5.4916
No neo-adjuvant therapy and 30-day interaction –3.4295 0.9152 0.0002 –5.2262 to –1.6329
No neo-adjuvant therapy and 6-month
interaction
–2.9066 0.9271 0.0018 –4.7266 to –1.0867
APR and 30-day interaction –2.6589 1.5995 0.0969 –5.7989 to 0.4810
APR and 6-month interaction 0.5959 1.6210 0.7133 –2.5862 to 3.7780
LAR and 30-day interaction –1.9226 1.2971 0.1387 –4.4688 to 0.6237
LAR and 6-month interaction –0.2858 1.3196 0.8286 –2.8764 to 2.3047
Obese and 30-day interaction –2.6187 1.1657 0.0250 –4.9071 to –0.3303
Obese and 6-month interaction –1.5758 1.1784 0.1816 –3.8891 to 0.7375
Overweight and 30-day interaction –0.5450 0.9780 0.5775 –2.4647 to 1.3748
Overweight and 6-month interaction –0.3320 0.9915 0.7378 –2.2784 to 1.6143
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TABLE 41 The SF-36v2 MCS: adjusted estimates of mean effects and 95% CIs from random intercept model
Effect Estimate Standard error Pr> |t| 95% CI
Intercept 40.4101 3.3900
30 days –2.3060 2.3656 0.3300 –6.9498 to 2.3378
6 months 4.4232 2.3888 0.0645 –0.2661 to 9.1125
Treatment: robotic-assisted laparoscopic surgery
(vs. standard)
–0.4875 1.0766 0.6508 –2.6008 to 1.6258
Sex: female (vs. male) –3.0157 0.9511 0.0016 –4.8828 to –1.1486
Neo-adjuvant therapy: no (vs. yes) 1.6362 1.1905 0.1697 –0.7008 to 3.9733
Intended procedure: APR (vs. HAR) –2.8133 2.0057 0.1611 –6.7505 to 1.1240
Intended procedure: LAR (vs. HAR) –0.7372 1.6047 0.6461 –3.8873 to 2.4130
BMI class: obese (vs. underweight/normal) 0.8777 1.4551 0.5466 –1.9786 to 3.7340
BMI class: overweight (vs. underweight/normal) –0.2983 1.2335 0.8090 –2.7198 to 2.1232
Age 0.1339 0.04350 0.0022 0.04845 to 0.2193
ASA grade: (II vs. I) 0.2121 1.4829 0.8863 –2.6988 to 3.1230
ASA grade: (III vs. I) –0.6905 1.8218 0.7048 –4.2668 to 2.8859
ASA grade: (IV vs. I) –13.0801 11.6604 0.2623 –35.9699 to 9.8097
Robotic-assisted laparoscopic surgery and 30-day
interaction
2.0753 1.1435 0.0699 –0.1694 to 4.3200
Robotic-assisted laparoscopic surgery and 6-month
interaction
0.2681 1.1576 0.8169 –2.0042 to 2.5404
ASA grade II and 30-day interaction 0.5556 1.5142 0.7137 –2.4168 to 3.5281
ASA grade III and 30-day interaction 0.1340 1.8290 0.9416 –3.4564 to 3.7243
ASA grade II and 6-month interaction –2.4933 1.5015 0.0972 –5.4408 to 0.4541
ASA grade III and 6-month interaction –1.5419 1.8273 0.3990 –5.1289 to 2.0451
No neo-adjuvant therapy and 30-day interaction –1.1184 1.2080 0.3548 –3.4897 to 1.2530
No neo-adjuvant therapy and 6-month interaction –1.0979 1.2230 0.3696 –3.4987 to 1.3029
APR and 30-day interaction –0.4158 2.1120 0.8440 –4.5618 to 3.7302
APR and 6-month interaction –1.0937 2.1408 0.6096 –5.2960 to 3.1087
LAR and 30-day interaction –1.4976 1.7126 0.3822 –4.8595 to 1.8644
LAR and 6-month interaction –1.9039 1.7421 0.2748 –5.3237 to 1.5159
Obese and 30-day interaction –1.7664 1.5395 0.2516 –4.7885 to 1.2557
Obese and 6-month interaction 0.4705 1.5564 0.7625 –2.5849 to 3.5258
Overweight and 30-day interaction 0.4266 1.2903 0.7410 –2.1063 to 2.9596
Overweight and 6-month interaction 1.2397 1.3073 0.3433 –1.3266 to 3.8059
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Patient self-reported fatigue
The MFI-20 is a self-report instrument. It contains 20 statements that cover different aspects of fatigue.
These 20 items are organised in five scales: general fatigue, physical fatigue, reduced activity, reduced
motivation and mental fatigue.
The scores per item run from 1 to 5. For each scale, consisting of four items, a total score is calculated
by summation of the scores of the individual items. Scores can range from the minimum of 4 to the
maximum of 20. The use of a total score over all 20 items is not recommended.
The MFI-20 was collected at baseline, at 30 days post operation and at 6 months post operation. A higher
































FIGURE 7 Adjusted estimates and 95% CIs of mean SF-36v2 PCS values at baseline, at 1 month and at 6 months
































FIGURE 8 Adjusted estimates and 95% CIs of mean SF-36v2 MCS values at baseline, at 1 month and at 6 months
post randomisation, by treatment group.
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Baseline characteristics of the population of patients with complete MFI-20 data, and a comparison with
those patients with missing MFI-20 data, are given in Appendix 8.
Figure 9 illustrates the model estimates and 95% CIs at baseline, at 1 month and at 6 months post
randomisation for each of the five scales, split by treatment group. The estimated differences between the
treatment groups in scores at baseline were as follows: general fatigue –0.2517 (95% CI –0.5965 to 1.0999;
p = 0.5603), physical fatigue 0.3964 (95% CI –0.4404 to 1.2332; p = 0.3527), reduced activity –0.1634
(95% CI –0.9777 to 0.6510; p = 0.6938), reduced motivation –0.03917 (95% CI –0.7324 to 0.6540;
p = 0.9117) and mental fatigue 0.1374 (95% CI –0.6626 to 0.9374; p = 0.7360). All of these differences are
small and none are statistically significant. Furthermore, this lack of a notable difference between the groups
persists over time, as seen in Figure 9 and in the non–significant interaction terms in the model; further































































FIGURE 9 Adjusted estimates and 95% CIs of mean values of each of the five scales of the MFI-20 at baseline,
at 1 month and at 6 months post randomisation, by treatment group. (a) General fatigue; (b) physical fatigue;
(c) reduced activity; (d) reduced motivation; and (e) mental fatigue. (continued )
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FIGURE 9 Adjusted estimates and 95% CIs of mean values of each of the five scales of the MFI-20 at baseline,
at 1 month and at 6 months post randomisation, by treatment group. (a) General fatigue; (b) physical fatigue;
(c) reduced activity; (d) reduced motivation; and (e) mental fatigue.
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Plane of surgery
A total of 456 out of 471 (96.8%) patients had a returned pathology report with data for the mesorectal
plane assessment. There were 351 out of 456 (77.0%) patients’ specimens graded as mesorectal plane
in the pathology report, 178 out of 233 (76.4%) in the laparoscopic group and 173 out of 223 (77.6%)
in the robotic group (unadjusted risk difference 1.2%, 95% CI –6.5% to 8.9%). Table 42 presents the crude
summary of plane of resection (mesorectum) between the treatment groups. Tables 43 and 44 present the
TABLE 42 Observed planes of resection (mesorectum), by treatment group
Mesorectum plane
Treatment group, n (%)





Mesorectal fascial plane 173 (73.9) 178 (75.1) 351 (74.5)
Intramesorectal plane 38 (16.2) 33 (13.9) 71 (15.1)
Muscularis propria plane 12 (5.1) 22 (9.3) 34 (7.2)
Missing 11 (4.7) 4 (1.7) 15 (3.2)















173/223 (77.6) 178/233 (76.4) 1.2 (–6.5 to 8.9) 0.943 0.565 to 1.572 0.8211
Sex: male (vs. female) 122/149 (81.9) 229/307 (74.6) 7.3 (–0.6 to 15.2) 0.729 0.411 to 1.295 0.2808
BMI class: overweight
(vs. underweight/normal)
142/177 (80.2) 134/175 (76.6) 3.7 (–4.9 to 12.3) 0.851 0.458 to 1.580 0.6086
BMI class: obese
(vs. underweight/normal)




197/256 (77.0) 154/200 (77.0) –0.1 (–7.8 to 7.7) 0.796 0.435 to 1.454 0.4569
Intended procedure:
HAR (vs. LAR)
251/308 (81.5) 55/68 (80.9) 0.6 (–9.7 to 10.9) 0.901 0.411 to 1.977 0.7943
Intended procedure:
APR (vs. LAR)
251/308 (81.5) 45/80 (56.3) 25.2 (13.5 to 37.0) 0.358 0.185 to 0.694 0.0024




Operating surgeon (random effect) 2.236 1.021
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multilevel logistic regression model. There was no significant difference of the odds of ‘mesorectal plane’
between the groups (adjusted OR 0.943, 95% CI 0.565 to 1.572; p = 0.821). Patients undergoing APR have
notably lower odds of a mesorectal plane grading [adjusted OR (vs. LAR) 0.358, 95% CI 0.185 to 0.694;
p = 0.0024].
Disease-free survival
A recurrence was observed in 73 out of 471 (15.5%) patients, 38 out of 234 (16.2%) in the laparoscopic
group and 35 out of 237 (14.8%) in the robotic group.
The date of recurrence was defined as the date of the relevant assessment (i.e. clinical, radiological and
pathological) that first detected the recurrence.
Kaplan–Meier estimates of DFS in each treatment group are presented in Figure 10.
Tables 45 and 46 present the estimated HRs and corresponding 95% CIs and Wald test p-values from the
shared frailty model. There is no statistically significant difference between the treatment groups. The
estimated adjusted HR suggests that a patient undergoing robotic surgery is 1.030 (95% CI 0.713 to 1.489;
p = 0.874) times more likely to experience a recurrence or a new primary cancer or to die than a patient
undergoing laparoscopic surgery, all else being equal.
There appears to be a substantial difference in DFS between patients undergoing different types of operation.
All else being equal, those patients undergoing an APR are most likely to have a recurrence, a new primary
cancer or to die (adjusted HR vs. LAR: 1.602, 95% CI 1.035 to 2.479; p = 0.034), and those patients
undergoing HAR are least likely to have a recurrence, a new primary cancer or to die (adjusted HR vs. LAR
0.421, 95% CI 0.191 to 0.925; p = 0.031).
Subgroup analyses
None of the prespecified subgroup analyses yielded meaningful evidence of an interaction between treatment
effect and subgroup, or evidence of a treatment effect within any individual subgroup. Given the clear (main)
effect of sex on DFS, and the clinical plausibility of a potential difference of treatment effect by sex, an ad hoc
sex subgroup analysis was performed. Similarly, this subgroup analysis showed no evidence of a subgroup by
treatment interaction and no significant treatment effect within either subgroup.
Further details are given in Appendix 9.
Overall survival
Death was observed for 46 out of 471 (9.8%) patients, 23 out of 234 (9.8%) in the laparoscopic group
and 23 out of 237 (9.7%) in the robotic group.
Kaplan–Meier estimates of OS in each treatment group are presented in Figure 11.
Tables 47 and 48 present the estimated HRs and corresponding 95% CIs and Wald test p-values from the
shared frailty model. There is not a statistically significant difference between the treatment groups. The
estimated adjusted HR suggests that a patient undergoing robotic surgery is 0.945 (95% CI 0.530 to 1.686;
p = 0.848) times more likely to die than a patient undergoing laparoscopic surgery, all else being equal.
There appears to be a notable difference in the risk of death between males and females. All else being equal,
the probability of death in males is 2.187 (95% CI 1.017 to 4.700; p = 0.045) times greater than in females.
RESULTS
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None of the prespecified subgroup analyses yielded meaningful evidence of an interaction between treatment
effect and subgroup, or evidence of a treatment effect within any individual subgroup. Given the clear (main)
effect of sex on OS, and the clinical plausibility of a potential difference of treatment effect by sex, an ad-hoc
sex subgroup analysis was performed. Similarly, this subgroup analysis showed no evidence of a subgroup by
treatment interaction and no significant treatment effect within either subgroup.
Further details are given in Appendix 9.
Health economics
The results of the primary analysis are reported in Table 49. There are very similar QoL figures across
the two groups, with a difference of 0.014 QALYs across the first 6 months of treatment. Across both
groups, the pattern is of baseline EQ-5D utilities being highest pre-surgery (0.810 vs. 0.828) and noticeably
lower at 30 days (0.680 vs. 0.700). The utilities are much closer to their pre-surgery values by 6 months
(0.774 vs. 0.798).
There is an overall cost difference of £980 across the two groups of the trial over the first 6 months of
treatment. Across the different categories of costs in the model, robotic surgery is around £1085 more
expensive than laparoscopic surgery. The main drivers of the higher operative costs for robotic surgery are
(1) the duration of surgery (357 minutes and 408 minutes, respectively), which has a knock-on effect on
the cost of theatre time and staff, and (2) the use of surgical instruments. There is very little difference in
the number of staff in attendance (mean number of assistants 1.7 and 1.63). As more stomas are formed
with laparoscopic surgery, the mean costs of both reversal surgeries (£585 vs. £481; £104) and stoma
supplies (£547 vs. £486; £61) are slightly higher for this form of surgery. Mean costs are marginally higher
for the robotic group in terms of medications and other health professional contacts (e.g. outpatients, GPs,
nurses, etc.), although these differences are small (£590 vs. £656; –£66).
TABLE 45 Disease-free survival: adjusted estimates of HRs and 95% CIs from random shared frailty model
Parameter HR 95% CI p-value
Treatment allocation: robotic (vs. laparoscopic) 1.030 0.713 to 1.489 0.8736
Sex: male (vs. female) 1.487 0.973 to 2.272 0.0665
Neo-adjuvant therapy: yes (vs. no) 1.259 0.857 to 1.848 0.2401
BMI classification: obese (vs. underweight/normal) 0.875 0.523 to 1.462 0.6095
BMI classification: overweight (vs. underweight/normal) 1.274 0.840 to 1.934 0.2542
Intended procedure: APR (vs. LAR) 1.602 1.035 to 2.479 0.0344
Intended procedure: HAR (vs. LAR) 0.421 0.191 to 0.925 0.0313




Operating surgeon (random effect) 0.0271 0.0745
RESULTS
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TABLE 47 Overall survival: adjusted estimates of HRs and 95% CIs from random shared frailty model
Parameter HR 95% CI p-value
Treatment allocation: robotic (vs. laparoscopic) 0.945 0.530 to 1.686 0.8483
Sex: male (vs. female) 2.187 1.017 to 4.700 0.0450
Neo-adjuvant therapy: yes (vs. no) 1.380 0.756 to 2.522 0.2945
BMI classification: obese (vs. underweight/normal) 0.577 0.258 to 1.290 0.1804
BMI classification: overweight (vs. underweight/normal) 0.652 0.339 to 1.255 0.2007
Intended procedure: APR (vs. LAR) 1.442 0.741 to 2.804 0.2815
Intended procedure: HAR (vs. LAR) 0.520 0.155 to 1.739 0.2881




Operating surgeon (random effect) < 0.001 0.1649
TABLE 49 Results of primary scenario: imputed data for all UK and US patients (n= 190)
Parameter
Treatment group
Laparoscopic surgery (n= 95) Robotic surgery (n= 95)
Mean SD Minimum Maximum Mean SD Minimum Maximum
Overall figures
QALY 0.364 0.097 –0.029 0.499 0.378 0.089 0.023 0.499
Total costs (£) 10,874 2676 6245 26,969 11,853 2940 7330 22,872
Health and QoL
Baseline 0.810 0.192 0.085 1.000 0.828 0.181 0.131 1.000
30 days 0.680 0.229 –0.458 1.000 0.700 0.244 –0.116 1.000
6 months 0.774 0.221 –0.287 1.000 0.798 0.201 –0.248 1.000
Stoma formed (%) 91 28 0 100 81 39 0 100
Days with stoma 146.35 58.71 – 182.00 132.92 69.30 – 182.00
Cost breakdown (£)
Total costs 10,874 2676 6245 26,969 11,853 2940 7330 22,872
Initial surgery 8423 1443 5249 12,466 9508 1219 6591 14,328
Stoma reversals 585 805 – 1691 481 763 – 1691
Stoma supplies 547 292 – 1057 486 351 – 1057
Other surgery 729 2245 – 15,242 723 2233 – 7621
All other costs 590 494 – 5178 656 468 – 3606
RESULTS
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Across this scenario, the expected costs for robotic surgery are higher (£980) and robotic surgery provides
marginally more health (QALY gain 0.014). These figures combine for an estimated incremental cost-
effectiveness ratio (ICER) of £69,837 per QALY. This figure is well in excess of a standard threshold of
£20,000–30,000 per QALY and suggests that robotic surgery, even when not including the sizeable cost
of the robot, is not cost-effective. The implication for this is that, even if this means that the robot is lying
idle, it is less cost-effective to use the robot for rectal resections.
The cost-effectiveness acceptability curve (Figure 12) for this scenario provides an estimate of the likelihood
that this is cost-effective at a cost-effectiveness threshold of £20,000 or £30,000 per QALY. Across the
cases calculated, robotic surgery is cost-effective only 10% of the time when the threshold is taken to be
£20,000 per QALY and only 20% of the time when the threshold is £30,000 per QALY.
Across the other scenarios (Table 50), there was no strong suggestion of cost-effectiveness. For those
patients who intended to receive low anterior surgery at randomisation, the QoL benefit for robotic surgery
is very close to zero; there is a benefit of 0.002 QALYs and the ICER for this scenario is nearly £700,000 per
QALY. Although there is still some small uncertainty about cost-effectiveness (there is a 10% chance that
robotic surgery is cost-effective at £30,000 per QALY), there is no clear case for cost-effectiveness in this
subgroup. Although the corresponding cost-effectiveness would be higher among the other intended
surgical groups at baseline, there is no clinical reason to justify the consideration of these subgroups.
Laparoscopic surgery
Robotic surgery



































FIGURE 12 Cost-effectiveness acceptability curve for the primary analysis.
TABLE 50 Results of the secondary scenarios: complete data for all patients (n= 97), imputed data for UK and US














980 0.014 69,837 9.8 19.5
Low anterior surgery
(UK, USA) (n = 135)
1096 0.002 698,000 5.9 9.8
Complete cases (n = 97) 1241 0.028 43,844 16.1 29.7
All patients (n = 471) 743 0.004 172,943 2.7 5.6
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Across the two remaining sensitivity analyses, the ICER varied greatly according to the group of patients
considered. Only 51% of UK and US patients in the subgroup had complete data on all costing categories
and all QoL values. Data on QoL were more complete, with 133 patients providing enough information to
allow QALYs to be computed. In contrast, only 99 patients provided full cost data. (Two patients provided
cost data but did not provide full data for QALYs.)
In the subgroup with complete data, the ICER was lower than the baseline value, although still above the
standard values for thresholds, at around £44,000 per QALY. It is worth noting that, here, the chance of
cost-effectiveness at £20,000 and £30,000 per QALY is still only 16% and 30%, respectively.
However, the complete-case data appear slightly misleading. Across the 133 patients observed to have
sufficient data to calculate QALYs, there is a 0.017 benefit (vs. 0.014 in the base case and 0.028 in the
complete case). Across the 99 patients with full cost data, the cost difference observed (£1169) is much
more similar to those in both the complete case (£1241) and the base case (£980). This suggests that
the base-case results are broadly consistent with the overall data set and more representative than the
complete-case example.
In contrast, the imputation across the pan-world trial (as opposed to the USA and the UK) produces quite
different numbers. In this case, the benefits estimated are much lower than in the baseline case, leading to
an ICER of > £170,000 per QALY.
RESULTS
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Chapter 4 Discussion
In this study, which, to our knowledge, is the largest randomised trial of robotic-assisted surgery forpatients with rectal adenocarcinoma suitable for curative resection, there were no statistically significant
differences in the rates of conversion to laparotomy for robotic-assisted laparoscopic surgery compared
with conventional laparoscopic surgery (8.1% vs. 12.2%, respectively), and there were no statistically
significant differences in resection margin positivity, complication rates or QoL at 6 months. There is
insufficient evidence to conclude that robotic-assisted laparoscopic surgery, compared with conventional
laparoscopic surgery, reduces the risk of conversion to laparotomy when performed by surgeons of varying
experience with robotic surgery.
The primary outcome measure was conversion to open surgery, based on the hypothesis that the
technological advantages of the robot should facilitate rectal cancer resection and avoid the need to
convert to an open operation. The sample size calculations were based on best available evidence in 2009
and included the largest randomised clinical trial of laparoscopic rectal cancer surgery, the MRC CLASICC
trial, which reported a 34% conversion rate to open surgery.5 A 25% conversion rate from laparoscopic to
open surgery was assumed, giving a sample size of 400 patients to demonstrate a 50% relative reduction
in conversion rate with robotic surgery. The actual overall conversion rate turned out to be much lower,
at 10.1%. A similar reduction in conversion rates with time has been reported in other laparoscopic
rectal cancer trials: COLOUR II 16%,7 ACOSOG Z6501 11%,11 ALaCaRT 9%.10 In our trial, a difference in
conversion rate between laparoscopic (12.2%) and robotic (8.1%) surgery was not statistically significant.
The higher overall conversion in patients undergoing LAR than those undergoing APR probably reflects the
fact that the majority of the oncological component of the operation is performed from the perineum in
the abdominoperineal approach and is less affected by the laparoscopic approach. Similarly, the higher
overall conversion rates for males than females, and obese patients than underweight/normal patients
probably reflects the increasing technical difficulty of carrying out these procedures on these patients.
The sensitivity analysis exploring learning effects suggested a potential benefit of robotic surgery when
performed by surgeons with substantial prior robotic experience, regardless of their level of laparoscopic
experience. This suggests that the majority of participating surgeons were experts in laparoscopic surgery,
but still in their learning phases for robotic surgery, and that at the higher end of the spectrum of
experience in robotic surgery there is evidence of a benefit (in terms of conversion rate) over standard
laparoscopic surgery.
In almost all of the subgroup analyses, there were insufficient numbers of patients to produce statistically
meaningful comparisons between the groups regarding the need to convert to an open operation.
However, differences were apparent in the conversion rates for the laparoscopic and robotic groups in
males, with robotic surgery appearing to offer a benefit. Although results yielded by a subgroup analysis
must be interpreted with caution, the moderate evidence of interaction between sex and treatment effect,
the evidence of a difference between treatments in males, and the clinical plausibility of the robot
facilitating dissections in the narrower male pelvis with more operator-controlled retraction, better optics
and instrument precision, all warrant further investigation into the potential benefit of robotic surgery in
this subgroup of technically challenging patients.
The experience of the participating surgeons was also evident in the low CRM+ rate (overall 5.7%),
which was lower than in previous laparoscopic rectal cancer trials: COLOR II 10%, ACOSOG Z6501 12.1%,
ALaCaRT 7%. Pathological grading of the plane of surgery showed a good standard, with mesorectal
plane surgery observed in 76% overall. This is lower than that reported in COLOR II (88%) and ALaCaRT
(87%), but similar to ACOSOG Z5601 (72.9%), and is probably because of the recognised variation in
reporting between pathologists. In our trial, reporting of pathological plane of surgery was standardised to
the method described by Nagtegaal and Quirke.23 Despite this, there was considerable variation between
DOI: 10.3310/eme06100 EFFICACY AND MECHANISM EVALUATION 2019 VOL. 6 NO. 10
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Jayne et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
55
local reporting of the plane of surgery and that reported on central review, illustrating the subjectivity in
assessment and the need to interpret the results of other trials with caution.
The complication rates following laparoscopic and robotic surgery were similar and there were no safety
issues attributable to the robotic system. Overall 30-day mortality was low at 0.9%, in keeping with the
results of meta-analyses.16,17 The leading causes of intraoperative morbidity were iatrogenic damage to
an organ/structure and significant haemorrhage. In contrast to other studies, haemorrhage was not more
frequently associated with robotic surgery.13 Rectal cancer surgery is a high-risk intervention with 32.4%
of patients experiencing a complication within 30 days and, after that, 15.5% of the patients experiencing
complications between 30 days and 6 months. Complications related to the gastrointestinal tract, including
anastomotic leak, were not surprisingly the most common cause of morbidity at both time points. Despite
advances in operative technique and perioperative care, the high morbidity associated with rectal cancer
surgery has not declined over the past few decades. There is a need for more sophisticated preoperative
stratification systems to enable surgeons to predict patients at risk of complications, to stratify surgery
accordingly and to put pathways in place to prevent complications from occurring and minimise the
consequences should they occur.
Previous studies have shown that both laparoscopic and robotic rectal cancer surgery can result in bladder
and sexual dysfunction, but suggest that recovery is earlier following robotic surgery.19 The analysis of
bladder and sexual function present in the ROLARR study was undertaken at the same time points and
using the same research questionnaires as the previously reported studies. The findings do not support the
published data; there was no significant benefit to postoperative bladder or sexual function from the use
of the robot. Notably, there was little change in any of the I-PSS, IIEF and FSFI scores between baseline and
6 months, suggesting that the ROLARR surgeons were accomplished in autonomic nerve preservation and
that clinically relevant bladder and sexual dysfunction were an infrequent event.
The case for laparoscopic surgery, rather than open surgery, for colorectal cancer is well established with
proven benefits in terms of a shorter stay in hospital and a faster return to normal function. However, it has
been difficult to demonstrate an advantage for the laparoscopic technique in terms of improvements in
QoL. Similarly, in the ROLARR study, we have not been able to show an obvious advantage for robotic
surgery over laparoscopic surgery in terms of QoL. A small benefit for robotic surgery was seen in QoL using
the EQ-5D score, but no advantage over laparoscopic surgery was seen in either the physical components or
the mental components in the SF-36v2 QoL analysis. Similarly, there was no difference in recovery following
robotic surgery or laparoscopic surgery, as measured by the MFI-20 questionnaire. This is probably not
surprising given that the extent of the surgery performed is not influenced by the surgical approach, with
the robot serving as an alternative tool to enable a laparoscopic operation to be performed. Similar trends
were noted using both the SF-36v2 questionnaire and the MFI-20 questionnaire, with the predictable
deterioration in QoL at the 1-month follow-up time point and a period of 6 months being required before
QoL returned towards baseline. This has implications for patients being scheduled for rectal cancer surgery
who should be counselled about a prolonged recovery period, which extends far beyond the immediate
postoperative period. Women, in particular, appear to be more likely to experience a protracted recovery
than males.
Results from the health economics analysis suggest that robotic rectal cancer surgery is unlikely to be cost
saving. The mean difference per operation, excluding the acquisition and maintenance costs, was £980
and was driven by longer operating theatre time and increased costs for robotic instruments. This concurs
with previously reported data, which consistently report longer operating times associated with the robot.21
When considering robotic surgery as a whole, rather than just rectal cancer surgery, one has to consider
the cost of the purchase and maintenance of the system, the operational life and the total utilisation of the
robot per year for all robotic procedures. Estimates of acquisition costs in 2017 varied between £0.43M
and £1.8M with maintenance costs between £0.06M and £0.12M per year.45 Assuming a mid-point
acquisition cost of £1.12M and a mid-point maintenance cost of £0.896M per year, with an operational
life/amortisation period of 7 years,46,47 the total cost of a robot would be around £1.738M. Estimates for
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total utilisation of the robot per year in 2017 varied between 819,000 and 843,000 procedures across
3919 installed systems, or 1505 procedures per robot over 7 years.45 This gives the total fixed costs of
around £1155 per procedure, in addition to the variable costs. Alternatively stated, the net benefits
(excluding fixed costs) of any robotic procedure included in a set of cost-effective procedures needs to be
positive, and the whole set of cost-effective procedures needs to have an average net benefit of at least
£1155. On average, all robot procedures combined must exceed this figure, with all procedures making at
least some positive contribution. On the basis of the evidence presented here, robotic rectal cancer surgery
does not appear to provide a positive contribution and does not appear to be justified given the extra costs
and the equivalency of clinical outcomes.
Analysis of the long-term outcomes, local recurrence, and DFS and OS, failed to show a difference
between the treatment groups and conformed to the recognised patterns seen following rectal cancer
surgery. Interestingly, local recurrence was more common in males than in females, which might reflect
the increased technical difficulty in operating in the narrower male pelvis, although there was no benefit
from robotic surgery compared with laparoscopic surgery in male patients. Although there was no
difference between the treatment groups in DFS, those patients undergoing APR were most at risk of
disease recurrence, and those undergoing HAR were least at risk. Males fared worse in terms of OS, which
might be related to the higher risk of local recurrence, but will also be influenced by the generally shorter
life expectancy for males, with no difference whether or not the operation was performed with the robot
or by standard laparoscopy.
Limitations
The ROLARR study had several limitations. The much lower than anticipated rate of conversion to
laparotomy limits the ability to provide conclusive evidence about our primary question of how robotic
surgery compares with conventional laparoscopic surgery in terms of the odds of conversion. However,
the fact that no statistically significant differences between the treatment groups were seen in any of
the end points does suggest that robotic surgery, when performed by surgeons with varying robotic
experience, does not confer a clinically important benefit over laparoscopic surgery in the short term.
No blinding to treatment allocation was incorporated into this trial. Our primary end point and the measure
of mortality will certainly be unaffected by this, as an objective end point. However, there is the potential for
end points that are not completely objective to have been affected. In our pathology end points, including
CRM+, we have guarded against this by carrying out a blinded central review of pathology assessments.
Despite enforcing a mandatory minimum experience level for surgeon participation, operations in this trial
were performed, on average, by a surgeon considered to be an expert in conventional laparoscopic surgery
and who may still have been in their learning phase for robotic surgery. The prespecified sensitivity analysis
of learning effects addresses this, by extending the primary analysis model to analyse the interaction
between operating surgeon experience and the treatment effect.
The primary analysis adjusted only for stratification factors (including operating surgeon) and thus it did
not include an adjustment for treating site in particular. A (prespecified) adjustment for treating site was
considered in a sensitivity analysis, but model estimation issues were caused by the small sizes of the
resulting strata, resulting in no meaningful output.
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The ROLARR study provides the first rigorous evaluation of robotic-assisted surgery compared withlaparoscopic surgery for rectal cancer. It has failed to show an advantage for the robotic technique,
although interesting trends have been noted. In particular, the trend to reduced conversions in males,
and perhaps those patients undergoing LAR, deserves further investigation. A registry is currently being
designed under the auspices of the European Society of Coloproctology that should enable data on several
hundred robotic rectal cancer operations to be collected in a relatively short time frame and might provide
further insight into the trends observed in the ROLARR study.
The health economic evaluation performed in the ROLARR study concludes that robotic rectal cancer
surgery is not cost-effective compared with laparoscopic surgery. Although it is tempting to generalise
this to wider surgical practice and the health-care provision of future robotic services, it should be borne
in mind that the ROLARR study investigated only a single robotic system, the da Vinci surgical robot, which
was the only system that was commercially available at the time. There have subsequently been rapid
developments in other surgical robotic platforms, with several expected to come to market within the
next couple of years. Future systems promise to be more competitive in terms of costs, with per-procedure
costs challenging those of laparoscopic surgery. The health economic data from the ROLARR study will be
beneficial to commercial companies developing robotic systems, in particular highlighting the need to bring
the cost of robotic instruments down in order to be competitive with laparoscopic surgery.
Any judgement about the future of robotic surgery based on the ROLARR study should be tempered with
future developments borne in mind. The situation is further complicated by the recent debate about the
benefits of laparoscopic surgery that has been stirred by the recent publication of two large randomised
trials comparing laparoscopic with open surgery for rectal cancer: the ALaCarte and ACOSOG trials. Both
these studies failed to show the non-inferiority of laparoscopic surgery compared with open surgery for
rectal cancer in terms of a short-term composite pathological outcome. It is therefore not clear whether or
not any future analysis of robotic rectal cancer surgery should include an assessment of open surgery as well
as laparoscopic techniques. In the UK’s NHS, the adoption of laparoscopic rectal cancer surgery is probably
too advanced to countenance reverting back to open surgery, unless there is hard long-term evidence to
suggest otherwise.
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Gangnam Severance Hospital (South Korea): Kang Young Lee; Hospital Herlev, Copenhagen University
(Denmark): Jacob Rosenburg, Henrik Loft Jakobsen, Mads Bundgaard, Jens Ravn Eriksen, Jesper Olsen and 
Thomas Bent Harvald; Jackson South Community Hospital (USA): Gustavo Plasencia and Henry J Lujan; 
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Appendix 1 Primary end point (conversion to
open surgery) analysis: further details
Model diagnostics
Residual index plot
Figure 13 presents the index plot of raw residuals (including EBEs of random effects) on the probability
scales (y-axis) versus patient ID (x-axis). Residual ri for patient i is calculated as:
ri = Yi − p^i, (5)
where
Yi = f1, Patient converted to open surgery0, Otherwise , (6)
and p^i is the predicted probability of conversion to open surgery for patient i (including EBE of the random
effect). Residuals with larger absolute values indicate poorer model fit. Patient 374 (labelled in Figure 13)
stands out as an instance of poor model fit, with the model yielding a predicted probability of conversion
of 0.676, but they were not converted. Many of the residuals for patients who did convert to open surgery
(shown in green in Figure 13) are large, indicating that the model fitted low probabilities of conversion for
those patients, but this is reasonable and perhaps expected because conversion to open surgery was an
infrequent event. The empirical probability plot helps us to objectively determine what magnitude of
residual is ‘expected’.






Random intercept 276.94 258.94 1.22 0.269
Random slope 277.72 257.72
374


















FIGURE 13 Conversion to open surgery: index plot of raw residuals of the random intercept model. Scatterplot:
raw residuals on the probability scale (including EBEs of random effects) by observed outcome.
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Figure 14 presents the empirical probability plot for the primary analysis model, which can be used to
compare actual Pearson residuals with expected Pearson residuals. The y-axis is the actual Pearson residual
value, the x-axis is the empirical median Pearson residual expected under our fitted model assumptions.
The dots represent patients. If the model was a perfect fit, then we would expect all of the dots to lie on
the reference line. The band in Figure 14 represents the interval between the empirical 2.5th percentile
and 97.5th percentile empirical Pearson residual. No values lie outside this region, indicating that we do
not have any substantial outliers.
Delta-betas
Figure 15 presents the plot of exponentiated delta-betas (y-axis) versus patient ID. Exponentiated delta-betas
further from 1 indicate greater influence of the observation on the estimated treatment effect. Conversions
to open surgery demonstrably have greater influence on the estimated treatment effect, which is perhaps
expected given that conversion to open surgery was an infrequent event. Patient 374 stands out as having
high influence for a non-conversion to open surgery. Patient 374 was in the robotic treatment group and
their exponentiated delta-beta is 1.051, indicating that the estimated OR for conversion to open surgery
(robotic vs. laparoscopic) increases by a factor of 1.051 when they are removed from the model, from the
original 0.614 (95% CI 0.311 to 1.211; p = 0.16) to 0.645 (95% CI 0.325 to 1.280; p = 0.21).
Further investigation of outliers
The observation for patient 374 is genuine. It is just a relatively unexpected outcome, rather than erroneous
data. Patient 374 was male, obese and underwent a LAR, all indicating a higher risk of conversion to open
surgery according to the model. Furthermore, their operating surgeon converted 10 out of 33 (30.3%) of
their ROLARR patients to open surgery: a much higher rate than average. The model therefore estimated a
67.6% probability of conversion to open surgery for patient 374 but they were not converted, hence the large
magnitude of the residual. The EBE of this surgeon’s effect on the odds of conversion was that they increased
the odds by a factor of around 5 (i.e. a patient being operated on by this surgeon was estimated to be five
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FIGURE 14 Conversion to open surgery: empirical probability plot (including simulated envelope of 2.5th–97.5th
percentile empirical Pearson residual) of raw residuals of the random intercept model.
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to this model). This is a larger effect than any of the other patient factors. However, patient 374 was this
surgeon’s last patient in the ROLARR study, and their level of robotic experience changed substantially
throughout their participation in the study, from 35 previous robotic operations before their first patient to
121 before patient 374. Most of the surgeon’s conversions came during their earlier ROLARR cases. The
learning effects analysis (see Chapter 3, Sensitivity analysis: learning effects) accounts for this improvement
over time and gives a predicted probability of conversion of 42.3% for patient 374, yielding a smaller residual
that lies more comfortably within the expected range of residual values. It seems that the large residual in
this model is therefore mainly because of poor fit as a consequence of assuming no learning effects.
Sensitivity analysis: actual operating surgeon – further details
TABLE 52 Sensitivity analysis by actual operating surgeon, by treatment group
Surgeon other than randomised







Yes 16 (7.0) 26 (11.0) 42 (9.0)
No 214 (93.0) 210 (89.0) 424 (91.0)
374

























FIGURE 15 Conversion to open surgery: plot of exponentiated delta-betas from the random intercept model.
Scatterplot: random intercept model delta-betas by observed outcome.
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Sensitivity analysis: actual procedure – further details
The most notable effect that adjusting for actual procedure had on the model estimates was on the effect
of APR (vs. LAR), which is attenuated compared with the primary analysis model. Specifically, in this model
(Table 57) the OR is 0.433 (95% CI 0.165 to 1.134; p = 0.088) compared with 0.184 (95% CI 0.054 to
0.627; p = 0.007) in the primary analysis model.
TABLE 54 Actual operating surgeon instead of intended operating surgeon: estimate of the variance component




Operating surgeon (random effect) 0.612 0.412
TABLE 55 Actual procedure performed, by treatment group
Procedure performed







HAR 19 (8.3) 28 (11.9) 47 (10.1)
LAR 165 (71.7) 152 (64.4) 317 (68.0)
APR 45 (19.6) 52 (22.0) 97 (20.8)
Other 1 (0.4) 4 (1.7) 5 (1.1)
















28/230 (12.2) 19/236 (8.1) 4.1 (–1.4 to 9.6) 0.612 0.310 to 1.207 0.16
Sex: male (vs. female) 8/149 (5.4) 39/317 (12.3) –6.9 (–12.1 to 1.8) 2.449 1.046 to 5.734 0.04
BMI class: overweight
(vs. underweight/normal)
13/179 (7.3) 9/180 (5.0) 2.3 (–2.7 to 7.2) 0.547 0.215 to 1.396 0.21
BMI class: obese
(vs. underweight/normal)




27/262 (10.3) 20/204 (9.8) 0.5 (–5.0 to 6.0) 1.094 0.512 to 2.338 0.82
Intended procedure:
HAR (vs. LAR)
37/312 (11.9) 6/68 (8.8) 3.0 (–4.6 to 10.7) 0.564 0.199 to 1.598 0.28
Intended procedure:
APR (vs. LAR)
37/312 (11.9) 4/86 (4.7) 7.2 (1.5 to 12.9) 0.185 0.054 to 0.631 0.007
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procedure Details of procedure
113 Robotic LAR Dorsal pelvic exenteration, ureter resection distally right sided
139 Robotic LAR Hartmann’s procedure
143 Standard LAR Laparoscopic biopsy of peritoneum
183 Robotic LAR HAR + subtotal colectomy
429 Robotic HAR Hartmann’s procedure















28/230 (12.2) 19/236 (8.1) 4.1 (–1.4 to 9.6) 0.572 0.289 to 1.132 0.1083
Sex: male (vs. female) 8/149 (5.4) 39/317 (12.3) –6.9 (–12.1 to 1.8) 2.401 1.034 to 5.573 0.0416
BMI class: overweight
(vs. underweight/normal)
13/179 (7.3) 9/180 (5.0) 2.3 (–2.7 to 7.2) 0.562 0.221 to 1.432 0.2264
BMI class: obese
(vs. underweight/normal)




27/262 (10.3) 20/204 (9.8) 0.5 (–5.0 to 6.0) 1.050 0.509 to 2.166 0.8956
Procedure: HAR (vs. LAR) 33/317 (10.4) 4/47 (8.5) 1.9 (–6.8 to 10.6) 0.718 0.209 to 2.464 0.5975
Procedure: APR (vs. LAR) 33/317 (10.4) 8/97 (8.3) 2.2 (–4.3 to 8.6) 0.433 0.165 to 1.134 0.0883
Procedure: other (vs. LAR) 33/317 (10.4) 2/5 (40.0) –29.6 (–72.7 to 13.5) 5.934 0.689 to 51.079 0.1047





Operating surgeon (random effect) 0.535 0.389
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Appendix 2 Key secondary end point:
circumferential resection margin positivity (CRM+)
Model diagnostics
Residual index plot
Figure 16 presents the index plot of raw residuals (including EBEs of random effects) on the probability
scales (y-axis) versus patient ID (x-axis). Residual ri for patient i is calculated as:
ri = Yi − p^i, (7)
in which:
Yi = f1, CRM+0, Otherwise, (8)
and p^i is the predicted probability of CRM+ for patient i (including EBE of the random effect). Residuals
with larger absolute values indicate poorer model fit. Many of the residuals for patients who did have
CRM+ (shown in green in Figure 16) are large, indicating that the model fitted low probabilities of CRM+
for those patients, but this is reasonable and perhaps expected because CRM+ was a rare event. There
are no clear outliers in Figure 16. The empirical probability plot helps us to objectively determine what
magnitude of residual is ‘expected’.
Figure 17 presents the empirical probability plot for the primary analysis model, which can be used to
compare actual Pearson residuals with expected Pearson residuals. The y-axis is the actual Pearson residual
value and the x-axis is the empirical median Pearson residual expected under our fitted model assumptions.
The dots represent patients. If the model was a perfect fit, then we would expect all of the dots to lie on
the reference line. The band in Figure 17b represents the interval between the empirical 2.5th percentile
and 97.5th percentile empirical Pearson residual. No values lie outside this region, indicating that we do
not have any substantial outliers.



















FIGURE 16 Circumferential resection margin positivity: index plot of raw residuals of the random intercept model.
Scatterplot: raw residuals on the probability scale (including EBEs of random effects) by observed outcome.
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There are two plots:
1. empirical probability plot with confidence region
2. same as plot 1 except restricted to only negative residuals (this has been added because the negative
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FIGURE 17 Circumferential resection margin positivity: empirical probability plot (including simulated envelope of
2.5th–97.5th percentile empirical Pearson residual) of raw residuals of the random intercept model.
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Delta-betas
Figure 18 presents the plot of exponentiated delta-betas (y-axis) versus patient ID. Exponentiated
delta-betas further from 1 indicate greater influence of the observation on the estimated treatment effect.
The CRM+ observations demonstrably have greater influence on the estimated treatment effect, which is
expected given that CRM+ was a rare event. There are no clear overly influential observations.
Subgroup analyses
























FIGURE 18 Circumferential resection margin positivity: plot of exponentiated delta-betas from the random
intercept model. Scatterplot: random intercept model delta-betas by observed outcome.






















4/73 (5.5) 0/75 (0.0) 5.5 (0.3 to 10.7) < 0.001 (0 to ∞) 1.000
a Adjusted for BMI class, preoperative radiotherapy, intended procedure and operating surgeon.
b p-value for the treatment effect is referring to a test of heterogeneity of treatment effect between the subgroups.
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7/85 (8.2) 5/93 (5.4) 2.9 (–4.6 to, 10.3) 0.604
(0.180 to 2.021)
0.4123
a Adjusted for sex, preoperative radiotherapy, intended procedure and operating surgeon.
b p-value for the treatment effect is referring to a (pairwise) test of heterogeneity of treatment effect between the
subgroups. For example, the second p-value in the ‘Treatment in obese patients’ row refers to a test of heterogeneity of
treatment effect between obese patients and underweight/normal patients.
TABLE 61 Estimated treatment effect ORs for CRM+ subgroup analysis by T-stage
Effect
Treatment group [number of
CRM+/number of patients (%)]
Risk difference and
(unadjusted 95% CI)Laparoscopic surgery Robotic surgery
Treatment in T0 patients: robotic-assisted
surgery (vs. laparoscopic)
0/25 (0.0) 0/26 (0.0) .
Treatment in T1 patients: robotic-assisted
surgery (vs. laparoscopic)
0/24 (0.0) 0/24 (0.0) .
Treatment in T2 patients: robotic-assisted
surgery (vs. laparoscopic)
1/62 (1.6) 2/68 (2.9) –1.3 (–6.4 to 3.8)
Treatment in T3 patients: robotic-assisted
surgery (vs. laparoscopic)
11/106 (10.4) 8/111 (7.2) 3.2 (–4.4 to 10.7)
Treatment in T4 patients: robotic-assisted
surgery (vs. laparoscopic)
2/7 (28.6) 2/5 (40.0) –11.4 (–65.9 to 43.0)
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Appendix 3 Key secondary end point: 3-year local
recurrence – further details
Local recurrences and censorings, including the reason for censoring, are summarised in Table 62.
The methods of confirmation are summarised in Table 63.
Table 64 shows the estimated cumulative incidence of local recurrence by treatment group at several time
points (1–5 years post randomisation).
TABLE 62 Nature of the end of follow-up for local recurrence analysis, by treatment group
Nature of the end of follow-up
for local recurrence analysis
(by treatment group)







Event: local recurrence 14 (6.0) 16 (6.8) 30 (6.4)
Censor: last known to be alive 195 (83.3) 199 (84.0) 394 (83.7)
Censora: death 16 (6.8) 15 (6.3) 31 (6.6)
Censor: withdrawal from further data
collection
5 (2.1) 4 (1.7) 9 (1.9)
Censor: non-standard circumstanceb 4 (1.7) 3 (1.3) 7 (1.5)
a Considered a competing risk event, rather than a censored observation, in the evaluation of the cumulative
incidence function.
b Three patients had benign disease (two laparoscopic, one robotic), three patients had a non-curative surgery outcome
(one laparoscopic, two robotic) and one patient did not undergo surgery (laparoscopic).
TABLE 63 Method of confirmation of local recurrences, by treatment group
Method of confirmation







Clinical 2 (14.3) 2 (12.5) 4 (13.3)
Radiological 5 (35.7) 6 (37.5) 11 (36.7)
Pathological 7 (50.0) 8 (50.0) 15 (50.0)




Laparoscopic surgery Robotic surgery
Probability of
local recurrence 95% CI
Probability of
local recurrence 95% CI
1 0.022 0.003 to 0.041 0.034 0.011 to 0.058
2 0.049 0.040 to 0.058 0.052 0.023 to 0.080
3 0.058 0.028 to 0.089 0.061 0.030 to 0.091
4 0.065 0.055 to 0.076 0.078 0.039 to 0.116
5 0.065 0.032 to 0.099 0.078 0.039 to 0.116
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As a result of heavy censoring, the deviance residuals form a bimodal distribution, as seen in Figure 19.
There are no clear outliers.
Figure 20 shows the standardised Schoenfeld residuals versus time. If the proportional hazards assumption
was being violated, then we would expect the relationship between these residuals and time to deviate
from a flat line in at least one of the treatment groups, but it does not. This is also reflected in Figure 21
(standardised score process), as the observed path lies within the simulated paths. Finally, the supremum
test of the PH assumption returned a p-value of 0.265 relating to the treatment effect. All of this suggests
that the proportional hazards assumption is viable for the treatment groups.

































FIGURE 19 Three-year local recurrence. (a) Histogram of deviance residuals; and (b) scatterplot of deviance
residuals.
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Delta-betas
Figure 22 presents the exponentiated delta-betas. As one might expect, given the low incidence of local
recurrence, the influence of all observed events of local recurrence is notably greater than the influence
of censored observations. There is, however, no clear overly influential observations.







































FIGURE 20 Three-year local recurrence: Loess plot of standardised Schoenfeld residuals (by treatment group) for
the shared frailty model.
– 1.0





















Pr > MaxAbsVal: 0.2650
(1000 simulations)
FIGURE 21 Three-year local recurrence: random sample of standardised score process simulated paths.
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Subgroup analyses
Odds ratios presented in Tables 65 and 66 are derived from the linear combination of the estimated
treatment (main effect) and treatment-by-subgroup interaction terms on the logit scale. The p-values are
presented for the test of the treatment effect within each subgroup; this is the first column of p-values.
For example, in Table 68 the test that the treatment effect is null (OR = 1) within the female subgroup is
1.000. The p-values are also presented for the test of heterogeneity of treatment effect across subgroups,
the details of which are given in the footnotes of the tables. Note that a full model was not fitted to test
T-stage subgroup analyses, because the small sample sizes and event rates within T-stage groups caused
model convergence issues and so crude summaries are given.
Figures 23–26 display the Kaplan–Meier graphs for the effect of neo-adjuvant therapy, operation type,
T-stage and sex, on 3-year local recurrence.


























FIGURE 22 Three-year local recurrence: plot of exponentiated delta-betas from the random intercept model.
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FIGURE 23 Three-year local recurrence by neo-adjuvant therapy. (a) No neo-adjuvant therapy; and (b) neo-adjuvant
therapy. (continued )
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FIGURE 23 Three-year local recurrence by neo-adjuvant therapy. (a) No neo-adjuvant therapy; and (b) neo-adjuvant
therapy.
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FIGURE 24 Three-year local recurrence by operation type. (a) Cumulative incidence of local recurrence
(operation =HAR); (b) cumulative incidence of local recurrence (operation = LAR); and (c) cumulative incidence
of local recurrence (operation =APR). (continued )
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FIGURE 24 Three-year local recurrence by operation type. (a) Cumulative incidence of local recurrence
(operation =HAR); (b) cumulative incidence of local recurrence (operation = LAR); and (c) cumulative incidence
of local recurrence (operation =APR). (continued )
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FIGURE 24 Three-year local recurrence by operation type. (a) Cumulative incidence of local recurrence
(operation =HAR); (b) cumulative incidence of local recurrence (operation = LAR); and (c) cumulative incidence
of local recurrence (operation =APR).
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FIGURE 25 Three-year local recurrence by T-stage. (a) T1; (b) T2; and (c) T3. (continued )
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FIGURE 25 Three-year local recurrence by T-stage. (a) T1; (b) T2; and (c) T3. (continued )
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FIGURE 25 Three-year local recurrence by T-stage. (a) T1; (b) T2; and (c) T3.
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FIGURE 26 Three-year local recurrence by sex. (a) Male; and (b) female. (continued )
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FIGURE 26 Three-year local recurrence by sex. (a) Male; and (b) female.
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TABLE 65 Estimated treatment effect HRs for neo-adjuvant therapy
Effect HR (adjusted 95% CI)a p-value
Treatment in patients who underwent neo-adjuvant therapy:
robotic surgery (vs. laparoscopic)
1.233 (0.426 to 3.566) 0.6990 0.8390
Treatment in patients who did not undergo neo-adjuvant
therapy: robotic surgery (vs. laparoscopic)
1.061 (0.397 to 2.838) 0.9062
a Adjusted for BMI class, preoperative radiotherapy, intended procedure and operating surgeon.
Hazard ratios were derived from the treatment term and treatment-by-neo-adjuvant therapy interaction term.
TABLE 66 Estimated treatment effect HRs by operation type
Effect HR (adjusted 95% CI)a p-value
Treatment in patients who underwent HAR: robotic surgery
(vs. laparoscopic)
1.344 (0.121 to 14.957) 0.8089 0.7737
Treatment in patients who underwent LAR: robotic surgery
(vs. laparoscopic)
0.975 (0.413 to 2.301) 0.9536
Treatment in patients who underwent APR: robotic surgery
(vs. laparoscopic)
1.924 (0.351 to 10.558) 0.4518
a Adjusted for BMI class, preoperative radiotherapy, intended procedure and operating surgeon.
Hazard ratios were derived from the treatment term and treatment-by-operation interaction term.
TABLE 67 Estimated treatment effect HRs by T-stage
Effect HR (adjusted 95% CI)a p-value
Treatment in T0 patients: robotic surgery (vs. laparoscopic)b 0.9832
Treatment in T1 and T2 patients: robotic surgery (vs. laparoscopic) 1.128 (0.301 to 4.224) 0.8576
Treatment in T3 and T4 patients: robotic surgery (vs. laparoscopic) 1.019 (0.423 to 2.453) 0.9670
a Adjusted for BMI class, preoperative radiotherapy, intended procedure and operating surgeon.
b Only one event in T0 patients (in the robotic group) was observed. Within-group comparison between treatment groups
was therefore not plausible.
Hazard ratios were derived from the treatment term and treatment-by-T-stage interaction term.
TABLE 68 Estimated treatment effect HRs by sex
Effect HR (adjusted 95% CI)a p-value
Treatment in males: robotic surgery (vs. laparoscopic) 1.166 (0.535 to 2.542) 0.6999 0.8794
Treatment in females: robotic surgery (vs. laparoscopic) 0.991 (0.142 to 6.935) 0.9927
a adjusted for BMI class, preoperative radiotherapy, intended procedure and operating surgeon.
Hazard ratios were derived from the treatment term and treatment-by-sex interaction term.
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Appendix 4 Patient self-reported bladder
function: further information
T able 69 presents the baseline characteristics of the 351 out of 471 (74.5%) patients who returnedquestionnaires with sufficient data to derive an I-PSS score. Stratification factors of these 351 patients
with complete data are well balanced between the groups, with distributions very similar to the group of
patients with missing data (Table 70). The I-PSS score at baseline was similar between the groups in these
patients, although there was a slightly more positive skew in the robotic group, with a marginally higher
mean score indicating slightly higher severity of symptoms at baseline on average.
TABLE 69 Baseline characteristics for complete-case patients with sufficient data to derive I-PSS score by treatment
group
Characteristics
Treatment group, n (%)






Male 116 (65.9) 121 (69.1) 237 (67.5)
Female 60 (34.1) 54 (30.9) 114 (32.5)
BMI classification
Underweight/normal 69 (39.2) 74 (42.3) 143 (40.7)
Overweight 67 (38.1) 67 (38.3) 134 (38.2)
Obese 40 (22.7) 34 (19.4) 74 (21.1)
Neo-adjuvant therapy
Yes 81 (46.0) 76 (43.4) 157 (44.7)
No 95 (54.0) 99 (56.6) 194 (55.3)
Intended procedure
HAR 26 (14.8) 25 (14.3) 51 (14.5)
LAR 119 (67.6) 117 (66.9) 236 (67.2)
APR 31 (17.6) 33 (18.9) 64 (18.2)
Total I-PSS score (baseline)
Mean (SD) 6.9 (6.91) 8.5 (7.28) 7.7 (7.13)
Median (range) 5.0 (0.0–33.0) 6.0 (0.0–32.0) 6.0 (0.0–33.0)
(Q1, Q3) (2.0, 9.0) (3.0, 12.0) (2.0, 11.0)
Missing 0 0 0
Categorical I-PSS score (baseline)
Mild 112 (63.6) 101 (57.7) 213 (60.7)
Moderate 50 (28.4) 58 (33.1) 108 (30.8)
Severe 14 (8.0) 16 (9.1) 30 (8.5)
Q1, first interquartile; Q3, third interquartile.
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TABLE 70 Baseline characteristics for patients excluded and included in I-PSS analysis
Characteristics
Complete-case analysis, n (%)
Total (N= 471), n (%)Excluded (N= 120) Included (N= 351)
Sex
Male 83 (69.2) 237 (67.5) 320 (67.9)
Female 37 (30.8) 114 (32.5) 151 (32.1)
BMI classification
Underweight/normal 37 (30.8) 143 (40.7) 180 (38.2)
Overweight 49 (40.8) 134 (38.2) 183 (38.9)
Obese 34 (28.3) 74 (21.1) 108 (22.9)
Neo-adjuvant therapy
Yes 50 (41.7) 157 (44.7) 207 (43.9)
No 70 (58.3) 194 (55.3) 264 (56.1)
Intended procedure
HAR 17 (14.2) 51 (14.5) 68 (14.4)
LAR 80 (66.7) 236 (67.2) 316 (67.1)
APR 23 (19.2) 64 (18.2) 87 (18.5)
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Appendix 5 Patient self-reported sexual
function: males
T able 71 presents the baseline characteristics of the 181 out of 320 (56.6%) male patients whoreturned questionnaires with sufficient data to derive an IIEF score. Stratification factors of these 181
patients with complete data are well balanced between the groups, with distributions very similar to the
group of male patients with missing data (Table 72). The IIEF score at baseline was similar between the
groups in these patients, although there was a slightly more positive skew in the robotic group, with a
marginally higher mean score indicating slightly higher severity of symptoms at baseline on average.
TABLE 71 Patient baseline characteristics for male complete-case patients with sufficient data to derive IIEF score
by treatment group
Characteristics
Treatment group, n (%)






Underweight/normal 34 (40.5) 34 (35.1) 68 (37.6)
Overweight 30 (35.7) 43 (44.3) 73 (40.3)
Obese 20 (23.8) 20 (20.6) 40 (22.1)
Neo-adjuvant therapy
Yes 33 (39.3) 45 (46.4) 78 (43.1)
No 51 (60.7) 52 (53.6) 103 (56.9)
Intended procedure
HAR 15 (17.9) 11 (11.3) 26 (14.4)
LAR 57 (67.9) 68 (70.1) 125 (69.1)
APR 12 (14.3) 18 (18.6) 30 (16.6)
Total IIEF score (baseline)
Mean (SD) 37.7 (23.85) 40.1 (24.93) 39.0 (24.40)
Median (range) 37.0 (5.0–72.0) 45.0 (5.0–72.0) 43.0 (5.0–72.0)
(Q1, Q3) (13.0, 62.0) (13.0, 65.0) (13.0, 63.0)
Q1, first interquartile; Q3, third interquartile.
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TABLE 72 Baseline characteristics for male patients excluded and included in IIEF analysis
Characteristics
Complete-case analysis, n (%)
Total (N= 20), n (%)Excluded (N= 139) Included (N= 181)
BMI classification
Underweight/normal 53 (38.1) 68 (37.6) 121 (37.8)
Overweight 51 (36.7) 73 (40.3) 124 (38.8)
Obese 35 (25.2) 40 (22.1) 75 (23.4)
Neo-adjuvant therapy
Yes 62 (44.6) 78 (43.1) 140 (43.8)
No 77 (55.4) 103 (56.9) 180 (56.3)
Intended procedure
HAR 20 (14.4) 26 (14.4) 46 (14.4)
LAR 87 (62.6) 125 (69.1) 212 (66.3)
APR 32 (23.0) 30 (16.6) 62 (19.4)
TABLE 73 The I-PSS analysis by treatment group at 6 months
Treatment group, n (%)





Total I-PSS score (6 months)
Mean (SD) 8.0 (7.69) 8.0 (6.81) 8.0 (7.26)
Median (range) 5.0 (0.0–34.0) 7.0 (0.0–34.0) 6.0 (0.0–34.0)
(Q1, Q3) (2.0, 12.5) (3.0, 12.0) (2.0, 12.0)
Categorical I-PSS score (6 months)
Mild 109 (61.9) 99 (56.6) 208 (59.3)
Moderate 50 (28.4) 67 (38.3) 117 (33.3)
Severe 17 (9.7) 9 (5.1) 26 (7.4)
Q1, first interquartile; Q3, third interquartile.
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Appendix 6 Patient self-reported sexual
function: females
T able 74 presents the baseline characteristics of the 54 out of 151 (35.8%) female patients whoreturned questionnaires with sufficient data to derive a FSFI score. Stratification factors of these
54 patients with complete data are well balanced between the groups, with distributions similar to the
group of female patients with missing data, with the exception of the higher rate of neo-adjuvant therapy
in the patients with complete data and the higher proportion of underweight/normal patients (Table 73).
The FSFI score at baseline was marginally lower in the robotic group, indicating slightly worse function at
baseline for female patients in the robotic group who were included in the analysis.
TABLE 74 Baseline characteristics for female complete-case patients with sufficient data to derive FSFI score by
treatment group
Charateristics
Treatment group, n (%)






Underweight/normal 15 (51.7) 12 (48.0) 27 (50.0)
Overweight 10 (34.5) 8 (32.0) 18 (33.3)
Obese 4 (13.8) 5 (20.0) 9 (16.7)
Neo-adjuvant therapy
Yes 15 (51.7) 16 (64.0) 31 (57.4)
No 14 (48.3) 9 (36.0) 23 (42.6)
Intended procedure
HAR 6 (20.7) 5 (20.0) 11 (20.4)
LAR 18 (62.1) 15 (60.0) 33 (61.1)
APR 5 (17.2) 5 (20.0) 10 (18.5)
FSFI (baseline)
Mean (SD) 16.7 (11.74) 14.8 (9.96) 15.8 (10.90)
Median (range) 19.1 (2.0–34.2) 14.8 (2.8–30.1) 16.5 (2.0–34.2)
(Q1, Q3) (4.4, 28.2) (5.4, 22.7) (4.7, 27.3)
Missing 0 0 0
Q1, first interquartile; Q3, third interquartile.
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TABLE 75 Baseline characteristics for female patients excluded and included in the complete-case analysis
Charateristics
Complete-case analysis, n (%)
Total (N= 54), n (%)Excluded (N= 97) Included (N= 54)
BMI classification
Underweight/normal 32 (33.0) 27 (50.0) 59 (39.1)
Overweight 41 (42.3) 18 (33.3) 59 (39.1)
Obese 24 (24.7) 9 (16.7) 33 (21.9)
Neo-adjuvant therapy
Yes 36 (37.1) 31 (57.4) 67 (44.4)
No 61 (62.9) 23 (42.6) 84 (55.6)
Intended procedure
HAR 11 (11.3) 11 (20.4) 22 (14.6)
LAR 71 (73.2) 33 (61.1) 104 (68.9)
APR 15 (15.5) 10 (18.5) 25 (16.6)
TABLE 76 Female Sexual Function Index at 6 months for patients included in analysis, by treatment group
FSFI (6 months)
Treatment group, n (%)





Mean (SD) 16.7 (11.25) 14.2 (10.34) 15.5 (10.81)
Median (range) 16.7 (2.0–33.6) 8.5 (2.9–31.4) 16.1 (2.0–33.6)
(Q1, Q3) (4.5, 28.3) (5.2, 24.4) (5.1, 25.9)
Missing 0 0 0
Q1, first interquartile; Q3, third interquartile.
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Appendix 7 Patient-reported generic health
T able 77 presents the baseline characteristics of the 459 out of 471 (97.5%) patients who returned atleast one questionnaire with sufficient data to derive a PCS/MCS score. Stratification factors and ASA
grades of these 459 patients are well balanced between the groups.
Tables 78 and 79 show the PCS/MCS at baseline, at 30 days post surgery and at 6 months post surgery in
the two groups. The baseline PCS and MCS were similar in the two treatment groups.
TABLE 77 Patient baseline characteristics for patients with sufficient data to derive a PCS/MCS score
Characteristics








Male 157 (67.7) 153 (67.4) 310 (67.5)
Female 75 (32.3) 74 (32.6) 149 (32.5)
Neo-adjuvant therapy
Yes 106 (45.7) 100 (44.1) 206 (44.9)
No 126 (54.3) 127 (55.9) 253 (55.1)
Intended procedure
HAR 34 (14.7) 33 (14.5) 67 (14.6)
LAR 155 (66.8) 154 (67.8) 309 (67.3)
APR 43 (18.5) 40 (17.6) 83 (18.1)
BMI classification
Underweight/normal 92 (39.7) 85 (37.4) 177 (38.6)
Overweight 89 (38.4) 88 (38.8) 177 (38.6)
Obese 51 (22.0) 54 (23.8) 105 (22.9)
ASA classification
A normal healthy patient 39 (16.8) 51 (22.5) 90 (19.6)
A patient with mild systemic disease 147 (63.4) 123 (54.2) 270 (58.8)
A patient with severe systemic disease 46 (19.8) 52 (22.9) 98 (21.4)
A patient with severe systemic disease
that is a constant threat to life
0 (0.0) 1 (0.4) 1 (0.2)
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TABLE 78 Physical component score by treatment group at baseline, at 30 days and at 6 months
PCS
Treatment group, n (%)






Mean (SD) 51.4 (8.90) 51.6 (8.79) 51.5 (8.84)
Median (range) 53.7 (24.8–67.4) 53.7 (24.2–67.4) 53.7 (24.2–67.4)
Missing 6 6 12
Number 226 221 447
30 days
Mean (SD) 42.4 (8.55) 42.0 (8.42) 42.2 (8.48)
Median (range) 42.3 (22.8–61.7) 42.1 (24.3–63.3) 42.2 (22.8–63.3)
Missing 19 29 48
Number 213 198 411
6 months
Mean (SD) 48.7 (7.95) 48.3 (8.90) 48.5 (8.43)
Median (range) 49.7 (27.4–61.2) 50.2 (18.9–63.2) 50.0 (18.9–63.2)
Missing 33 32 65
Number 199 195 394
TABLE 79 Mental component score by treatment group at baseline, at 30 days and at 6 months
MCS
Treatment group, n (%)






Mean (SD) 47.3 (11.82) 48.1 (11.48) 47.7 (11.65)
Median (range) 50.5 (13.6–67.0) 50.9 (10.3–65.8) 50.8 (10.3–67.0)
Missing 6 6 12
Number 226 221 447
30 days
Mean (SD) 45.6 (11.73) 44.1 (12.86) 44.8 (12.30)
Median (range) 46.4 (12.9–64.5) 46.3 (7.2–68.0) 46.4 (7.2–68.0)
Missing 19 29 48
Number 213 198 411
6 months
Mean (SD) 48.9 (11.62) 49.6 (10.04) 49.2 (10.85)
Median (range) 52.3 (10.8–66.3) 51.9 (20.1–67.2) 52.1 (10.8–67.2)
Missing 33 31 64
Number 199 196 395
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(N= 471), n (%)Not included (N= 12) Included (N= 459)
Sex
Male 10 (83.3) 310 (67.5) 320 (67.9)
Female 2 (16.7) 149 (32.5) 151 (32.1)
Neo-adjuvant therapy
Yes 6 (50.0) 206 (44.9) 212 (45.0)
No 6 (50.0) 253 (55.1) 259 (55.0)
Intended procedure
HAR 2 (16.7) 67 (14.6) 69 (14.6)
LAR 8 (66.7) 309 (67.3) 317 (67.3)
APR 2 (16.7) 83 (18.1) 85 (18.0)
BMI classification
Underweight/normal 3 (25.0) 177 (38.6) 180 (38.2)
Overweight 6 (50.0) 177 (38.6) 183 (38.9)
Obese 3 (25.0) 105 (22.9) 108 (22.9)
ASA classification
A normal healthy patient 1 (8.3) 90 (19.6) 91 (19.3)
A patient with mild systemic disease 4 (33.3) 270 (58.8) 274 (58.2)
A patient with severe systemic disease 0 (0.0) 98 (21.4) 98 (20.8)
A patient with severe systemic disease
that is a constant threat to life
0 (0.0) 1 (0.2) 1 (0.2)
Missing 7a (58.3) 0 (0.0) 7 (1.5)
a The remaining five patients were not included because they did not have a PCS/MCS score (the same patients are
missing PCS and MCS scores).
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Appendix 8 Patient self-reported fatigue
T able 81 presents the baseline characteristics of the 440 out of 471 (93.4%) patients who returned atleast one questionnaire with sufficient data to derive a score for at least one of the scales. Stratification
factors and ASA grades for these 440 patients are well balanced between the groups.
Tables 82–86 show each of the scales at baseline, at 30 days post surgery and at 6 months post surgery in
the two groups. The baseline scores were similar between the two treatment groups for all five scales.
Tables 88–92 show the fitted model estimates for each of the five scales.
TABLE 81 Baseline characteristics for patients included in fatigue analysis
Characteristics








Male 150 (67.6) 146 (67.0) 296 (67.3)
Female 72 (32.4) 72 (33.0) 144 (32.7)
Neo-adjuvant therapy
Yes 104 (46.8) 94 (43.1) 198 (45.0)
No 118 (53.2) 124 (56.9) 242 (55.0)
Intended procedure
HAR 34 (15.3) 33 (15.1) 67 (15.2)
LAR 145 (65.3) 145 (66.5) 290 (65.9)
APR 43 (19.4) 40 (18.3) 83 (18.9)
BMI classification
Underweight/normal 85 (38.3) 77 (35.3) 162 (36.8)
Overweight 86 (38.7) 87 (39.9) 173 (39.3)
Obese 51 (23.0) 54 (24.8) 105 (23.9)
ASA classification
A normal healthy patient 36 (16.2) 47 (21.6) 83 (18.9)
A patient with mild systemic disease 143 (64.4) 121 (55.5) 264 (60.0)
A patient with severe systemic disease 43 (19.4) 49 (22.5) 92 (20.9)
A patient with severe systemic disease
that is a constant threat to life
0 (0.0) 1 (0.5) 1 (0.2)
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Mean (SD) 10.4 (4.73) 10.1 (4.49) 10.3 (4.61)
Median (range) 10.0 (4.0–20.0) 10.0 (4.0–20.0) 10.0 (4.0–20.0)
Missing 13 11 24
Number 209 207 416
30 days
Mean (SD) 12.5 (4.31) 12.6 (4.36) 12.6 (4.33)
Median (range) 12.0 (4.0–20.0) 13.0 (4.0–20.0) 13.0 (4.0–20.0)
Missing 31 37 68
Number 191 181 372
6 months
Mean (SD) 11.0 (4.62) 10.8 (4.41) 10.9 (4.51)
Median (range) 11.0 (4.0–20.0) 11.0 (4.0–20.0) 11.0 (4.0–20.0)
Missing 36 41 77
Number 186 177 363









Mean (SD) 10.1 (4.64) 9.5 (4.52) 9.8 (4.58)
Median (range) 9.0 (4.0–20.0) 9.0 (4.0–20.0) 9.0 (4.0–20.0)
Missing 12 12 24
Number 210 206 416
30 days
Mean (SD) 12.5 (4.42) 13.1 (4.44) 12.8 (4.43)
Median (range) 12.5 (4.0–20.0) 13.0 (4.0–20.0) 13.0 (4.0–20.0)
Missing 28 31 59
Number 194 187 381
6 months
Mean (SD) 10.7 (4.09) 10.9 (4.55) 10.8 (4.32)
Median (range) 11.0 (4.0–20.0) 10.5 (4.0–20.0) 11.0 (4.0–20.0)
Missing 39 36 75
Number 183 182 365
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Mean (SD) 9.9 (4.44) 9.9 (4.40) 9.9 (4.42)
Median (range) 9.5 (4.0–20.0) 9.0 (4.0–20.0) 9.0 (4.0–20.0)
Missing 14 17 31
Number 208 201 409
30 days
Mean (SD) 12.7 (4.31) 13.1 (4.33) 12.9 (4.32)
Median (range) 13.0 (4.0–20.0) 13.0 (4.0–20.0) 13.0 (4.0–20.0)
Missing 30 37 67
Number 192 181 373
6 months
Mean (SD) 10.6 (4.23) 10.5 (4.20) 10.6 (4.21)
Median (range) 10.0 (4.0–20.0) 11.0 (4.0–20.0) 10.0 (4.0–20.0)
Missing 38 32 70
Number 184 186 370









Mean (SD) 8.5 (3.56) 8.5 (3.58) 8.5 (3.56)
Median (range) 8.0 (4.0–18.0) 8.0 (4.0–20.0) 8.0 (4.0–20.0)
Missing 14 14 28
Number 208 204 412
30 days
Mean (SD) 9.7 (3.89) 10.2 (3.75) 9.9 (3.82)
Median (range) 9.0 (4.0–20.0) 10.0 (4.0–20.0) 10.0 (4.0–20.0)
Missing 33 34 67
Number 189 184 373
6 months
Mean (SD) 8.5 (3.39) 8.7 (3.47) 8.6 (3.43)
Median (range) 8.0 (4.0–18.0) 9.0 (4.0–20.0) 8.0 (4.0–20.0)
Missing 45 40 85
Number 177 178 355
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Mean (SD) 8.5 (4.12) 8.4 (4.38) 8.4 (4.25)
Median (range) 8.0 (4.0–20.0) 7.0 (4.0–20.0) 8.0 (4.0–20.0)
Missing 14 12 26
Number 208 206 414
30 days
Mean (SD) 9.0 (4.33) 9.4 (4.37) 9.2 (4.35)
Median (range) 9.0 (4.0–20.0) 9.0 (4.0–20.0) 9.0 (4.0–20.0)
Missing 30 37 67
Number 192 181 373
6 months
Mean (SD) 8.3 (3.90) 8.5 (3.84) 8.4 (3.87)
Median (range) 8.0 (4.0–20.0) 8.0 (4.0–19.0) 8.0 (4.0–20.0)
Missing 37 34 71
Number 185 184 369
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Male 24 (77.4) 296 (67.3) 320 (67.9)
Female 7 (22.6) 144 (32.7) 151 (32.1)
Neo-adjuvant therapy
Yes 14 (45.2) 198 (45.0) 212 (45.0)
No 17 (54.8) 242 (55.0) 259 (55.0)
Intended procedure
HAR 2 (6.5) 67 (15.2) 69 (14.6)
LAR 27 (87.1) 290 (65.9) 317 (67.3)
APR 2 (6.5) 83 (18.9) 85 (18.0)
BMI classification
Underweight/normal 18 (58.1) 162 (36.8) 180 (38.2)
Overweight 10 (32.3) 173 (39.3) 183 (38.9)
Obese 3 (9.7) 105 (23.9) 108 (22.9)
ASA classification
A normal healthy patient 8 (25.8) 83 (18.9) 91 (19.3)
A patient with mild systemic disease 10 (32.3) 264 (60.0) 274 (58.2)
A patient with severe systemic disease 6 (19.4) 92 (20.9) 98 (20.8)
A patient with severe systemic disease
that is a constant threat to life
0 (0.0) 1 (0.2) 1 (0.2)
Missing 7 (22.6) 0 (0.0) 7 (1.5)
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TABLE 88 Results for statistical analysis for general fatigue
Effect Estimate Standard error Pr> |t| 95% CI
Intercept 9.5014 0.8549
30 days 1.5634 0.7257 0.0316 0.1385 to 2.9882
6 months –0.2130 0.7108 0.7645 –1.6085 to 1.1824
Treatment: robotic-assisted laparoscopic surgery
(vs. standard)
0.2517 0.4320 0.5603 –0.5965 to 1.0999
Sex: female (vs. male) 1.0912 0.3728 0.0035 0.3592 to 1.8232
Neo-adjuvant therapy: no (vs. yes) –1.0316 0.4638 0.0264 –1.9421 to –0.1210
Intended procedure: APR (vs. HAR) 1.4207 0.6392 0.0266 0.1657 to 2.6758
Intended procedure: LAR (vs. HAR) 0.6583 0.5147 0.2013 –0.3522 to 1.6689
BMI class: obese (vs. underweight/normal) –0.1142 0.5732 0.8421 –1.2397 to 1.0113
BMI class: overweight (vs. underweight/normal) –0.5285 0.4972 0.2882 –1.5047 to 0.4477
ASA grade: (II vs. I) 0.09524 0.5837 0.8704 –1.0509 to 1.2413
ASA grade: (III vs. I) 1.4558 0.7238 0.0447 0.03480 to 2.8769
Robotic-assisted laparoscopic surgery and 30-day
interaction
–0.3385 0.4715 0.4730 –1.2642 to 0.5872
Robotic-assisted laparoscopic surgery and 6-month
interaction
–0.2278 0.4758 0.6322 –1.1619 to 0.7063
ASA grade II and 30-day interaction –0.2271 0.6349 0.7207 –1.4736 to 1.0194
ASA grade III and 30-day interaction –0.9397 0.7672 0.2211 –2.4461 to 0.5666
ASA grade II and 6-month interaction 0.5650 0.6239 0.3655 –0.6599 to 1.7899
ASA grade III and 6-month interaction –1.0492 0.7621 0.1691 –2.5455 to 0.4472
No neo-adjuvant therapy and 30-day interaction 1.4474 0.4810 0.0027 0.5030 to 2.3917
No neo-adjuvant therapy and 6-month interaction 0.8010 0.4859 0.0997 –0.1531 to 1.7551
Obese and 30-day interaction 1.4919 0.6187 0.0162 0.2771 to 2.7067
Obese and 6-month interaction 0.9778 0.6335 0.1232 –0.2661 to 2.2216
Overweight and 30-day interaction 0.4738 0.5378 0.3787 –0.5822 to 1.5297
Overweight and 6-month interaction 0.8162 0.5383 0.1299 –0.2408 to 1.8731
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TABLE 89 Results of statistical analysis for physical fatigue
Effect Estimate Standard error Pr> |t| 95% CI
Intercept 7.8866 0.8527
30 days 3.8465 0.7294 < 0001 2.4146 to 5.2785
6 months 0.6665 0.7218 0.3561 –0.7505 to 2.0836
Treatment: robotic-assisted laparoscopic surgery
(vs. standard)
0.3964 0.4262 0.3527 –0.4404 to 1.2332
Sex: female (vs. male) 0.7560 0.3635 0.0379 0.04242 to 1.4696
Neo-adjuvant therapy: no (vs. yes) –0.5301 0.4614 0.2510 –1.4359 to 0.3758
Intended procedure: APR (vs. HAR) 1.6339 0.6251 0.0091 0.4066 to 2.8611
Intended procedure: LAR (vs. HAR) 1.1461 0.5021 0.0228 0.1603 to 2.1320
BMI class: obese (vs. underweight/normal) –0.2618 0.5675 0.6447 –1.3761 to 0.8524
BMI class: overweight (vs. underweight/normal) –0.8362 0.4923 0.0898 –1.8027 to 0.1302
ASA grade: (II vs. I) 0.9504 0.5846 0.1045 –0.1974 to 2.0983
ASA grade: (III vs. I) 2.0824 0.7252 0.0042 0.6586 to 3.5062
Robotic-assisted laparoscopic surgery and 30-day
interaction
–0.9425 0.4749 0.0476 –1.8749 to –0.01009
Robotic-assisted laparoscopic surgery and 6-month
interaction
–0.7351 0.4815 0.1273 –1.6804 to 0.2102
ASA grade II and 30-day interaction –1.7434 0.6408 0.0067 –3.0015 to –0.4853
ASA grade III and 30-day interaction 0.003981 0.6358 0.9950 –1.2443 to 1.2522
ASA grade II and 6-month interaction –1.6193 0.7721 0.0363 –3.1353 to –0.1034
ASA grade III and 6-month interaction –1.1335 0.7782 0.1457 –2.6613 to 0.3943
Obese and 30-day interaction 0.9738 0.6242 0.1192 –0.2517 to 2.1993
Obese and 6-month interaction 1.4096 0.6396 0.0279 0.1539 to 2.6654
Overweight and 30-day interaction 0.6666 0.5417 0.2189 –0.3970 to 1.7302
Overweight and 6-month interaction 0.8577 0.5480 0.1180 –0.2182 to 1.9336
No neo-adjuvant therapy and 30-day interaction 1.0634 0.4833 0.0281 0.1146 to 2.0123
No neo-adjuvant therapy and 6-month interaction 0.7799 0.4919 0.1133 –0.1858 to 1.7455
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TABLE 90 Results of statistical analysis for reduced activity
Effect Estimate Standard error Pr> |t| 95% CI
Intercept 8.4917 0.8260
30 days 3.0550 0.7251 < 0001 1.6314 to 4.4786
6 months –0.4520 0.7075 0.5231 –1.8410 to 0.9370
Treatment: robotic-assisted laparoscopic surgery
(vs. standard)
–0.1634 0.4148 0.6938 –0.9777 to 0.6510
Sex: female (vs. male) 0.7244 0.3482 0.0378 0.04081 to 1.4080
Neo-adjuvant therapy: no (vs. yes) –0.7325 0.4477 0.1022 –1.6115 to 0.1465
Intended procedure: APR (vs. HAR) 2.0437 0.6001 0.0007 0.8654 to 3.2221
Intended procedure: LAR (vs. HAR) 1.0258 0.4829 0.0340 0.07763 to 1.9739
BMI class: obese (vs. underweight/normal) –0.4832 0.5515 0.3813 –1.5659 to 0.5996
BMI class: overweight (vs. underweight/normal) –0.5767 0.4777 0.2277 –1.5146 to 0.3611
ASA grade: (II vs. I) 0.8395 0.5703 0.1415 –0.2802 to 1.9591
ASA grade: (III vs. I) 1.7121 0.7019 0.0150 0.3341 to 3.0901
Robotic-assisted laparoscopic surgery and 30-day
interaction
–0.3080 0.4725 0.5147 –1.2356 to 0.6196
Robotic-assisted laparoscopic surgery and 6-month
interaction
0.08269 0.4743 0.8616 –0.8485 to 1.0139
ASA grade II and 30-day interaction –1.0403 0.6383 0.1036 –2.2935 to 0.2130
ASA grade III and 30-day interaction 0.3085 0.6239 0.6211 –0.9164 to 1.5334
ASA grade II and 6-month interaction –0.7610 0.7664 0.3211 –2.2658 to 0.7437
ASA grade III and 6-month interaction –0.4147 0.7528 0.5819 –1.8927 to 1.0633
Obese and 30-day interaction 1.5630 0.6212 0.0121 0.3434 to 2.7825
Obese and 6-month interaction 1.1287 0.6275 0.0725 –0.1033 to 2.3608
Overweight and 30-day interaction 0.4547 0.5363 0.3969 –0.5983 to 1.5077
Overweight and 6-month interaction 0.4901 0.5386 0.3631 –0.5673 to 1.5476
No neo-adjuvant therapy and 30-day interaction 0.9029 0.4786 0.0596 –0.03670 to 1.8424
No neo-adjuvant therapy and 6-month interaction 1.1007 0.4822 0.0228 0.1539 to 2.0475
APPENDIX 8
NIHR Journals Library www.journalslibrary.nihr.ac.uk
112
TABLE 91 Results of statistical analysis for reduced motivation
Effect Estimate Standard error Pr> |t| 95% CI
Intercept 8.1637 0.6844
30 days 0.9350 0.5761 0.1051 –0.1961 to 2.0662
6 months –0.3237 0.5658 0.5675 –1.4347 to 0.7873
Treatment: robotic-assisted laparoscopic surgery
(vs. standard)
–0.03917 0.3531 0.9117 –0.7324 to 0.6540
Sex: female (vs. male) 0.7819 0.3053 0.0107 0.1824 to 1.3813
Neo-adjuvant therapy: no (vs. yes) –0.4394 0.3716 0.2374 –1.1689 to 0.2902
Intended procedure: APR (vs. HAR) 1.0636 0.5227 0.0422 0.03734 to 2.0898
Intended procedure: LAR (vs. HAR) 0.4422 0.4242 0.2976 –0.3907 to 1.2750
BMI class: obese (vs. underweight/normal) –0.03125 0.4627 0.9462 –0.9398 to 0.8773
BMI class: overweight (vs. underweight/normal) –0.1524 0.4059 0.7075 –0.9493 to 0.6445
ASA grade: (II vs. I) –0.1479 0.4712 0.7536 –1.0731 to 0.7773
ASA grade: (III vs. I) 0.03344 0.5745 0.9536 –1.0945 to 1.1614
Robotic-assisted laparoscopic surgery and 30-day
interaction
–0.4805 0.3794 0.2057 –1.2253 to 0.2644
Robotic-assisted laparoscopic surgery and 6-month
interaction
–0.3817 0.3853 0.3222 –1.1381 to 0.3748
ASA grade II and 30-day interaction –0.08389 0.5096 0.8693 –1.0845 to 0.9167
ASA grade II and 6-month interaction 0.8070 0.5026 0.1088 –0.1799 to 1.7939
ASA grade III and 30-day interaction 0.3101 0.6122 0.6127 –0.8920 to 1.5121
ASA grade III and 6-month interaction 0.5378 0.6112 0.3792 –0.6622 to 1.7379
Obese and 30-day interaction 0.9059 0.4994 0.0701 –0.07469 to 1.8864
Obese and 6-month interaction 0.4964 0.5084 0.3292 –0.5018 to 1.4945
Overweight and 30-day interaction 0.1694 0.4309 0.6944 –0.6768 to 1.0155
Overweight and 6-month interaction –0.09029 0.4392 0.8372 –0.9526 to 0.7720
No neo-adjuvant therapy and 30-day interaction 0.8648 0.3857 0.0253 0.1075 to 1.6221
No neo-adjuvant therapy and 6-month interaction 0.1111 0.3935 0.7777 –0.6614 to 0.8836
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TABLE 92 Results of statistical analysis for mental fatigue
Effect Estimate Standard error Pr> |t| 95% CI
Intercept 8.3964 0.7944
30 days 0.8814 0.5758 0.1263 –0.2491 to 2.0118
6 months –0.7408 0.5652 0.1904 –1.8506 to 0.3689
Treatment: robotic-assisted laparoscopic surgery
(vs. standard)
0.1374 0.4075 0.7360 –0.6626 to 0.9374
Sex: female (vs. male) 0.8899 0.3613 0.0140 0.1807 to 1.5992
Neo-adjuvant therapy: no (vs. yes) –0.1726 0.3656 0.6370 –0.8905 to 0.5453
Intended procedure: APR (vs. HAR) 1.1727 0.6192 0.0586 –0.04292 to 2.3884
Intended procedure: LAR (vs. HAR) 0.6569 0.5025 0.1915 –0.3296 to 1.6435
BMI class: obese (vs. underweight/normal) –0.6885 0.5392 0.2021 –1.7471 to 0.3702
BMI class: overweight (vs. underweight/normal) –0.1299 0.4685 0.7817 –1.0497 to 0.7899
ASA grade: (II vs. I) –0.8621 0.5458 0.1147 –1.9336 to 0.2095
ASA grade: (III vs. I) –0.5135 0.6657 0.4407 –1.8205 to 0.7935
Robotic-assisted laparoscopic surgery and 30-day
interaction
–0.4997 0.4152 0.2291 –1.3148 to 0.3154
Robotic-assisted laparoscopic surgery and 6-month
interaction
–0.5284 0.4171 0.2056 –1.3473 to 0.2905
ASA grade II and 30-day interaction –0.06827 0.5569 0.9025 –1.1615 to 1.0250
ASA grade II and 6-month interaction 0.9765 0.5473 0.0748 –0.09799 to 2.0510
ASA grade III and 30-day interaction –0.4344 0.6625 0.5123 –1.7351 to 0.8664
ASA grade III and 6-month interaction 0.1242 0.6547 0.8496 –1.1612 to 1.4096
Obese and 30-day interaction 1.0461 0.5460 0.0558 –0.02591 to 2.1181
Obese and 6-month interaction 1.1519 0.5494 0.0364 0.07317 to 2.2307
Overweight and 30-day interaction 0.1229 0.4735 0.7952 –0.8068 to 1.0527
Overweight and 6-month interaction 0.5304 0.4753 0.2648 –0.4027 to 1.4636
APPENDIX 8
NIHR Journals Library www.journalslibrary.nihr.ac.uk
114
Appendix 9 Disease-free survival:
further information
D isease-free survival events and censorings, including reason for censoring, are summarised in Table 93.
Types of events (i.e. what event contributed to the DFS event) are summarised in Table 94.
The methods of confirmation are summarised in Table 95.
Table 96 shows Kaplan–Meier estimates of DFS by treatment group at several time points (1–5 years post
randomisation).
Subgroup analyses: further information
Figures 27–30 display the Kaplan-Meier graphs for the effect of neo-adjuvant therapy, operation type,
T-stage and sex, on 3-year DFS.
TABLE 93 Disease-free survival events and censoring, by treatment group
Nature of the end of
follow-up for DFS analysis







Event 56 (23.9) 58 (24.5) 114 (24.2)
Censor: last known to be alive
and disease-free
169 (72.2) 172 (72.6) 341 (72.4)
Censor: withdrawal from
further data collection
5 (2.1) 4 (1.7) 9 (1.9)
Censor: non-standard
circumstancea
4 (1.7) 3 (1.3) 7 (1.5)
a Three patients had benign disease, three patients had a non-curative surgery outcome and one patient did not
undergo surgery.
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TABLE 95 Methods of confirmation of DFS event, by treatment group
Method of confirmation of
recurrences







Clinical 1 (2.6) 3 (8.6) 4 (5.5)
Radiological 26 (68.4) 24 (68.6) 50 (68.5)
Pathological 10 (26.3) 8 (22.9) 18 (24.7)
Positron emission tomography
scan
1 (2.6) 0 (0.0) 1 (1.4)
TABLE 96 Kaplan–Meier estimates of DFS, by treatment group
Time (years)
Treatment group
Laparoscopic surgery Robotic surgery
Probability of a
DFS event 95% CI
Probability of a
DFS event 95% CI
1 0.084 0.048 to 0.121 0.116 0.075 to 0.157
2 0.183 0.132 to 0.234 0.186 0.136 to 0.236
3 0.220 0.165 to 0.274 0.225 0.171 to 0.279
4 0.259 0.193 to 0.324 0.274 0.210 to 0.338
5 0.390 0.192 to 0.588 0.274 0.210 to 0.338
TABLE 94 Explanation for DFS events, by treatment group
Type of (first) recurrence or
death (by treatment group)







Locoregional spread 13 (23.2) 14 (24.1) 27 (23.7)
Liver metastasis 15 (26.8) 6 (10.3) 21 (18.4)
Lung metastasis 10 (17.9) 15 (25.9) 25 (21.9)
New primary cancer 8 (14.3) 10 (17.2) 18 (15.8)
Death 9 (16.1) 8 (13.8) 17 (14.9)
Othera 1 (1.8) 5 (8.6) 6 (5.3)
a ’Other’ recurrences were: peritoneal carcinomatosis, early peritoneal disease, extramural vascular invasion, bone
metastasis, skeleton and adrenal gland.
Note
This is a summary of just the first recurrence event for patients who had a recurrence (i.e. they are the events that
contributed to the analysis of DFS). These patients may have had additional recurrences that are not included in this table.
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TABLE 98 Disease-free survival: subgroup analysis for type of operation
Effect HR (adjusted 95% CI)a p-value
Treatment in patients who underwent HAR: robotic surgery
(vs. laparoscopic)
0.437 (0.097 to 1.957) 0.2825 0.1818
Treatment in patients who underwent LAR: robotic surgery
(vs. laparoscopic)
0.914 (0.580 to 1.440) 0.6985
Treatment in patients who underwent APR: robotic surgery
(vs. laparoscopic)
1.703 (0.832 to 3.487) 0.1450
a Adjusted for BMI class, preoperative radiotherapy, intended procedure and operating surgeon.
Hazard ratios derived from the treatment term and treatment–by-operation interaction term.
TABLE 99 Disease-free survival: subgroup analysis by T-stage
Effect HR (adjusted 95% CI)a p-value
Treatment in T0 patients: robotic surgery (vs. laparoscopic) 1.878 (0.309 to 11.391) 0.4934 0.6226
Treatment in T1 and T2 patients: robotic surgery (vs. laparoscopic) 1.252 (0.623 to 2.516) 0.5287
Treatment in T3 and T4 patients: robotic surgery (vs. laparoscopic) 0.925 (0.585 to 1.463) 0.7402
a Adjusted for BMI class, preoperative radiotherapy, intended procedure and operating surgeon.
Hazard ratios derived from the treatment term and treatment-by-T stage interaction term.
TABLE 97 Disease-free survival: subgroup analysis for neo-adjuvant therapy
Effect HR (adjusted 95% CI)a p-value
Treatment in patients who underwent neo-adjuvant therapy: robotic
surgery (vs. laparoscopic)
1.338 (0.795 to 2.251) 0.2728 0.1653
Treatment in patients who did not undergo neo-adjuvant therapy:
robotic surgery (vs. laparoscopic)
0.787 (0.459 to 1.350) 0.3843
a Adjusted for BMI class, preoperative radiotherapy, intended procedure and operating surgeon.
Hazard ratios derived from the treatment term and treatment-by-neo-adjuvant therapy interaction term.
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Sex
TABLE 100 Disease-free survival: subgroup analysis by sex
Effect HR (adjusted 95% CI)a p-value
Treatment in males: robotic surgery (vs. laparoscopic) 0.971 (0.633 to 1.490) 0.8925 0.5570
Treatment in females: robotic surgery (vs. laparoscopic) 1.251 (0.599 to 2.613) 0.5520
a Adjusted for BMI class, preoperative radiotherapy, intended procedure and operating surgeon.
Hazard ratios derived from the treatment term and treatment–by-sex interaction term.
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Appendix 10 Overall survival: further information
Overall survival events and censorings, including reason for censoring, are summarised in Table 101.
Table 102 shows Kaplan–Meier estimates of DFS by treatment group at several time points (1–5 years post
randomisation).
Subgroup analyses: further information
Figures 31–34 display the Kaplan-Meier graphs for the effect of neo-adjuvant therapy, operation type,
T-stage and sex, on 3-year OS.
TABLE 101 Overall survival: deaths and censoring, by treatment group
Nature of the end of follow-up
Treatment group, n (%)





Event 23 (9.8) 23 (9.7) 46 (9.8)
Censor: last known to be alive 205 (87.6) 210 (88.6) 415 (88.1)
Censor: withdrawal from
further data collection
6 (2.6) 4 (1.7) 10 (2.1)
TABLE 102 Kaplan–Meier estimate of OS, by treatment group
Time (years)
Treatment group
Laparoscopic surgery Robotic surgery
Probability of survival 95% CI Probability of survival 95% CI
1 0.970 0.947 to 0.992 0.970 0.949 to 0.992
2 0.939 0.908 to 0.970 0.940 0.909 to 0.971
3 0.925 0.891 to 0.959 0.914 0.878 to 0.950
4 0.891 0.844 to 0.939 0.887 0.840 to 0.933
5 0.786 0.626 to 0.945 0.887 0.840 to 0.933
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TABLE 104 Overall survival: subgroup analysis by type of operation
Effect HR (adjusted 95% CI)a p-value
Treatment in patients who underwent HAR: robotic surgery
(vs. laparoscopic)
0.275 (0.025 to 3.053) 0.2933 0.5713
Treatment in patients who underwent LAR: robotic surgery
(vs. laparoscopic)
0.980 (0.460 to 2.088) 0.9591
Treatment in patients who underwent APR: robotic surgery
(vs. laparoscopic)
1.122 (0.389 to 3.238) 0.8312
a Adjusted for BMI class, preoperative radiotherapy, intended procedure and operating surgeon.
Hazard ratios derived from the treatment term and treatment–by-operation interaction term.
TABLE 105 Overall survival: subgroup analysis by T-stage
Effect HR (adjusted 95% CI)a p-value
Treatment in T0 patients: robotic surgery (vs. laparoscopic)b 0.8240
Treatment in T1 and T2 patients: robotic surgery (vs. laparoscopic) 1.310 (0.464 to 3.701) 0.6106
Treatment in T3 and T4 patients: robotic surgery (vs. laparoscopic) 0.875 (0.421 to 1.819) 0.7215
a Adjusted for BMI class, preoperative radiotherapy, intended procedure and operating surgeon.
b Only one event in T0 patients (in laparoscopic group). Within-group comparison between treatment groups not plausible.
Hazard ratios derived from the treatment term and treatment-by-T-stage interaction term.
TABLE 103 Overall survival: subgroup analysis by neo-adjuvant therapy
Effect HR (adjusted 95% CI)a p-value
Treatment in patients who underwent neo-adjuvant therapy:
robotic surgery (vs. laparoscopic)
0.977 (0.448 to 2.133) 0.9544 0.9018
Treatment in patients who did not undergo neo-adjuvant therapy:
robotic surgery (vs. laparoscopic)
0.908 (0.379 to 2.172) 0.8279
a Adjusted for BMI class, preoperative radiotherapy, intended procedure and operating surgeon.
Hazard ratios derived from the treatment term and treatment-by-neo-adjuvant therapy interaction term.
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Sex
TABLE 106 Overall survival: subgroup analysis by sex
Effect HR (adjusted 95% CI)a p-value
Treatment in males: robotic surgery (vs. laparoscopic) 0.930 (0.491 to 1.763) 0.8248 0.9092
Treatment in females: robotic surgery (vs. laparoscopic) 1.018 (0.251 to 4.128) 0.9801
a Adjusted for BMI class, preoperative radiotherapy, intended procedure and operating surgeon.
Hazard ratios derived from the treatment term and treatment–by-sex interaction term.
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Appendix 11 Pathology central review
The agreement of the local pathology fields with the central review was assessed for pathology fieldsthat fed into analyses. Summaries of agreement are presented below.
Circumferential resection margin positivity (CRM+)
A total of 359 out of 471 (76.2%) patients had both local pathology data and central review data for the
CRM+ field, allowing for the evaluation of agreement. Agreement was non-evaluable for the remaining
112 patients, with reasons summarised in Table 107.
There was agreement between local and central pathology in 343 out of 359 (95.5%) cases. The local and
central evaluation of CRM+ is cross-tabulated in Table 108. In these 359 patients, the central review yields
a CRM+ rate of 29 out of 359 (8.1%), which is greater than the rate of 21 out of 359 (5.8%) yielded by
local pathology.
TABLE 107 Reasons for non-evaluable CRM+ agreement between local and central pathology review, by treatment
group
Reasons
Treatment group, n (%)





Central review data for CRM+
missing or non-evaluable
50 (83.3) 50 (96.2) 100 (89.3)
Local pathology data for CRM+
missing
1 (1.7) 1 (1.9) 2 (1.8)
Local pathology data and
central review data for CRM+
missing or non-evaluable
9 (15.0) 1 (1.9) 10 (8.9)




Total (N= 359), n (%)Yes (N= 21) No (N= 338)
Yes 17 (81.0) 12 (3.6) 29 (8.1)
No 4 (19.0) 326 (96.4) 330 (91.9)
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Plane of surgery
A total of 420 out of 471 (89.2%) patients had both local pathology data and central review data for the
plane of surgery field, allowing for the evaluation of agreement. Agreement was non-evaluable for the
remaining 51 patients, with reasons summarised in Table 109.
There was agreement between local and central pathology in 262 out of 420 (62.4%) cases. The local and
central evaluation of plane of surgery is cross-tabulated in Table 110. In these 420 patients, the central
review yields a rate of mesorectal fascial plane of 179 out of 420 (42.6%), which is notably less than the
rate of 319 out of 420 (76.0%) yielded by local pathology. The large majority of the disagreement between
local and central pathology is seen when local pathology considered the plane of surgery to be mesorectal
fascial, which is then downgraded to intramesorectal or muscularis propria plane by the central review.
TABLE 109 Reasons for non-evaluable agreement for plane of surgery, by treatment group
Reasons
Treatment group, n (%)





Central review data for plane of
surgery missing or non-evaluable
15 (57.7) 21 (84.0) 36 (70.6)
Local pathology data for
plane of surgery missing
3 (11.5) 2 (8.0) 5 (9.8)
Local pathology data and central
review data for plane of surgery
missing or non-evaluable
8 (30.8) 2 (8.0) 10 (19.6)
TABLE 110 Agreement between local and central review of plane of surgery. Cross-tabulation of central (rows) and
local (columns) for mesorectum plane
Mesorectum plane









Mesorectal fascial plane 174 (54.5) 4 (6.0) 1 (2.9) 179 (42.6)
Intramesorectal plane 124 (38.9) 58 (86.6) 3 (8.8) 185 (44.0)
Muscularis propria plane 21 (6.6) 5 (7.5) 30 (88.2) 56 (13.3)
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Pathological T-stage
A total of 456 out of 471 (96.8%) patients had both local pathology data and central review data for the
pT-stage field, allowing for the evaluation of agreement. Agreement was non-evaluable for the remaining
15 patients, with reasons summarised in Table 111.
There was agreement between local and central pathology in 424 out of 456 (93.0%) cases. The local and
central evaluation of pT-stage is cross-tabulated in Table 112.
TABLE 112 Agreement between local and central pathology review for T-stage. Cross-tabulation of central (rows)
and local (columns) for pT stage
pT-stage
pT stage, n (%)
Total (N= 456),
n (%)0 (N= 52) 1 (N= 46) 2 (N= 129) 3 (N= 217) 4 (N= 12)
0 46 (88.5) 0 (0.0) 0 (0.0) 1 (0.5) 0 (0.0) 47 (10.3)
1 4 (7.7) 46 (100.0) 2 (1.6) 1 (0.5) 0 (0.0) 53 (11.6)
2 2 (3.8) 0 (0.0) 116 (89.9) 6 (2.8) 0 (0.0) 124 (27.2)
3 0 (0.0) 0 (0.0) 11 (8.5) 205 (94.5) 1 (8.3) 217 (47.6)
4 0 (0.0) 0 (0.0) 0 (0.0) 4 (1.8) 11 (91.7) 15 (3.3)




Treatment group, n (%)





Central review data for T-stage
missing or non-evaluable
2 (20.0) 1 (20.0) 3 (20.0)
Local pathology data for T-stage
missing
1 (10.0) 2 (40.0) 3 (20.0)
Local pathology data and central
review data for T-stage missing or
non-evaluable
7 (70.0) 2 (40.0) 9 (60.0)
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Appendix 12 Summary of protocol changes
Version and date Summary of changes
V1.0 dated 17 February 2010 N/A – original protocol submitted for ethical review
V2.0 dated 25 March 2010 Changes were required to the PIS/ICF document following ethical review, protocol was
upversioned to match revised version of PIS/ICF (no changes made to the protocol)
V3.0 dated 2 August 2010 l Contents and references updated
l Clarification of eligibility criteria
l Surgeon eligibility: it was initially stipulated that surgeons must have performed at least
15 rectal cancer resections per annum and have prior experience of at least 10 robotic-
assisted rectal cancer resections. It was felt that to ensure that the ‘learning curve’ effect
did not bias the trial data, only surgeons who had performed at least 30 rectal cancer
resections, with a minimum of 10 of these to be standard laparoscopic procedures,
and 10 of these to be robotic-assisted procedures, should be included in the trial to
ensure surgeon competency in both arms of the trial
l BMI added as a stratification factor due to recent publications that increased BMI may
be associated with an increased risk of conversion to open surgery
l Schedule of Events modified for clarity
l Pathology section updated, including collection of extra tumour samples for tissue
banking (explicit consent was obtained)
l Update of Study Organisational Structure diagram
l Clarification of pathology appendix
l Minor administrative changes
V4.0 dated 1 March 2011 l Funder (EME) requested changes to reference to EME and removal of logos on
front cover
l Contacts and table of contents updated
l Section 2 and 19: addition of ROLARR protocol publication
l Section 4 Eligibility: clarifications to procedures following feedback from the
international trial launch meetings
l Section 5.2 Randomisation: clarification of timings following feedback from the
international launch meetings
l Table 1: expedited safety reporting timeline revised to 30 days (correction to
previous version)
l Clarification added that all procedures will be video’d and the CTRU will inform sites
which procedures to submit
l Pregnancy statement added
l Section 7.5 and Appendix 1: clarifications were made to pathology processes following
consultation with a trial pathologist following the analysis of the first trial specimen.
Also procedures for submitting the slides for trial purposes and extra tumour/normal
tissue blocks as an optional separate study were updated to ensure HTA compliance
and clarity in procedures
l Section 7.7: clarification of annual follow-up timing and addition of stoma details
l Section 7.9 Pregnancy: section added to ensure patients who may become pregnant on
trial are handled correctly
l Section 7.12: end of study definition included as it was omitted in previous version
of protocol
l Section 8: safety updates following feedback from the international launch meetings.
Clarification of timing for expedited safety reports
l Sections 8.5 and 15.1: sections regarding procedures/responsibilities for Serious
Breaches of GCP added in line with the latest CTRU policies
l Section 16 indemnity: updated following discussion with the insurers
l Section 17.2 Responsibilities: LIMM responsibilities added regarding the central
pathology assessment and optional separate tissue block study
l Section 18: clarification to publication policy as journal author restrictions may be
in place
l Section 23 Abbreviations: updated
V5.0 dated 19 March 2014 l Contacts updated
l Removal of secondary endpoint: Global Operative Assessment of Laparoscopic Skills tool
(GOALS). It was planned that an assessment of surgical skills would be carried out using
the GOALS assessment. Videos were to be taken of the complete mesorectal dissection
from all cases inclusive of both laparoscopic and robotic operations however this proved
to be unfeasible due to the large size of the files
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Version and date Summary of changes
l Clarification of inclusion criteria surrounding diagnosis of rectal cancer amenable to
curative surgery. The inclusion criteria stated that a T-staging of 1–3 was a component
of a patient being ‘amenable to curative surgery’ for the purpose of this trial. This was
discussed by the Trial Management Group who agreed that the decision of the team to
perform surgery acts as a sufficient indication that the patient is amenable to curative
surgery. Therefore T-staging of 1–3 is a guide only; to reflect this, ‘i.e.’ was removed
and replaced with ‘for example’
l Specified that histopathology reports are only to be collected if reported in English
l Clarification to assessment of Unexpected Serious Complications: the chief investigator
can upgrade or downgrade assessment in the event of disagreement between local
assessment in line with CTRU standard guidance
l Increase in sample size. Following a successful extension request, the trial recruited to
target ahead of the revised milestones, and the opportunity to recruit further patients
within the revised timelines and budget was taken to maximise study power. The
sample size was amended from 400 to a maximum of 520 participants, to increase the
power of the study from 80% to a maximum of 90% power
l Removal of South-East Asian Spoke to reflect actual spoke arrangements. The South-East
Asian Spoke were unable to secure additional funding for them to deliver the CTU spoke
function in Singapore, so were unable to act as a spoke. CTRU, Leeds (i.e. the Hub)
therefore co-ordinated centres in South-East Asia and sites across the rest of the world
(with the exception of sites in the USA which were coordinated by the North American
Spoke)
l Neo-adjuvant therapy: clarification that eligibility should be reassessed on completion of
neo-adjuvant therapy and guidance added on timing of consent
l Analyses on a surgeon basis: additional wording added to expand on planned analyses
(wording omitted in error from previous protocols)
l Expected complications list expanded and grouped into relevant categories
l Minor administrative changes
V6.0 dated 1 July 2015 This amendment to the protocol included an additional one-off questionnaire as a
supplementary study to the ROLARR trial to determine the incidence and severity of Low
Anterior Resection Syndrome (LARS) within participants of the ROLARR trial. It was felt that
the results would have important consequences when counselling future patients with
rectal cancer on the likely functional outcomes of surgery. The protocol was amended
to include an additional appendix (Appendix 4) to cover the Low Anterior Resection
Syndrome (LARS) supplementary study. Eligible ROLARR participants from Denmark,
Germany, Italy, the USA and the UK were invited to complete a one-off postal survey
CTU, Clinical Trials Unit; ICF, informed consent form; GCP, Good Clinical Practice; LIMM, Leeds Institute of Molecular
Medicine; N/A, not applicable; PIS: patient information sheet.
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